Children's Mercy Kansas City

SHARE @ Children's Mercy
Clinical Practice Guidelines

Quality Improvement and Clinical Safety

5-2019

Asthma Care in the Emergency Department and Urgent Care
Center
Children's Mercy Kansas City

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/clinical_guidelines
Part of the Pediatrics Commons

These guidelines do not establish a standard of care to be followed in every case. It is
recognized that each case is different and those individuals involved in providing health care are
expected to use their judgment in determining what is in the best interests of the patient based
on the circumstances existing at the time. It is impossible to anticipate all possible situations
that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Approval Date: May 20, 2019
Children’s Mercy Hospital
Evidence Based Practice Clinical Practice Guide
Asthma Care in the Emergency Department and Urgent Care Center

1

Approval Date: May 20, 2019

2

Approval Date: May 20, 2019
Cha
Definition
Asthma is a chronic disease, characterized by airway inflammation (GINA, 2018;
Lougheed et al., 2012; NAEP-EPR-3, 2007). Respiratory symptoms such as chest
tightness, cough, shortness of breath, wheeze, and variable expiratory airflow are
common. Symptoms can be chronic, or they can occur suddenly, with acute amplification
of symptoms (GINA, 2018; Lougheed et al., 2012; NAEP-EPR-3, 2007). Triggers can
induce an asthma exacerbation. Common triggers are respiratory infections,
environmental factors, such as cold air exposure, exposure to allergens (including pollens
and foods), exercise, and emotional factors (Dynamed Plus, 2017, December 11).
Objective of Guideline
The objective of this guideline is to improve and standardize care of children seen in the
Emergency Department (ED) and Urgent Care Centers (UCC) for an asthma exacerbation.
Perspective of Guideline
•
Provider
•
Patient
•
Families
•
Health System (CMKC)
•
Community
Target Users
ED/UCC physicians, General Pediatricians, Fellows, Resident Physicians, Pediatric Nurse
Practitioners
Target Population
Guideline Inclusion Criteria
•
Children 2- 18 years of age
•
History consistent with an asthma exacerbation
Guideline Exclusion Criteria
•
Children < 2 years of age
Patients with co-morbidities (chronic lung disease, congenital heart disease, etc.)
The guideline can be used as a reference for management of an asthma exacerbation.
Management decisions made in context with underlying disease management are outside
the scope of this guideline.
Clinical Questions Answered by Guideline. The Global Initiative for Asthma, GINA (2018)
is the governing guideline for this Clinical Practice Guideline (CPG). Literature has been
searched and analyzed to further answer the following questions:
1. For the pediatric patient who presents to the emergency department or urgent care
center (ED/UCC) with an acute asthma exacerbation, is there a score that is reliable
and valid to assess the severity of the exacerbation, and the patient’s response to
treatment?
2. What oxygen saturation (SpO2) level should be maintained during an acute asthma
exacerbation?
3. For the patient who presents to the ED/UCC with a mild to moderate asthma
exacerbation, are metered-dose inhalers (MDI) comparable to nebulizer mask
treatment for the provision of albuterol?
4. For the patient who presents to the ED/UCC with mild, moderate, or severe asthma
symptoms what is the optimal dose (including maximum dose) of glucocorticosteroids
to improve asthma symptoms, reduce admission to the hospital, and decrease length
of stay in the ED/UCC?
5. Is oral dexamethasone more efficacious than prednisone/prednisolone for a pediatric
asthma exacerbation?
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6. For the patient who presents to the ED/UCC with an asthma exacerbation, is treatment
with inhaled glucocorticosteroids (ICS) as efficacious as treatment with oral
glucocorticosteroids (CS)?
7. For the patient who presents to the ED/UCC with a moderate/severe asthma
exacerbation, should ipratropium bromide (IB) be considered as an adjunct to
standard treatment with albuterol to reduce hospital admissions, adverse effects and
improve pulmonary function?
8. For the patient who presents to the ED/UCC with a severe or non-resolving asthma
exacerbation, should the patient be treated with intravenous (IV) magnesium sulfate?
9. For the patient who presents to the ED/UCC with an asthma exacerbation should noninvasive ventilation, either continuous positive airway pressure or non-invasive
spontaneous timed positive airway pressure be used to reduce hospital admission, ED
length of stay, or improve pulmonary function?
10. Should epinephrine 1:1000 IM be considered in a severe exacerbation/ impending
respiratory failure?
Practice Recommendations.
1. Evaluation.
a. Definition. The universal symptom of asthma is airway inflammation. Airways
become narrower from inflammation. Mucous formation within the airway, and
muscles compressing outside the airway cause the defining symptoms of
wheeze, shortness of breath, cough, and chest tightness. Symptoms are
triggered by a myriad of factors, including respiratory viral illness, allergens,
irritants, and exercise. Triggers are not the same for all people with asthma.
(GINA, 2018, p. 14)
b. Physical Exam. A brief history and physical exam focused on the signs and
symptoms of the exacerbation should be performed. If a moderate, severe, or
life-threatening exacerbation is recognized, treatment should begin without
delay. (GINA, 2018 p. 79).
c. Pediatric Respiratory Assessment Measure (PRAM Score). Screening
tools have been developed to assess the severity of an acute asthma
exacerbation. (Chalut, Ducharme, & Davis, 2000). Other uses of screening
tools may be to identify treatments that may be required by patients or assess
patient’s progress through treatment of an exacerbation (Ducharme et al.,
2008; GINA, 2018, p. 27). The PRAM Score has been selected as the tool to
assess asthma severity in the ED/UCC. It as has been tested in children aged
2 to 17 years of age. PRAM is a twelve-point score, with lower scores reflecting
less respiratory distress.
2. Interventions in Ambulatory Treatment Settings- Treatment escalates with the
severity of the exacerbation.
a.

The PRAM score guides the initial management of an exacerbation in the first interval of
treatment, usually the first hour.
i.
Mild Asthma (PRAM <5). Administration of supplemental oxygen and
provision of albuterol, a short-term beta-agonist is recommended for mild
asthma. Oxygen should be provided to maintain an oxygen saturation
(SpO2) of 90%. Provision of albuterol using a metered dose inhaler (MDI)
is preferred, if the patient can perform the maneuver. Otherwise, treat
with nebulized albuterol.
Albuterol
a)
Dose (MDI and spacer)
1. Less than or equal to 5-years-old: 4 puffs every 20
minutes PRN times 3
2. Greater than 5-years-old: 8 puffs every 20 minutes PRN
times 3
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b)

Dose (nebulized single dose)
1. 2.5 mg (0.5 mL of 0.5% inhalation solution) every 20
minutes PRN times 3, with or without ipratropium

Consider Glucocorticosteroids if more than two doses of albuterol are
required.
Dose
2. Prednisone/Prednisolone – 2 mg/kg (maximum 60 mg)
3. Dexamethasone – 0.3-0.6 mg/kg (maximum 12 mg) once
daily, for 1 or 2 days
4. Methylprednisolone (IV) – 2 mg/kg (maximum 60 mg)
Consider Ipratropium Bromide
a)
Dose (nebulized, intermittent)
5. 500 mcg every 20 minutes PRN times 3 doses with the
albuterol nebulized treatment.
ii.

iii.

iv.

Moderate Asthma (PRAM 5-7). Treat with oxygen and albuterol as for
Mild Asthma. Glucocorticosteroids are added to treatment for moderate
asthma. Ipratropium bromide can be considered for moderate asthma
exacerbations.
Albuterol
a)
Dose (MDI and spacer)
1. Less than or equal to 5-years-old: 4 puffs every 20
minutes PRN times 3
2. Greater than 5-years-old: 8 puffs every 20 minutes PRN
times 3
b)
Dose (nebulized single intermittent)
1. 2.5 mg (0.5 mL of 0.5% inhalation solution) every 20
minutes PRN times 3 doses, with or without ipratropium
c)
Dose (nebulized continuous) x 1 hour
1. Less than 5-years-old: 10 mg/hour
2. Greater or equal to 5-years-old: 15 mg/hour
Glucocorticosteroids
d)
Dose
1. Prednisone/Prednisolone – 2 mg/kg (maximum 60 mg)
2. Dexamethasone– 0.3-0.6 mg/kg (maximum 12mg), once
daily, for 1 or 2 days
3. Methylprednisolone (IV) – 2 mg/kg (maximum 60 mg)
Consider Ipratropium Bromide
e)
Dose (nebulized, single, intermittent)
1. 500 mcg every 20 minutes PRN times 3 doses with the
single dose nebulized albuterol treatment, or
f)
Dose (nebulized, continuous) with the 1-hour continuous
albuterol treatment
1. 1500 mcg/hour times 1 hour
Severe Asthma (PRAM > 8). Treat with oxygen, albuterol,
glucocorticosteroids, as for Moderate Asthma. Ipratropium is added to
treatment for severe asthma. Albuterol may be delivered by MDI and
spacer or continuously nebulized. Magnesium sulfate (IV) can be
considered. Epinephrine 1:1000 can be considered for impending
respiratory arrest.
Consider Magnesium Sulfate
a)
Dose (IV)
1. 50 mg/kg (maximum 2 grams)
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Consider Epinephrine 1:1000
b)
Dose (IM)
1. 0.1 mg/kg (maximum 0.5 mL)
b. Response to treatment should be assessed after one hour of initial treatment.
i.
All providers should assess to see if symptoms are resolving. If so, discharge
from the ED/UCC should be initiated.
ii.
If symptoms are not resolving
a) Continue oxygen and albuterol therapy
b) Add glucocorticosteroids, if not already administered
c)
Consider ipratropium (nebulized continuous) and/or
magnesium sulfate (IV) if not already administered
d) Continue to monitor and treat as needed, until a decision to
Admit or Discharge is made
e) Urgent Care Providers – consider the need to transfer to a
higher level of care
c. Response to treatment should be assessed after two hours of initial treatment.
i.
Continue to monitor and treat as necessary, until the decision to Admit
or Discharge is made
ii.
Consider admission if the patient requires oxygen, is treated with a
SABA less than every 4 hours, remains on continuous albuterol, if there
is concern for the ability of the patient to be cared for at home, or if
close outpatient follow up with their health care provider cannot be
arranged.
iii.
Discharge if the patient is symptom free, does not require oxygen, and
the SABA can be spaced out to every 4 hours PRN, the patient can be
cared for at home and has close outpatient follow up with their health
care provider.
d. Not routinely recommended
i.
Chest x-ray, unless differential includes pneumothorax, parenchymal disease, or
inhaled foreign body. (GINA, 2018, p.82)
ii.
Antibiotics, unless strong indication of lung infection, such as fever, purulent
sputum or x-ray evidence of pneumonia (GINA, 2018 p. 86)
3. Complications
a. Respiratory complications may arise with an acute asthma exacerbation.
Respiratory failure when the exacerbation is severe, along with (DynaMedPlus,
2019):
i. Pneumothorax
ii. Atelectasis
iii. Pneumonia
b. Medications used to treat an acute asthma exacerbation have complications or
adverse events. Adverse events for medications routinely used are (LexiComp,
2019):
i. Albuterol – Hypersensitivity to any component, tachycardia, jitteriness
ii. Glucocorticosteroids –
1. Adrenal suppression, especially in younger children receiving
high doses.
2. Greater frequency of vomiting with prednisolone administration
iii. Ipratropium – Dizziness, headache
iv. Magnesium (IV) –
1. Rate related – hypotension and vasodilation
2. Dose related - flushing
4. Discharge Criteria
a. Symptom resolution
b. Albuterol requirement > every 4 hours
c. Able to be cared for at home
d. Close outpatient follow-up with a health care provider
5. Discharge Care Plan
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a.
b.
c.
d.
e.
f.

Continue treatment with albuterol
Continue course of oral systemic steroid to complete a 5 day course of
prednisone/olone; or a second dose of oral dexamethasone per provider
preference.
Continue inhaled glucocorticosteroid if already prescribed, consider initiation of
an inhaled glucocorticosteroids if not already prescribed.
Review medications along with inhaler technique
Review/consider initiation of an Asthma Action Plan
Recommend close medical follow up.

Measures
The following measures will be tracked after guideline implementation:
1. Asthma in the ED CPG PowerPlan utilization
2. For Mild and Moderate Asthma, the administration of albuterol by MDI versus
nebulizer
Guideline Preparation
This guideline was prepared by The Office of Evidence Based Practice (EBP) in
collaboration with content experts at Children’s Mercy Hospitals and Clinics. Development
of this guideline supports the Department of Clinical Effectiveness’s initiative to promote
care standardization that builds a culture of quality and safety that is evidenced by
measured outcomes. If a conflict of interest is identified the conflict will be disclosed next
to the team members name.
Table 1
Agree II Summary for GINA (2018)
Domain

Percent Agreement

1 – SCOPE AND PURPOSE

92%

2 – STAKEHOLDER INVOLVEMENT

79%

3 – RIGOR OF DEVELOPMENT

92%

4 – CLARITY AND PRESENTIATION

89%

5 – APPLICABILITY
6 – EDITORIAL INDEPENDENCE

90%
92%

Overall Guideline Assessment
93%
Note: Four EBP Scholars completed the AGREE II on this guideline
A quality score is calculated for each of the six AGREE II domains (scope and purpose;
stakeholder involvement; rigor of development; clarity of presentation; applicability; editorial
independence. A higher domain percent reflects a stronger agreement that the guideline met
the domain criteria. The AGREE II quality score does not judge the evidence used or the
strength of the recommendations made by the guideline, only the process used to develop the
guideline (Brouwers, et al., 2010)
Potential Cost Implications.
Understanding the effect of a CPG on the cost of an asthma exacerbation in the ED/UCC has
been difficult to discern. Increasing the use of MDI with spacer instead of nebulizer for the
provision of albuterol for mild to moderate exacerbations was believed to decrease the cost of
an exacerbation. However, for exacerbations that require treatment with IB, albuterol is given
concomitantly with IB as a nebulized therapy. In March of 2013 approximately 57/144 (40%)
of patients in the ED/UCC were treated with MDI/spacer. From the data collected at that time,
it is not known if only MDI was the route of administration, or if MDI was added after
albuterol/IB was given by nebulizer, either intermittent or continuous. Continuing the work of
understanding the cost benefit is a planned work outflow of the CPG update.
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Potential Organizational Barriers.
The utilization of the PRAM score as the determinant of asthma severity will be an
organizational barrier. PRAM has been rolled out as part of a Nursing Standing Order (NSO)
initiative at the Children’s Mercy Kansas (CMK) location. Work is being done at the Adele Hall
ED to start using the PRAM to fire a Nursing Standing Order to assure administration of
albuterol and corticosteroids in a timely fashion. Work to initiate or improve the
implementation of the PRAM score continues at both CMH Emergency Departments.
Table 2
PRAM Utilization at Kansas ED FY20192Q
Acuity
Patients Seen
Documented PRAM
Critical
0
0
Emergent
76
39
Urgent
124
44
Semi Urgent
126
25
Non-Urgent
6
0

Percent
51%
35%
20%
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Power Plan
General Orders
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Mild Asthma Subphase
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Moderate Asthma Subphase
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Severe Asthma Subphase

Nursing Standard Orders for Timely Administration of Asthma Medication:
Internal policy link: Division of Emergency Medicine Asthma Initiation Standing Order. May be available to external users upon request.
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How guideline was placed into practice
Once approved, the guideline was presented to the appropriate care teams and
implemented. Care measurements will be assessed and shared quarterly with appropriate
care teams to determine if changes need to occur.
Guideline Preparation
This guideline was prepared by the Evidence Based Practice (EBP) Department in
collaboration with content experts at Children’s Mercy Kansas City. Development of this
guideline supports the Center of Clinical Effectiveness’ initiative to promote care
standardization that builds a culture of quality and safety that is evidenced by measured
outcomes. If a conflict of interest is identified the conflict will be disclosed next to the
team members name.
Team
•
•
•
Team

Leaders
Amanda Nedved, MD
Erin Scott, DO
Renie Walsh, MD (retired)
Members
• George Abraham, MD
• Teresa Bontrager, RN, BSN, MSN, CPEN
• Molly Camis, PharmD, BCPS
• Cheri Hobbs, RN, BSN
• Bridgette Jones, MD, MSCR
• Kerrie Meinert, BHS, RRT-NPS
• Helen Murphy, BHS, RRT, AE-C
• Ibad Siddiqi, PharmD
• Jade Tam-Williams, MD
• Tracy Taylor, RHIA
• Emily Wilkinson, MBA, RRT-NPS
• Jessica Williams, RN BSN
Office of EBP Team Members:
• Nancy H Allen, MS, MLS, RD, LD, CPHQ
• Jacqueline A Bartlett, PhD, RN
• Jarrod D Dusin, MS, RD, LD, CPHQ
• Jeffery Michael, DO, FAAP
Funding of Guideline Development
The development of this guideline was underwritten by the EBP, and the Divisions of
Emergency and Urgent Care.
Development Process
The CPG Team adopted the following development process:
1. Reviewed existing internal and external guidelines and standards
a. Internal guidelines: Children’s Mercy Asthma Care in the Emergency Department
and Urgent Care Center
b. External guidelines: Global Initiative for Asthma, (2018) https://ginasthma.org/
2. If external guidelines did not include relevant CMKC care standards
a. PICOT questions established
b. Medical librarians identified appropriate databases to search and search terms
c. Team leaders confirmed databases and search terms
3. See individual Critically Appraised Topics for
a. The databases searched
b. The CPG team members responsible for identifying the literature
c. The literature review process
4. Critically analyze the evidence
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a. Guidelines
i. AGREE II criteria were used to analyze published clinical guideline used as
the governing guideline for this clinical practice guideline.
b. Recommendations from literature
i. The CPG Team’s recommendations were determined through the GRADE
Evidence to Decision (EtD) criteria for interventions and diagnostic testing
i. Intervention EtD criteria:
1) Is the problem a priority?
2) How substantial is the anticipated desirable effects?
3) How substantial are the undesirable effects?
4) What is the overall certainty of the evidence of effects?
5) Is there important uncertainty about or variability in how much
people value the main outcomes?
6) Does the balance between the desirable and undesirable effects
favor the intervention of the comparison?
7) Is the intervention acceptable to key stakeholders?
8) Is the intervention feasible to implement?
ii. Diagnostic EtD criteria:
1) Is the problem a priority?
2) How accurate is the test?
3) How substantial is the anticipated desirable effects?
4) How substantial are the undesirable effects?
5) What is the overall certainty of the evidence of effects?
6) Is there important uncertainty about or variability in how much
people value the main outcomes?
7) Does the balance between the desirable and undesirable effects
favor the intervention of the comparison?
8) Is the intervention acceptable to key stakeholders?
9) Is the intervention feasible to implement?
iii. EtD definitions employed by the team to measure the certainty of
evidence:
1) High—Evidence is consistent from well-performed RCTs or
exceptionally strong evidence from unbiased observational studies
2) Moderate—Evidence from RCTs with important limitations
(inconsistent results, methodological flaws, indirect evidence, or
imprecise results) or unusually strong evidence from unbiased
observational studies.
3) Low—Evidence for at least 1 critical outcome from observational
studies, from RCTs with serious flaws or indirect evidence.
4) Very low—Evidence for at least 1 of the critical outcomes from
unsystematic clinical observations or very indirect evidence.
iv. EtD definitions employed for developing the team recommendations:
1) Strong—Desirable effects clearly outweigh undesirable effects or
vice versa
2) Conditional—Desirable effects closely balanced with undesirable
effects
5. Recommendations for the guideline were developed by a consensus process
incorporating the three principles of EBP (current literature, content experts, and patient
and family preference [when possible])
Approval Process
Guidelines were reviewed and approved by Michelle DePhillips, MD (internal expert
reviewer), Bernie (Bernadette) Johnson, MD (external expert reviewer), Content Expert
Team, the EBP Department, and other appropriate hospital committees as deemed
suitable for the guidelines intended use. Guidelines are reviewed and updated as
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necessary every 3 years within the EBP Department. Content expert teams will be
involved with every review and update.
Disclaimer
The content experts and the Office of EBP are aware of the controversies surrounding
Asthma Care in the Emergency Department and Urgent Care Centers. When evidence is
lacking or inconclusive, options in care are provided in the guideline and the power plans
that accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is
recognized that each case is different, and those individuals involved in providing health
care are expected to use their judgment in determining what is in the best interests of
the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the
understanding that departures from them may be required at times.
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Question 1 – Specific Care Question: PRAM Score
Specific Care Question
For the pediatric patient who presents to the emergency department or urgent care center (ED/UCC) with an acute asthma
exacerbation, is there a score that is reliable and valid to assess the severity of the exacerbation, and the patient’s response to
treatment?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. Challenges exist when assessing the severity of an acute asthma exacerbation of a young pediatric patient. In older
children and adults peak expiratory flow rate (PEFR) spirometry is used to assess the severity of an exacerbation. The technique to
perform PEFR spirometry is difficult for some pediatric patients, especially the very young patient or those with a severe exacerbation
(Gorelick, Stevens, Schultz, & Scribano, 2004). Adult guidelines rely on these measures, however since they are not reliable in
pediatrics, instruments otherwise known as asthma scores have been developed. Some of the scores available for use are the Asthma
Severity Score (ASS), Clinical Asthma Score (CAS), Preschool Respiratory Assessment Measure (PRAM), and Pulmonary Score (PS).
The scores have included various items, such as wheeze, inspiratory: expiratory ratio, or oxygen saturation. Since there are many
scores, the Asthma in the ED CPG Team inquired, which of the available scores has been tested for validity and reliability to assess the
severity of a pediatric patient’s asthma exacerbation, and their response to treatment.
Study characteristics. The search for suitable studies was completed on May 25, 2018. Nineteen titles and abstracts were found in
the search and reviewed Nancy Allen, MS, MLS, RD, LD CPHQ. Five articles were believed to address the question. After an in-depth
review two articles (Alnaji, Zemek, Barrowman, & Plint, 2014; Gouin et al., 2010) answered the question. Also included in this analysis
are three articles (Birken, Parkin, & Macarthur, 2004; Chalut, Ducharme, & Davis, 2000; Ducharme et al., 2008) from the previous
Critically Appraised Topic (CAT).
Key results. Based on low quality evidence, a strong recommendation is made to use the PRAM score to assess asthma severity in the
ED/UCC for a pediatric patient with an acute asthma exacerbation. The expansion of the PRAM from a score to be used in pre-school
patients to the overall pediatric population is clearly described (Ducharme et al., 2008). Subsequent studies have identified a high
PRAM score as a strong predictor of hospital admission (Alnaji, Zemek, Barrowman, & Plint, 2014; Gouin et al., 2010) and extended ED
stays (Alnaji et al., 2014; Gouin et al., 2010).
Summary by Outcome
Asthma Score testing. Three studies are included for this outcome. Birken et al. (2004) is a systematic review on 10 asthma scores
develop for use in the inpatient and outpatient care areas. The asthma scores are Bronchiolitis Score (BS), Clinical Asthma Score
(CAS), Clinical Asthma Evaluation Score (CAES), Clinical Score (CS), Clinical Symptom Grading System (CSGS), Clinical Scoring System
– 1 (CSS - 1), Clinical Scoring System– 2 (CSS - 2), Pulmonary Index (PI), Preschool Respiratory Assessment Measure (PRAM), and
Respiratory Distress Assessment Index (RDAI). However, the criteria for study selection, risk of bias across studies, number of articles
selected, or number of subjects were not reported. The authors did not perform a meta-analysis. The two prospective cohort studies
that tested the PRAM are Chalut et al. (2000) in the pre-school population and Ducharme et al. (2008) that expanded the use of the

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO
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PRAM to the full range of pediatric ages. Cohort studies start as low quality and could not be upgraded for (a) large effect size, (b)
plausible confounding that would reduce the effect, or (c) a dose response gradient (Schunemann, Brozek, Guyatt, & Oxman, 2013).
The quality of the evidence reported in the three studies is graded as low.
Birken et al. (2004) recognized the CAS (inpatient) and PRAM (outpatient) as having the most robust psychometrics of the 10 scores.
The PRAM score has the following features:
•
The basis for scored items is based on research findings
•
Items were checked for comprehension
•
Validity- PRAM moderately correlated with provider assessment (r = .5)
•
Criterion validity correlated with respiratory resistance pre- and post- bronchodilation (r = .22 and r = .36) respectively
•
Responsiveness- assessed by change in score pre and post treatment with corticosteroids, and inhaled beta 2-agonists (p < .01)
Birken et al (2004) concludes that asthma severity scores have been informally developed, and although the PRAM and the CAS have
the most rigorous testing, score development and testing should continue to assure accurate classification of the severity of asthma
exacerbation in pediatrics.
Chalut et al. (2000) evaluated 19 clinical signs to discriminate the severity of the exacerbation in the pre-school population. From this
work, the PRAM score was developed. Suprasternal retractions, scalene muscle contraction, air entry, wheezing, and oxygen saturation
were the five signs selected to be included in the PRAM (Chalut et al, 2000). PRAM has a range from zero to 12 with 12 indicating a
severe exacerbation and zero no exacerbation. PRAM was found to be a responsive tool, correlating (r = .58) with a change in
respiratory resistance measured by Rfo8. PRAM was found to be able to discriminate exacerbation severity, “A PRAM score of 5 (95% CI
[4.5, 5.2]), corresponded to 175% of predicted Rfo8 and thus would be suggestive of moderate airway obstruction; a change to 3 (95%
CI [2.2, 3.0]) corresponded to a > 25% change from baseline Rfo8” (Chalut et al. 2000).
To assess the PRAM score in pediatric patients of all ages, Ducharme et al. (2008) examined the performance of the PRAM in children
2-17 years of age. Construct validity, both internal consistency and predictive validity; responsiveness, and interrater agreement were
assessed. The internal validity of the PRAM was good both overall and across the age groups (Cronbach α =.71). PRAM score at triage
and after initial bronchodilation was strongly associated with rate of admission (r =.4, p < .0001, and r = .5, p < .0001) respectively.
The Guyatt responsiveness coefficient (Guyatt et al., 2002), which measures sensitivity to clinical change, identified that PRAM was 0.7,
showing the PRAM score detected change after bronchodilation. Finally, inter-rater reliability was high (к = .78) between physician and
nurse groups and was consistent for all ages studied. The authors found the PRAM score is the most extensively reported score, and
shows strong psychometrics.
Hospital admission. Two studies (n = 580) are included for this outcome (Alnaji et al., 2014; Gouin et al., 2010). The evidence is
graded as very low quality as the severity of the exacerbation varied in the two studies. Gouin et al. (2010) enrolled patients of all
severities, while (Alnaji et al., 2014) included those with moderate or severe exacerbation. Although the mean age for subject recruitment
spanned zero to 17 years, the included studies report the mean ages with a range of 1.6 to 5 years of age. Alanaji et al. (2014) reports
a PRAM performed at two and three hours were the best predictors of hospital admission OR = 1.84 95% CI [1.47, 2.29], AUC = .85,
95% CI [.77, .92], and OR = 2.05 95% CI [1.57-2.68], AUC = .85, 95% CI [.79, .93], respectively. While (Gouin et al., 2010) reports a
PRAM performed at 90 minutes predicts admission PRAM - AUC = .91, 95% CI [.87, .95].

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO
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Extended ED stay. One study (n = 283) is included for this outcome. (Gouin et al., 2010) is graded as very low as it is a cohort study
and the only study measuring this outcome. The outcome reported upon is “LOS > 6 hours and or hospital admission” AUC = .69 for
PRAM conducted at the start of the ED visit and AUC = .82 when conducted at 90 minutes.
Search Strategy and Results (see PRISMA diagram, page 20)
CINAHL

S4

S1 AND S2 Limiters - Published Date: 20140101 - 20171231

S3 S1 and S2 Search modes _Boolean/Phrase
S2 (MH"Asthma+") OR "asthma" Search modes _Boolean/Phrase
S1 "PRAM' OR Pediatric Respiratory Assessment Measure" Search modes
_Boolean/Phrase
Search: ("PRAM" OR "Pediatric Respiratory Assessment Measure") AND asthma
Filters: From 2014/01/01 to 2018/12/31
Total number: 16 articles returned

PubMed

Studies Included in this Review (in Alphabetical Order)
(Alnaji et al., 2014)
(Birken, Parkin, & Macarthur, 2004)
(Chalut, Ducharme, & Davis, 2000)
(Ducharme et al., 2008)
(Gouin et al., 2010)
Studies Not Included in this Review with Exclusion Rationale (in Alphabetical Order)
Authors (YYYY)
(Alansari et al., 2015)
(Cronin et al., 2012)
(Eggink et al., 2016)
(Schuh, Willan, Stephens, Dick, &
Coates, 2009)

Reason for exclusion
Used an asthma score, did not test the asthma
score
Used an asthma score, did not test the asthma
score
Did not include all items on the PRAM score
Used an asthma score, did not test the asthma
score

Method Used for Appraisal and Synthesis
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011)a was used to synthesize the five included studies.
GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
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aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0
ed.): The Cohcrane Collaboration, 2011.

Medical Librarian Responsible for the Search Strategy
Keri Swaggart, MLIS, AHIP
EBP Scholar’s Responsible for Analyzing the Literature
Erin Lindhorst, MS, RD, LD
Teresa Bontrager, RN, BSN, MSNed, CPEN
Becky Frederick, PharmD
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
Nancy H. Allen, MS, MLS, RD, LD CPHQ
Acronyms Used in this Document
Acronym
Explanation
ASS
Asthma Severity Score
AUC
Area under the curve
BS
Bronchiolitis Score
CAES
Clinical Asthma Evaluation Score
Clinical Asthma Score
CAS
CAT
Critically Appraised Topic
CSGS
Clinical Symptom Grading System
CSS1
Clinical Scoring System 1
CSS2
Clinical Scoring System 2
EBP
Evidence Based Practice
ED
Emergency Department
PASS
Pediatric Asthma Severity Score
PEFR
Peak expiratory flow rate
PI
Pulmonary Index
PRAM
Pediatric Respiratory Assessment Measure
PS
Pulmonary Score
RDAI
Respiratory Distress Assessment Index
UCC
Urgent Care Center
Date Developed/ March 2019
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Records identified through
Database searching
(n = 16)

Additional records identified
through other sources
(n =3)
Previous CAT

Included

Eligibility

Screening

Records after duplicates removed
(n = 19)

Records screened
(n = 19)

Records excluded
(n =10)

Full-text articles assessed
for eligibility
(n = 9)

Full-text articles excluded,
with reasons
(n = 4)

Studies included in
qualitative synthesis
(systematic review)
(n = 5)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 0)
Unable to pool findings

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b
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Characteristics of Studies
Alnaji 2014
Methods

Retrospective cohort chart review

Participants

Setting: Patients presenting to pediatric Emergency Department of the Children's Hospital of Eastern Ontario
(CHEO), Ontario, Canada between February and May 2010.
Number enrolled: N = 297
Number completed: N = 297
Gender, males: n = 193 (65%)
Age, years, median [range]: 4.7 [2.8 - 7.6]
Inclusion Criteria:
•
Age 2 through 17-Patients must have received a prior diagnosis of asthma by a physician or have
three or more episodes of wheezing responsive to beta-2 agonists
•
Presented with moderate to severe acute asthma exacerbations, defined as triage PRAM score > 4
•
Patients who received intensive asthma therapy based on their presenting triage PRAM scores.
o Intensive asthma therapy defined for moderate exacerbations, PRAM 4 through 7, as three
initial salbutamol treatments via metered dose inhaler using a valved-spacer along with oral
corticosteroid administration by the triage nurse between first and second inhaled treatment
o
Intensive asthma therapy defined for severe exacerbations, PRAM 8, or greater, as three
inhaled salbutamol plus ipratropium bromide treatments via nebulization along with oral
corticosteroid administration by the triage nurse between first and second inhaled treatment.
o In all cases, oral systemic corticosteroids plus all three initial inhaled treatments were
administered within 1 hour of patient arrival at triage
Exclusion Criteria:
•
Children with PRAM scores < 4 or > 11•
Hypersensitivity to dexamethasone or oral corticosteroids
•
Chronic respiratory conditions such as bronchopulmonary dysplasia or cystic fibrosis
•
Cardiac, metabolic, or immunologic disease
•
History of adrenal suppression
•
Coexisting acute illness such as pneumonia, pertussis, or croup
•
Any use of oral corticosteroids in the past 14 days
•
Exposure to varicella in the previous three weeks in a susceptible child
•
Patients who did not receive intensive asthma therapy based on their presenting triage PRAM score

Interventions

To determine the association between asthma severity as measured by the Pediatric Respiratory Assessment
Measure (PRAM) score and the likelihood of admission for pediatric patients who present to the emergency
department with moderate-to-severe asthma exacerbations and who receive intensive asthma therapy. This
was a secondary analysis of data collected from a study examining the effectiveness of an asthma medical
directive in the ED that permitted nurses to initiate corticosteroid administration at triage.
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Outcomes

The PRAM performed at two and three hours were the best predictors of hospital admission OR = 1.84 95% CI
[1.47, 2.29], AUC = .85, 95% CI [.77, .92], and OR = 2.05 95% CI [1.57-2.68], AUC = .85, 95% CI [.79,
.93], respectively.
The PRAM at triage was the best predictor of long ED stay OR = 1.26 95% CI [1.03, 1.55], AUC = .62, 95% CI
[.52, .72]

Notes

•
•

There is a discrepancy regarding the number of participants eligible for the study. The authors report
297 patients eligible, but subtraction of those listed as excluded result in 295 eligible patients.
Note that PRAM assessments were not available for all patients every hour. For example, patients may
have been discharged within the 4-hour period of data collection.
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Birken 2004
Design
Objective of SR:
Methods

Qualitative Synthesis
Compare the measurement properties of available clinical asthma scores for children 0 – 6 years of age.
Protocol and registration Not reported
Eligibility Criteria: Searched for studies that either evaluated the properties of the score (psychometrics) or
used the score in the assessment of preschool children.
Information sources: Medline (1966 – 2002)
Search Strategy: A Medline search (1966-2002) was performed to identify all studies that described the
development or use of and asthma score for children < 6 years of age.
Study Selection Used a framework, but it is not reported. They do not report studies, but they report the
scores they evaluated. The scores are:
BS –Bronchiolitis Score
CSS1 - Clinical Scoring System 1
CAS-Clinical Asthma Score
CSS2- Clinical Scoring System 2
CAES – Clinical Asthma Evaluation PRAM – Preschool Respiratory
Score
Assessment Measure
CSGS – Clinical symptom Grading
RDAI – Respiratory Distress
System
Assessment Index
PI – Pulmonary Index
CS –Clinical Score
Data collection process: For each score, they gathered data from studies
Development studies•
Basis of item generation
•
Endorsement frequency
•
Restrictions in range
•
Item heterogeneity,
•
Item comprehension
Risk of Bias across studies Not reported
Summary measures Reliability, Validity, Responsiveness, Usability

Results

Study Selection: Neither the number of studies identified in the literature search, nor the method for study
selection were reported. They state, “
Synthesis of results
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Of the scores developed for inpatient use (CAS, CSGS, and CSS1) only the CAS reported on metrics. The CAS
showed good internal consistency, inter-rater reliability, construct validity, and responsiveness. Of the scores
developed for the ED setting, (BS, CAES, CS, CSS2, PI, PRAM, and RDAI), RDAI and PRAM had the best
measurement properties. Although RDAI had good inter-rater reliability, the PRAM showed that and construct
validity, responsiveness, criterion validity.
Additional analyses. The PRAM appears to be the score that has been extensively tested, and shows strong
psychometrics, however, results of testing are not reported.
Risk of bias across studies Not reported
Discussion

Summary of evidence
Limitations Asthma scores in general are not well tested. The major limitation is the individual studies reported
various results; could not perform a meta-analysis.
Conclusions: CAS (inpatient) and the PRAM (ED) have supporting metrics.

Funding

Funding: Not reported
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Chalut 2000
Methods
Participants

Interventions

Prospective cohort- convenience sample
All data was collected, then the results were separated into 2 groups
Participants: Children, 3-6 years
Setting: ED, presenting with acute asthma exacerbation, Montreal, Canada
Number enrolled: N = 217
• Test group - to elaborate the PRAM: n = 145
• Validation group - to test the PRAM characteristics: n = 72
Number completed: N =217
Gender, males: Percent
• Test group - 61%
• Validation group - 58%
Age, years/month Mean, [range]:
• Test: Mean = 5, [4,6]
• Validation: Mean = 5, [4,6]
Inclusion Criteria:
• < 6 years of age
• Required treatment with nebulized SABAs
• Were able to perform a predicted respiratory resistance (forced oscillation at 8 Hz) (Rfo 8) X 3 times
Exclusion Criteria:
• Severe asthma, requiring continuous SABA
• Could not tolerate the delay to perform the (Rfo8)
• Acute illness - Pneumonia, croup, varicella, pertussis,
• Chronic illness - cystic fibrosis, bronchopulmonary dysplasia, cardiac or renal disease
• Birth weight < 1500 grams
• Previous enrollment
Covariates identified:
•
Age, younger patients were more likely to be unable to perform the Rof8
All subjects received the same treatment, collection of 19 clinical signs pre and post bronchodilation,
including:
• Cough
• Grunting
• Nasal flaring
• Muscle contractions
• Scalene muscles
• Sternomastoid
• Retractions
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•
•
•
•
•
•
•
•
•
•
•
•
•
Outcomes

Notes

Supraclavicular
Suprasternal
Intercostal
Thoracoabdominal asynchrony
Wheezing
Air entry
Inspiratory/expiratory time ratio
Mental status
Heart rate
Respiratory rate
Pulsus paradoxus
Speech impairment
Oxygen saturation

Primary:
• Validate the PRAM in detecting the severity of an asthma exacerbation in preschool children
Secondary
• Establish the responsiveness to change in airway obstruction, as measure by the Rof8
Results:
In the test group, seven of the above signs explained a significant (but modest) proportion of the %
predicted Rfo8. The best multivariate model included:
• Wheezing
• Air entry
• Contraction of scalene muscles
• Suprasternal retractions
• Oxygen saturation
This model was modestly discriminative, r2 = .13, p = .5
The PRAM was able to detect a change as a result of treatment r = .58, p < .0004
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Ducharme 2008
Methods
Participants

Prospective cohort study
Participants: Children 2 to 17 years of age
Setting: Children's Hospital, Montreal, Canada
Number enrolled: N = 728 initial PRAM scores recorded, in triage
Number completed: N = 554 with a second PRAM recorded, within 60 minutes of first dose of B2-agonist
Gender, males: Percent
• Number enrolled: 63%
Age, years/month median (IQR):
• Number enrolled: 5.8 [3.5, 9.6]
Inclusion Criteria:
• Age -- 2-17 years
• Two or more wheezing episodes, responsive to B2-agonist
• Required at least one treatment with nebulized B2-agonist
Exclusion Criteria:
• Chronic lung disease, example bronchopulmonary dysplasia
• Repeat patient visits were not counted
·Covariates identified:

Interventions

Outcomes

Notes

•

Determined internal consistency of PRAM at triage, or which of the tested items contributed to the
overall PRAM score (Cronbach α)
To assess predictive validity an outcome (disposition, either hospital admission or ED discharge) was selected
and the association between admission rate and either PRAM (triage or after first treatment with
bronchodilator) was calculated using the Spearman’s rank correlation with value between age groups compared
with the Mann-Whitney U - test, and by multivariate regression.

•
•

Primary outcome: Internal consistency,
Secondary outcome(s):
o Predictive validity
o Responsiveness using disposition as the outcome
o Interrater reliability

Results:
Internal consistency -- for each of the age ranges (2 to 6 years and 7-17 years) the PRAM showed good
construct validity (Cronbach α = .71). Each of the 5 items included in PRAM contributed equally to the overall
score, with Cronbach α range [.59 .74] for both age groups
Predictive validity -- both the PRAM had strong association with hospital admission.
r = 0.4, p = .0001 triage
r = 0.5, p = .0001 after bronchodilation
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Responsiveness -- The PRAM was able to differentiate change in condition from triage to disposition. Patients
who were discharged had greater improvement in PRAM score than those admitted to the hospital
Interrater reliability -- For a sub-group of 254 patients who had data to assess interrater reliability, for all age
groups κ coefficient = 0.92, 95% CI [0.84, 1].
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Gouin 2010
Methods
Participants

Interventions

Prospective Cohort
Participants:
Setting: Pediatric ED, Canada, October 2006- October 2007
Number enrolled: N = 283
1. Length of stay > 6 hours discharged home, n = 43
2. Length of stay > 6 hours with hospital admission, n = 12
3. Length of stay < 6 hours with hospital admission, n = 24
4. Length of stay < 6 hours discharged home, n = 204
Number completed: N = 283
Gender, males:
• 63%
Age, years/month (mean):
• Mean = 3.4, 95% CI [2.2, 4.6]
Inclusion Criteria:
• 18 months to 7 years of age
• Presented with an acute asthma exacerbation, while the recruiting respiratory therapists (RT) were
present
Exclusion Criteria:
• Chronic respiratory disease such as cystic fibrosis, bronchopulmonary fibrosis etc.
• Chronic cardiac condition
• Bronchiolitis
• Pneumonia, laryngitis, whooping cough
• Patients transferred to the ED, and had been treated with SABAs
Power Analysis was performed: The AUC of PASS was used to estimate the number of subjects. PRAM was
assumed to have the same AUC. Therefore, 50 subjects in each group was necessary.

•

•
Outcomes

All patients had an assessment of clinical findings and completion of the following asthma scores by a
RT at initial assessment, and after being in the ED 90 minutes
o Preschool Respiratory Assessment Measure (PRAM)
o Pediatric Asthma Severity Score (PASS)
Scores were completed by the RT, ED provider cared for the patient without knowing the scores

Evaluated as four groups:
1. Length of stay > 6 hours without hospital admission
2. Length of stay > 6 hours with hospital admission
3. Length of stay < 6 hours with hospital admission
4. Length of stay < 6 hours without hospital admission
Primary outcome(s):
• PRAM and PASS scores of a combination of Group 1, Group 2 and Group 3
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Secondary outcome(s)
• PRAM and PASS scores of a combination of Group 2 and Group 3
Safety outcome(s): Providers estimate of severity (mild, moderate, severe, or extreme)
Notes

Results:
Primary: PRAM and PASS scores of a combination of Group 1, Group 2 and Group 3- those with extended ED
stays or hospital admission n = 79
• At study entry (0 min)
o PRAM - AUC = .69, 95% CI [.59, .79]
o PASS - AUC = .70,95% CI [06, 08]
• Reassessment (90 min)
o PRAM - AUC = .82,95% CI [.73, .90]
o PASS - AUC = .72,95% CI [.62, .82]
PRAM and PASS scores of a combination of Group 2 and Group 3 - those who were admitted n = 36
• At study entry (0 min)
o PRAM - AUC = .86, 95% CI [.8, .91]
o PASS - AUC = .86, 95% CI [.83, .89]
• Reassessment (90 min)
o PRAM - AUC = .91, 95% CI [.87, .95]
o PASS - AUC = .88, 95% CI [085. .91]
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Specific Care Question
For the child who presents to the ED with an asthma exacerbation, what is the optimal value for oxygen saturation (SpO2)?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. Various professional organizations and international guidance groups give differing levels for target SpO2 during an
asthma exacerbation. There is a difference in the value of oxygen saturation as measured by SpO2 in the governing guideline for this
update (GINA, 2016) and the value that was used in the previous Children’s Mercy Asthma CPG. Our goal is to use the safest value to
guide the treatment of a child with an asthma exacerbation.
Study Characteristics. There was no literature to review. Therefore, a search of guidelines was conducted, looking for values used for
SpO2.
Key Results. The recommendation will continue to be keep SpO2 > 90%. However, if the patient has other signs of respiratory distress,
supplemental oxygen should be continued. The decision for supplemental oxygen and hospitalization should not be made solely on
oxygen saturation but on other important factors, such as work of breathing, respiratory rate, exhaustion, anemia, etc. (NAEP-EPR-3,
2007).
EBP Scholar’s responsible for analyzing the literature
Teresa Bontrager, RN, BSN, MSNed, CPEN
Kori Hess, PharmD
Katina Rahe, RN, BSN, CPN
Robert Rhodes, MHA, RRT-NPS
EBP team member responsible for reviewing, synthesizing, and developing this document
Nancy H Allen, MS, MLS, RD, LD
Jacqueline A Bartlett, PhD, RN
Jarrod D Dusin MS, RD, LD, CNSC
Search Strategy and Results
Search: (("Bronchiolitis, Viral"[Mesh] OR "bronchiolitis"[tw] OR "Asthma" OR asthma[tw]) AND ("Oximetry"[Mesh] OR "oxygen
saturation"[tw]) AND ("Patient Admission"[Mesh] OR "Patient Discharge"[Mesh] OR "admission criteria" OR "discharge criteria")) AND
(infant OR child OR paediatr* OR pediatr* OR adolescent OR adolescence OR children) AND ("2010/01/01"[PDAT] : "2017/12/31"[PDAT])
Search performed on May 1 2017 12 results.
Studies included in this review: 0 (See Figure 1, page 32)
Studies not included in this review with exclusion rationale:
Authors
Reason for exclusion
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Mansbach et al., (2015)
Mayfield, Bogossian, O'Malley, & Schibler,
(2014)
Mayor, (2016)
Yusuf, Caviness, & Adekunle-Ojo, (2012)

Does not answer the question
Does not answer the question
Does not answer the question
Does not answer the question

Guidelines Reviewed
Location
British Thoracic Society/ Scottish (British guideline on the management of asthma,
2014)
https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-themanagement-of-asthma/
Colorado Children’s Hospital- (Federico et al., 2016)
https://www.ihconline.org/media/cms/Childrens_Hospital_Colorado_asthmac_147F03BB6763A.pdf
Children’s Hospital of Philadelphia (Zorc et al., 2016)
http://www.chop.edu/clinical-pathway/asthma-emergent-care-clinical-pathway
CHOP uses ESI Triage for designating severity of exacerbation
Also Pulse Oximetry >/= 95% is ESI 4, Pulse Oximetry < 92% is Urgent, and Pulse Oximetry
<90% is Critical
GINA – (Global Initiative for Asthma)- http://ginasthma.org/ (GINA, 2016)
National Hospital Medical Care Survey (Rui, Kang, & Albert, 2013)
https://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2013_ed_web_tables.pdf
Seattle Children’s Asthma Pathway (Atkins et al., 2015)
US (EPR-3, 2007)- https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines

Guidance
Children with life-threatening
asthma or SpO2 < 94% should
receive high flow oxygen via a
tight-fitting face mask or nasal
cannula at sufficient flow rates
to achieve normal saturation
of 94-98%.
Start supplemental oxygen for
any child whose oxygen
saturation is less than 90%
Maintain oxygen saturation >
90% using nasal cannula or
facemask
Target SpO2- 93% to 95%
Normal is > 95% by pulse
oximetry
Supplemental O2 should be
administered to keep O2
saturation > 90%
Algorithm states Oxygen to
achieve SaO2 >/= 90%

Method Used for Appraisal and Synthesis
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the XXX included studies.
GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0
ed.): The Cohcrane Collaboration, 2011.
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Acronyms Used in this Document
Acronym
Explanation
CHOP
Children’s Hospital of Philadelphia
ED
ESI
GINA
SaO2

Emergency Department
Emergency Severity Index
Global Initiative for Asthma
Oxygen saturation of arterial blood

SpO2

Pulse oximeter oxygen saturation

Date Developed/Updated: March 2018
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Records identified through
database searching
(n = 12)

Additional records identified
through other sources
(n =6 Guidelines)

Eligibility

Screening

Records after duplicates removed
(n = 18)

Records screened
(n = 18)

Records excluded
(n = 8)

Full-text articles assessed
for eligibility
(n = 10)

Full-text articles excluded,
with reasons
(n = 4)

Included

Studies included in
qualitative synthesis
(n = 0)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 0)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Question 3 – Specific Care Question: Albuterol, MDI versus Nebulizer
Specific Care Question
For the patient who presents to the ED/UCC with a mild to moderate asthma exacerbation, are metered-dose inhalers (MDI)
comparable to nebulizer mask treatment for the provision of albuterol?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. In an asthma attack, the airways, or the small tubes in the lungs, get narrow and swell. Chest tightness, coughing, and
wheezing are usually present as well. This makes the patient feel “short of breath” (DynaMed Plus,2018). Patients inhale or breathe in
medications to stop asthma symptoms during an asthma attack. Metered-dose inhaler (MDI) is one method to deliver the medication,
and using a nebulizer is the other way to give the medicine. Literature was reviewed to see which method was better was better in
delivering medications when a patient came to the Emergency Department or Urgent Care Center for an asthma exacerbation.
Study Characteristics. The search for suitable studies was completed Sept 5, 2017. Drs. Walsh and Michael reviewed the 86 titles
and abstracts found in the search. Seven studies were identified that compared the two methods. Overall the studies were of very low
quality (see Figure 2). It appears the methods are comparable when treating patients with mild to moderate asthma attacks when
measuring how quickly the patient's breathing (respiratory rate) returns to normal and the asthma score shows improvement. The
methods used to perform the included studies could have been stronger. For example, in 2/3rds of the studies, neither subjects nor
researchers were blinded to the treatment delivered to the subject. Also, the asthma score used to determine the severity of the
asthma attack were not the same.
Key results. Based on low to very low evidence published since the parent guideline (GINA, 2016) the Asthma ED CPG team makes a
strong recommendation to use an MDI with spacer (add a mask in children < 4 years old) be used preferentially for mild to moderate
asthma exacerbations in the ED/UCC. There was no difference in the number of patients admitted to the hospital when either method
is used, which means that either therapy is appropriate. Using an MDI did not cause any adverse effects.
Summary by Outcome
Hospitalization. Based on six randomized control trials (Dhuper et al., 2011; Jamalvi, Raza, Naz, Shamim, & Jamalvi, 2006;
Mitselou, Hedlin, & Hederos, 2016; Rotta, Amantea, Froehlich, & Becker, 2010; Schuh et al., 1999; Vangveeravong, 2008) that
compared albuterol given as 4-10 100 mcg/puff MDI with spacer to albuterol given 15 mg/hour continuously by nebulization there
was no difference in number of subjects admitted to the hospital, OR = .80, 95% CI [0.44, 1.46] (see Table 1 and Figure 3). The
included studies had a total of 478 subjects. The studies are graded as very low-quality evidence due to (a) lack of blinding in the
RCTs, two of the studies are non-randomized studies, and one is a cross-sectional study (See Figure 2); (b) inconsistency in the
equipment used to deliver the medication; and (c) there was a low number of admissions.
Respiratory Rate. Based on two randomized control trials (Deerojanawong et al., 2005; Jamalvi et al., 2006) that compared
albuterol given as 4-10 100 mcg/puff MDI with spacer to albuterol given 15 mg/hour continuously by nebulization there was no
difference in the respiratory rate of subjects one hour after treatment, Mean difference = 0.98, 95% CI [-4.01, 20.4] (see Table 1
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and Figure 4).The included studies had a total of 197 subjects. The studies are graded as low very low-quality evidence due to (a)
lack of blinding, it is not clear how blinding was attained, and one study is a non-randomized cross-sectional study (see Figure 2);
(b) inconsistency in the equipment used to deliver the medication; and (c) the confidence interval is wide, and the mean difference
is less than one breath per minute.
Asthma Score. Based on three randomized control trials (Deerojanawong et al., 2005; Jamalvi et al., 2006; Vangveeravong,
2008) that compared albuterol given as 4-10 100 mcg/puff MDI with spacer to albuterol given 15 mg/hour continuously by
nebulization there was no difference in the asthma score one hour after treatment. The mean asthma score after one hour of
treatment was 3.9 points, and those treated with MDI and spacer had an asthma score that was 0.07 points lower, with a range of
0.4 points lower to 0.26 points higher, Mean Difference = -0.07, 95% CI [-0.40, 0.26] (see Table 1 and Figure 5). The included
studies had a total of 233 subjects. The studies are graded as very low quality due to (a) lack of blinding, it is not clear how
blinding was attained, and one study is a non-randomized cross-sectional study (see Figure 2); (b) various asthma scores were
utilized in the studies; and (c) the mean difference in the asthma scores is less than one point.

Search Strategy and Results:
Search: (("status asthmaticus") OR (("Asthma"[Mesh] OR asthma[tw]) AND ("accident and emergency" OR "A and E" OR "Emergency
Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical Services"[Mesh] OR "Emergency Medicine"[Mesh] OR
"emergency department"[tw]))) AND (("administration and dosage" [Subheading] OR "Administration, Inhalation"[Mesh] OR "Nebulizers
and Vaporizers"[Mesh] OR "Metered Dose Inhalers"[Mesh] OR dose[tw] OR dosing[tw]) AND ("Albuterol"[Mesh] OR albuterol[tw] OR
levalbuterol[tw] OR SABAs[tw] OR "Adrenergic beta-2 Receptor Agonists"[Mesh] OR "Short-acting beta-agonists" OR "adrenergic β2
receptor agonists")) AND (infant OR child OR paediatr* OR pediatr* OR adolescence OR children OR childhood) AND ("2010/01/01"[PDAT]:
"2017/12/31"[PDAT]) 86 results, ten were selected for inclusion by the team leaders. Five articles from the previous CAT are included
(see Figure 1).
Studies included in this review:
Mitselou, Hedlin, & Hederos (2016)
Dhuper et al., (2011)
Deerojanawong et al., (2005)
Jamalvi, Raza, Naz, Shamim, & Jamalvi, (2006)
Rotta, Amantea, Froehlich, & Becker, (2010)
Schuh et al., (1999)
Vangveeravong, (2008)
Studies not included in this review with exclusion rationale:
Authors

Reason for exclusion
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Pardue Jones, Fleming,
Otillio, Asokan, & Arnold,
(2016)
Mecklin, Paassilta, &
Korppi, (2012)
Fagbuyi et al., (2016)
Wisecup, Eades, Hashmi,
Samuels, & Mosquera,
(2015)
Phumeetham, Bahk, AbdAllah, & Mathur, (2015)
Kenyon et al., (2014)
Sarnaik et al., (2013)
Wilkinson et al., (2017)

Narrative review
Does not answer the question
Outcome: hourly diastolic blood pressure; does not answer the question
Outcome: hourly diastolic blood pressure; does not answer the question
Outcome: hourly diastolic blood pressure; does not answer the question
Outcome: clinical deterioration; does not answer the question
Outcome: hourly diastolic blood pressure; does not answer the question
Does not compare MDI to nebulizer

EBP Scholar’s responsible for analyzing the literature:
Jennifer Foley, RT(R)(N), CNMT
Jena Servatius, BS, RDMS, CPST
EBP team member responsible for reviewing, synthesizing, and developing this document:
Nancy H. Allen, MS, MLS, RD, LD
Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the XXX included
studies. GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0
ed.): The Cohcrane Collaboration, 2011.

Date Developed/Updated: December 2017
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Identification
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Records identified through
Database searching
(n = 86 )

Additional records identified
through other sources
(n = 5) from the previous CAT

Eligibility

Screening

Records after duplicates removed
(n = 91)

Records screened
(n = 91)

Records excluded
(n = 76)

Full-text articles assessed
for eligibility
(n = 15)

Full-text articles excluded,
with reasons
(n = 8)

Included

Studies included in
quantitative synthesis
(meta-analysis)
(n = 7)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) b
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Figure 2. Risk of Bias Summary
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Figure 3. MDI versus Nebulizer, Outcome: Hospitalization

Figure 4. MDI versus Nebulizer, Outcome: Respiratory Rate
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Figure 5. MDI versus Nebulizer, Outcome: Asthma Score
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Table 1

Summary of Findings Table
Albuterol administered by MDI and spacer versus NEB for children 6 years and older with a severe asthma exacerbation in the ED
Certainty assessment
№ of
Risk of
participants bias
(studies)
Follow-up

Summary of findings

Inconsistency Indirectness Imprecision Publication Overall
Study event rates
bias
certainty (%)
of
With
evidence With 4-

10 puff
100
mcg/puff
[MDI and
spacer]
repeat
every 20
minutes
of 1
hours

albuterol
15
mg/hour
NEB

31/261
(11.9%)

31/217
(14.3%)

Relative Anticipated absolute
effect
effects
(95%
Risk with Risk
CI)

4-10 puff
100
mcg/puff
[MDI and
spacer]
repeat
every 20
minutes
of 1
hours

difference
with
albuterol
15
mg/hour
NEB

119 per
1,000

21 fewer
per 1,000
(63 fewer
to 46
more)

Hospitalization
478
(6 RCTs)

serious not serious
a

serious

b

serious

c

none

⨁◯◯◯
VERY
LOW

OR
0.80
(0.44
to
1.46)
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Respiratory Rate
197
(2 RCTs)

serious not serious

not serious

serious

e

none

d

⨁⨁◯◯
LOW

108

89

⨁◯◯◯
VERY
LOW

126

107

-

The mean
respiratory
Rate was
37.3
breaths
per
minute

MD 0.98
breaths
per
minute
lower
(4.01
lower to
2.04
higher)

The mean
asthma
Score was
3.9 points

MD 0.07
points
lower
(0.4
lower to
0.26
higher)

Asthma Score
233
(3 RCTs)

serious
d

not serious

serious

f

serious

g

none

-

CI: Confidence interval; OR: Odds ratio; MD: Mean difference
Explanations
a. Lack of blinding of patients, personnel, or outcome assessors occurred in 67% of the included studies. Two of the included studies are nonrandomized studies, a prospective cohort study and a cross-sectional study.
b. The equipment used varied across studies. Some MDIs used spacers, and other used did not. Some of the spacers were specific products,
"nebunnett”, or ‘Easyhaler’, etc. Nebulized albuterol was administered by mouthpiece, or mask in the included studies.
c. There is a low number of events. The confidence intervals of the included studies are wide.
d. It is not clear how the included studies randomized study participant or if allocation to study groups was concealed. Jamalvi et al. (2006) is
a non-randomized, cross sectional study.
e. Confidence interval is wide, and the mean difference is less than one breath per minute.
f. Various asthma scores were employed in the included studies.
g. Confidence intervals of the included studies are wide. The difference in the scores is less than one.
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Study Characteristics
Deerojanawong 2005
Methods
Participants

Interventions

Outcomes
Notes

Randomized Control Trial
Children up to 5 years of age. 47 children
Group 1: Two puffs placebo via MDI with spacer followed by .15 mg/kg salbutamol respiratory via jet
nebulizer,
N = 23
Group 2: Two puffs (100 micrograms per puff) of salbutamol via MDI spacer followed by placebo via jet
nebulizer,
N = 24
Medication was actuated into the spacer 30 seconds apart. 5 tidal breaths were allowed after each actuation.
All patients received 50 mg/kg of chloral hydrate 30 minutes prior to the study.
30 minutes after the assigned aerosol treatment, pulmonary function tests were completed.
•
•
•

Clinical scores
Tidal breathing pulmonary function test
Vital signs

Thailand. Nebulizer takes longer and is more expensive

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Probably, but does not give details

Allocation concealment
(selection bias)

Unclear risk

Probably, but does not give details

Blinding of participants and
personnel (performance
bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

Low risk

Power calculation performed on airway resistance as the outcome. The calculated sample size
was 21 per group.
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Dhuper 2008
Methods
Participants

Randomized Control Trial
Setting: Two emergency departments, New York, USA 2004-2005. Data was collected from August 2004August 2005
Randomized into study: N = 60
• Group 1 LiteAire: n = 30
• Group 2 Nebulizer: n = 30
Completed Study: N= 58
• Group 1 LiteAire: n = 29
• Group 2 Nebulizer: n = 29
Gender, males:
• Group 1 LiteAire: n = 5 (17%)
• Group 2 Nebulizer: n = 12 (41%)
Age: ALL ADULTS
Inclusion Criteria:
• Diagnosis of asthma
• Age 18–70 years
• Ability to perform peak flow maneuvers with good effort
Exclusion Criteria:
• Requiring intubation and mechanical ventilation,
• Smoking history 20 pack years,
• The presence of coexistent systemic diseases such as congestive heart failure, pulmonary disease
other than asthma such as pneumonia, tuberculosis, bronchiectasis, interstitial lung disease,
sarcoidosis, pleural diseases, kyphoscoliosis, chronic obstructive pulmonary disease, renal failure, or
cancer.
Power Analysis:
•
The authors did not disclose a specific power value, but discussed how the sample size was projected

Interventions

•

Group 1 (LiteAire): The MDI/spacer group received 540 micrograms of chloroflourocarbon (CFC)
albuterol by MDI (six actuations of 90 micrograms/actuation; Warwick Pharmaceutical Corporation,
Reno, NV) with the spacer followed by 3 mL of normal saline solution (0.9%) by nebulizer every hour
until disposition.
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•

Group 2 (Nebulizer): The Nebulizer group received six actuations of placebo MDI with spacer
followed by 2.5 mg (3 cc) albuterol (Dey, Napa, CA) by nebulizer (Cardinal Health Edison, NJ) on a
similar schedule.
Technique:
• MDI was shaken before each actuation and medication was administered one actuation at a time into
the spacer
• Each actuation was delivered just before inhalation and the aerosol was inhaled from the spacer by six
tidal breaths
• All MDI/spacer treatments were self-administered by the patient after a one-time demonstration of its
use by a respiratory therapist (RT)
• All nebulizer treatments were administered by a RT in the asthma treatment room in the ED
• The Respiratory Therapist documented in the electronic medical chart the vital signs, room air oxygen
saturation, lung examination, and a pre- and post-treatment peak flow rate for every treatment
administered
Outcomes

Notes

Primary outcome(s):
• Changes in patients’ symptoms
• Peak flow rates,
• Disposition (admission to hospital or discharge to home from the ED)
Secondary outcome(s)
• Length of stay in the ED
• Cost of therapy
• Number of rescue treatments required
•
•
•

Median and interquartile range values were reported
Medians (IQR) for increase in peak flow from entry to disposition were similar for the two groups, with
120 (75–180) L/minute for the MDI/spacer group and 120 (80 – 155) L/minute for the Nebulizer group
(p = .56)
The median length of ED stay was 2 h for both groups, with an IQR of 1.5–3.0 hour for the MDI/spacer
group and an IQR of 1–2.5 hours for the Nebulizer group (p =.78)

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Randomization table

Allocation concealment
(selection bias)

Low risk

Randomization codes were selected by a pharmacist who was not involved in the study
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Blinding of participants and
personnel (performance
bias)

Low risk

Only the pharmacist knew the study codes. All personnel involved in patient recruitment and
medication delivery were blinded to the randomization

Blinding of outcome
assessment (detection bias)

Low risk

Placebo MDIs were prepared by a pharmacist who was not involved in the study or in the
assignment of randomization codes

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

Low risk

Other bias

Unclear risk

median and interquartile range values were reported.
The study was funded by a grant from the manufacturer of the LiteAire device
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Jamalvi 2006
Methods
Participants
Interventions

Outcomes

Notes

Cross-sectional study
150 children > 6 months
Group A: standard dose of beta agonist (salbutamol) by MDI/accessory device (100 microgram/puff) 2 puffs
three times per hour at 20-minute intervals with the help of a one way valve accessory device. Two types of
spacers, a mouthpiece spacer for older children and a babyhaler with mask for younger children. (N= 84)
Group B: standard dose of beta agonist (salbutamol) by small volume nebulizer (0.3 mg/kg/ salbutamol
solution) Salbutamol solution with 2 ml Normal Saline in one hour with 20 minutes interval with the help of
New Nebulizer type 3 Nuova S.P.A. Bresia, Italy (N= 66)
•
•
•

Clinical exam
Peak Expiratory Flow Rate (PEFR)
Assessment at 10, 20 minutes, and 2 hours, after completion of treatment

3 drop outs- no indication of which group they came from

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Did not describe

Allocation concealment
(selection bias)

Unclear risk

Did not describe

Blinding of participants and
personnel (performance
bias)

Unclear risk

Blinding of outcome
assessment (detection bias)

Unclear risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

High risk

Other bias

Low risk

No indication from which group the dropout came from
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Mitselou 2016
Methods
Participants

Interventions

Outcomes

Prospective study
Setting: Pediatric emergency department at Central Hospital, Karlstad, Sweden
Randomized into study: N = 98
• Group 1: Nebulizer: beta-2-agonist salbutamol (Ventoline 5 mg/ml) 4ml n = 53
• Group 2: Spacer: salbutamol MDI (Airomir 100ug/puff) with spacer (nebunette) n=45
Completed Study: N = 98
• Group 1: 53
• Group 2: 45
Gender, males:
• Group 1: 34 (64.2%)
• Group 2: 33 (73.3%)
Age, months: Mean +/- (SD)
• Group 1: 23.36 (15.77)
• Group 2: 22.71 (11.85)
Inclusion Criteria:
• 0-6 y/o
• Presented with virus infection associated with wheezing or acute exacerbation of asthma to ED
Exclusion Criteria:
• Symptoms consistent with pseudocroup
• Clinically suspected or lab confirmed RSV
• Multi-handicapped pts
• Life threatening asthma exacerbation
• Signs of impending respiratory failure
Power Analysis: Based on finding a 25% difference in hospitalization rate, the power estimation found that
80% power with 95% significance is 49 subjects were in each group.
Group 1: Nebulizer: beta-2-agonist salbutamol (Ventoline 5 mg/ml) 4ml
• <35kg: continuous nebulization for one minute
• >35kg: continuous nebulization for two minutes
Group 2: Spacer: salbutamol MDI (Airomir 100ug/puff) with spacer (nebunette)
• <2y/o: 4 puffs (10 breathes/puff)
• >2 y/o: 6 puffs (5 breathes/puff)
Treatment could be repeated up to 3x for first hour (20-30min intervals) in both groups.
Primary outcomes:
• Length of stay in PED-similar
• Admission rate-similar
• Parents experience-no significant difference
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Notes

•
•

Family history of asthma and atopic diagnosis was greater in nebulizer group.
Comparison of who had asthma medication versus who parents described as having asthma was not
similar-parental report may lead to underestimation of asthma prevalence.

Risk of bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Concealed in respective envelopes mixed in a box containing the same number of envelopes.

Allocation concealment
(selection bias)

Low risk

Doctor picked new envelope from box in a blind manner.

Blinding of participants and
personnel (performance
bias)

Low risk

No blinding but not likely to be influenced

Blinding of outcome
assessment (detection bias)

Low risk

Assessors were blinded

Incomplete outcome data
(attrition bias)

Low risk

No missing data

Selective reporting
(reporting bias)

Low risk

Outcomes were reported upon, but difficult to locate them in the paper

Other bias

Unclear risk

Appears free of other bias
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Rotta 2010
Methods
Participants

Randomized Control Trial
Children 1-5 years of age with the diagnosis of acute asthma in the ED

Interventions

Experimental: salbutamol MDI with spacer 50 microgram per kilo, 1 puff for every 2 kg of body weight. Each
dose was administered 3 times in a one-hour period.
Control: salbutamol nebulizer 150 microgram per kilo. Each dose was administered 3 times in a one-hour
period.
each patient received 1 mg/kg/ prednisone after the first treatment
one blood sample drawn for plasma concentration of salbutamol drawn 10 minutes after third treatment

Outcomes

Plasma salbutamol concentration < 2 years and > 2 years reported as median and interquartile range- cannot
use.
need for hospitalization

Notes

Brazil
Exclusion criteria O2 sat < 90% on ambient air, fever > 38 degrees C., signs of cardiac instability, use of beta
agonist in 12 prior to ED visit.

Risk of bias table
Bias
Random sequence
generation (selection bias)
Allocation concealment
(selection bias)

Scholars'
judgment
Unclear risk
Low risk

Support for judgment
Computer generated, blocks of five, children were "selected by the clinical staff" not certain
what this means
Medication prepared independent from the care team.

Blinding of participants and
personnel (performance
bias)

Unclear risk

Not described

Blinding of outcome
assessment (detection bias)

Unclear risk

Not described

Incomplete outcome data
(attrition bias)

Unclear risk

Used a pilot study to determine sample size, 46 patients, and 23 in each group.

Selective reporting
(reporting bias)

Low risk

Other bias

Low risk
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Schuh 1999
Methods
Participants
Interventions

Outcomes
Notes

Randomized Control Trial
90 children between 5 and 17 years of age, % predicted FEV1 between 50-79%.
High MDI group 4-8 puffs of albuterol via MDI number of puffs based on weight: < 25 kg 4 puffs, 25-34 kg 6
puffs and > 35 kg 8 puffs
Low MDI group 2 puffs albuterol regardless of weight
Nebulizer 0.15 mg/kg albuterol (maximum 5 mg) by jet nebulizer.
Primary outcome: % predicted FEV1. Secondary outcomes respiratory rate, heart rate, room air oxygen
saturation, and accessory muscle score, wheezing score and dyspnea score.
Exclusion criteria- In the ED in the 2.5-year time frame, 6000 potential subjects were treated. Exclusion
criteria- < 5 years of age, able to perform spirometry, FEV1 < 50% or greater than 80% predicted, first
wheezing or bronchodilator treatment, use albuterol within the previous 4 hours, associated medical problem,
language barriers, refusal to participate, arrived at the ED outside 0800-2200 when study nurses were
available.

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Randomized in the pharmacy using a block randomization schedule and random numbers.

Allocation concealment
(selection bias)

Low risk

Randomization occurred in the pharmacy, and study drug came up with identical labels

Blinding of participants and
personnel (performance
bias)

Low risk

Only the pharmacy knew the treatments

Blinding of outcome
assessment (detection bias)

Low risk

Only the pharmacy knew the treatments

Low risk

Intent to treat analysis was used. There was a protocol violation. Sixteen subjects received
albuterol within 4 hours of being enrolled. High Dose group- 6 subjects, low dose group- 2
subjects and nebulizer group-8 subjects.

Selective reporting
(reporting bias)

Low risk

All outcomes reported upon

Other bias

Low risk

None identified

Incomplete outcome data
(attrition bias)
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Vangveeravong 2008
Methods
Participants
Interventions

Outcomes

Randomized Control Trial multicenter- 7 study sites, in Thailand
children 5-18 years of age mild to moderate asthma
Group 1: Nebulizer 0.5% Ventolin respiratory solution 0.03 ml/kg/dose (maximum dose 1 ml) diluted with
NSS to 3 ml, delivered via an oxygen-driven flow 6-8 liters per minute.
Group 2: MDI with volumatic spacer MDI spacer, using 6 puffs of Ventolin evohaler (100mg/puff) delivered
via volumatic spacer 2 puffs at a time for 3 times.
Group 3 DPI Easyhaler- DPI (Easyhaler) using 6 puffs of Buventol Easyhaler (100 mg/puff), 1 puff at a time
for 6 times.
3 actuations in an hour
Asthma score, Oxygen saturation, vital signs, side effects (tremor, palpitations).
Improvement defined at clinical score reduces < 50% form baseline, or clinical score < 3, or a total of 3
treatments. If subjects failed 3 treatments, they were admitted.

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Not described

Allocation concealment
(selection bias)

Unclear risk

Not described

Blinding of participants and
personnel (performance
bias)

Unclear risk

Not described

Blinding of outcome
assessment (detection bias)

Unclear risk

Not described

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

Low risk

Other bias

Low risk
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Question 4 – Optimal Dose Glucocorticosteroids
Specific Care Question:
For the child who presents with mild, moderate, or severe asthma symptoms to the Emergency Department (ED) or Urgent Care
Center (UCC) what is the optimal dose (including maximum dose) of glucocorticosteroids to improve asthma symptoms, reduce
admission to the hospital, and decrease length of stay in the ED/UCC?
Question Originator:
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. There is a difference in the maximum dose of steroid medications in the parent guideline (GINA, 2018) for this update
and the maximum dose that was used in the previous CM Asthma CPG (2011). To make sure the dose we use for this update is
correct, we conducted a search for studies on this topic, looking for maximum steroid doses. The Global Strategy of Asthma
Management and Prevention (2016) was selected as the parent guideline for this CPG. For asthma exacerbation in children they
recommend the following maximum doses of CS:
Age
5 years
and
younger

Severity
Severe or
life
threatening
Mild or
moderate

5-12
years
> 12
years

All
severities
All
severities

Medication and Dose
Prednisolone 2 mg/kg (max 20
mg for < 2 years; max 30 mg for
2-5 years)
Prednisolone 2 mg/kg (max 20
mg for < 2 years; max 30 mg for
2-5 years)- After up to 2 hours
after SABA administration, and
still requiring treatment.
1-2 mg/kg (max 40 mg)
1 mg/kg (max 50 mg)

However, the previous US National Guideline (NAEP-EPR-3, 2007) and Lexi-Comp (Lexicomp Online 2017) give the following
recommendation for CS in asthma exacerbation, and they reference each other for the dosing recommendation:
Age
Children
< 12
All > 12
years

Medication and Dose
1-2 mg/kg in 2 divided doses (maximum 60 mg/d)
40-80 mg/d in one or 2 divided doses

Study Characteristics. A literature search was conducted 4/19/2019. Irene Walsh MD and Erin Scott, DO reviewed the 80 studies to
assess if there was research on the optimal maximum dose of CS for children and adolescents who present to the ED/UCC. Eighteen
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were read closely to determine if maximum dose of CS was reported. Additionally, eighteen unique studies from a recent systematic
review/meta-analysis (Normansell, Kew, & Mansour, 2016) on CS use in asthma exacerbation were appraised for CS maximum
dosing. In all, three studies reported on maximum dose, and the maximum dose ranged from 50-60 mg. (Bhogal et al., 2012; Davis,
Burke, Hogan, & Smith, 2012; Krebs, Flood, Peter, & Gerard, 2013). However, none of these studies were specifically looking for an
optimal dose.
Key Results:
Based on high quality evidence, the GINA (2018) guideline, the Asthma in the ED/UCC Team makes a strong recommendation to keep
prednisone/prednisolone dosing at 2 mg/kg for all three levels of asthma exacerbations. For children with mild exacerbations that do
not respond to initial therapy, a strong recommendation is made to consider CS administration (GINA, 2018). Based on low quality of
the Asthma in the ED/UCC Team makes a recommendation for maximum dose of prednisone/prednisolone of 60 mg/d (see Table 1
for dose ranges) (Qureshi et al., 2001).
For dexamethasone, there is no established lowest effective dose; the duration and number of doses is also not known. See Table 1
for the doses used across trials that studied dexamethasone in pediatric asthma exacerbations. Dexamethasone doses ranged from
0.15 to 1.7 mg/kg, maximum dose ranged from 10-36 mg/d and number of doses ranged from one to two days. The Asthma in the
ED/UCC Team recommends 0.6 mg/kg/d of dexamethasone (Altamimi et al., 2006; Ducharme et al., 2015; Gordon et al., 2007;
Greenberg et al., 2008; Qureshi et al., 2001). A maximum dexamethasone dose of 12 mg/day times 1-2 doses is recommended by
the Asthma in the ED CPG Team (Cronin et al., 2016). These dose recommendations agree with the U.S. National Asthma Guideline
(NAEP-EPR-3, 2007) and Lexi-Comp, a drug information database (Lexicomp Online 2017).
No studies assessing optimal dosing of CS were identified, therefore a meta-analysis for prednisone/prednisolone or dexamethasone
dosing could not be performed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, BSN, MSNed, CPEN
Jennifer Foley, RT(R)(N), CNMT
Kori Hess, PharmD
Kelly Huntington, RN, BSN, CPN
David Keeler, RN, BSN, CPN
Erin Lindhorst, MS, RD, LD
Helen Murphy, BHS RRT AE-C
Katina Rahe, RN, BSN, CPN
Robert Rhodes, MHA, RRT-NPS
Hope Scott, RN CPEN
EBP team member responsible for reviewing, synthesizing, and developing this literature:
Nancy H Allen, MS, MLS, RD, LD
Jacqueline A Bartlett, PhD, RN
Jarrod D Dusin MS, RD, LD, CNSC
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Search Strategy and Results:
PubMed
Search: ((("Asthma" OR asthma[tw]) AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical
Services"[Mesh] OR "Emergency Medicine"[Mesh] OR "emergency department"[tw] OR "Acute Disease"[Mesh] OR exacerbation[tw] OR
attack[tw])) AND (("Dexamethasone"[Mesh] OR "Dexamethasone Isonicotinate"[Mesh] OR "Methylprednisolone"[Mesh] OR
"Methylprednisolone Hemisuccinate"[Mesh] OR "Prednisolone"[Mesh] OR "Prednisone"[Mesh] OR corticosteroid[tw] OR
“pregnadienediols”[Mesh] OR “pregnadienetriols"[Mesh]) AND ("Injections, Intramuscular"[Mesh] OR "Administration, Oral"[Mesh] OR
"Infusions, Intravenous"[Mesh] OR "Injections, Intravenous"[Mesh] OR "administration and dosage "[Subheading]))) AND (MetaAnalysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Guideline[ptyp] OR Comparative Study[ptyp] OR
"Cohort Studies"[Mesh] OR systematic[sb]) AND (infant OR child OR paediatr* OR pediatr* OR adolescent OR adolescence OR children)
AND ("2010/01/01"[PDAT] : "2017/12/31"[PDAT]) (80 results)
Studies included in this review: 9
Arulparithi et al. (2015)
Bhogal et al. (2012)
Cronin et al. 2012)
Davis, Burke, Hogan, & Smith, (2012)
Krebs, Flood, Peter, & Gerard, (2013)
Normansell, Kew, & Mansour, (2016)
Keskin et al. (2016)
Wyatt, Borland, Doyle, & Geelhoed, (2015)
Zemek et al. (2012)
Studies not included in this review with rationale for exclusion: 10
Author/Year
Reason for Exclusion
Andrews, Wong,
This is a cost study
Heine, & Scott
Russell, (2012)
Chen et al., (2013) This is an inhaled corticosteroid study; oral corticosteroids were given
as a rescue treatment
Ducharme et al.
This is a protocol only- results have not been published
(2014)
Edmonds, Milan,
This does not answer the question. It evaluates inhaled corticosteroids
Brenner, Camargo,
& Rowe, (2012)
Fernandes et al.,
This does not give dosing information
(2014)
Knapp, Hall, &
This does not give dosing information
Sharma, (2010)
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Meyer, Riese, &
Biondi, (2014)
Visitsunthorn,
Lilitwat,
Jirapongsananuruk,
& Vichyanond,
(2013)
Vuillermin et al.
(2010)
Williams, Andrews,
Heine, Russell, &
Titus, (2013)

This is a systematic review
This does not give dosing information

Does not answer the question, pertains to parent-initiated
corticosteroids
This does not answer the question. It is a CS duration study

Acronyms Used in this Document:
Acronym
CPG
CSED/UCC
EPR-3(NAEPEPR-3,
2007)
GINA
SABA-

Explanation
Clinical Practice Guideline
Corticosteroids
Emergency Department/ Urgent Care Center
Expert Panel Report 3: Guidelines for the Diagnosis and Management of
Asthma
Global Strategy of Asthma Management and Prevention, 2018
Short acting beta-agonist such as albuterol

Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (RevMan 5.3.5), was used to assess the bias? of the nine included
studies.
Updated: July 2017; August 2017
Characteristics of included studies:
Arulparithi et al., 2015
Methods

Participants

Randomized double-blind placebo-controlled trial
Setting: Pediatric ED in South India from May 2008 to November 2010
Randomized into study: N = 61
• Group 1- (beclomethasone): n = 30
• Group 2- (oral steroids): n = 31
Completed Study: N=61
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•
•

Group 1- (beclomethasone): n = 30
Group 2- (oral steroids): n = 31
Gender %Male:
•
Group 1 (beclomethasone) :57% (17/30)
•
Group 2 (oral steroids): 48% (15/31)
Age, years (mean):
• Group 1- 7.8 (1.93)
• Group 2- 7.14 (1.93)
Inclusion Criteria:
• Children ages 5-12 years presenting with acute asthma exacerbation
Exclusion Criteria:
• First wheezing episode
• Life threatening asthma
• Received oral steroids in last 7 days
• Children on high dose inhaled corticosteroid (ICS)
o 1000mcg or more of beclomethasone or budesonide per day or 500mcg or more of
fluticasone per day)
• Concurrent cardiopulmonary disease
• Immunodeficiency
• Diabetes
• Allergy to corticosteroids
• Exposure to varicella in previous 21 days
Power Analysis: not given

Interventions

Outcomes

Group 1:
• Three doses of salbutamol (0.15 mg/kg) and 800mcg budesonide mixed in same nebulizer chamber
at intervals of 20 minutes
• Single dose of placebo tablets
Group 2:
• Three doses of salbutamol (0.15 mg/kg) along with placebo solution mixed together in same
nebulizer chamber at intervals of 20 minutes
• Single dose of oral steroids (2mg/kg)
Both groups:
• Assessed every 20 minutes for up to one hour with vital signs (HR, RR, o2 sat)
• Peak flow done at one and four hours
• Fitness for discharge assessed at the end of 2 hours using clinical severity score
o Score of 0 or 1 for HR, RR, dyspnea, accessory muscle use, wheezing
Primary:
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•

Notes

Efficacy of nebulized budesonide in treatment of acute asthma
o vital signs
o fitness for discharge

Both physicians and patients were blinded to treatment.

Risk of bias table
Bias

Scholars'
judgment

Random sequence generation
(selection bias)

Low risk

Computer generation

Allocation concealment
(selection bias)

Low risk

Opaque sealed envelopes used

Support for judgment

Blinding of participants and
personnel (performance bias)

Unclear risk

Patients and clinicians were blinded regarding drugs

Blinding of outcome
assessment (detection bias)

Unclear risk

Not mentioned

Incomplete outcome data
(attrition bias)

Unclear risk

Intention to treat

Selective reporting (reporting
bias)
Other bias

Low risk

All outcomes reported

High risk

Small sample size
Power analysis was not performed

Bhogal et al., 2012
Methods
Participants

Cohort study
Participants: Children (2-17 years) presenting to the ED with and asthma exacerbation between
September-December 2006 (N=406)
Setting: Montreal Children's Hospital
Number complete: 406 patients
% male: 63%
Inclusion criteria: 2 to 17 years, with a diagnosis of an acute exacerbation treated with 1 or more
albuterol nebulizations in the ED, had moderate or severe obstruction as documented by a baseline PRAM
score of 5-12
Exclusions: Chronic illness (i.e. cystic fibrosis, bronchopulmonary dysplasia, cardiac or renal diseases),
acute illness for which the administration of systemic corticosteroid was indicated (i.e. croup) or
contraindicated (i.e. varicella) and ongoing oral corticosteroids use on presentation
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Power analysis: 406 patients with moderate or severe asthma receiving either early or delayed therapies
Interventions

Three groups:
1. Early administration of systemic corticosteroids w/in 75 minutes (n=205)
2. Delayed administration > 75 minutes (n=133)
3. No administration (n=68)
•
•

For moderate asthmatics: 1 or more nebulizations of albuterol (0.03 mL/kg of 5% albuterol solution and
a dose of prednisone or prednisolone (1 mg/kg; maximum dose = 50 mg)
For severe asthmatics: 3 nebulizations of 0.03 mL/kg of albuterol and 1 mL of 250 mcg ipratropium
bromide and 1 mg/kg of prednisone or prednisolone (although 4 to 8 mg/kg of intravenous
hydrocortisone was occasionally administered

Outcomes

Primary outcome: Admission (defined as hospital admission or time from triage was greater than 6 hours)
Secondary outcomes: Length of treatment (time between first and last nebulized albuterol therapy) and
relapse (return visit to ED for acute asthma within 72 hours of discharge)

Notes

-Asthma score not measured
-Doses of corticosteroids not measured
The authors report values for the three groups and therefore multiple comparisons were created, the last
comparison combined the Delayed and Not Given data sets for the outcomes of Admission and Relapse. This
action could not be accomplished for the outcome Length of Active Treatment, hours

Risk of bias table
Bias

Scholars'
judgment

Random sequence generation
(selection bias)

High risk

Support for judgment
Random sequence generation was not used due to study design

Allocation concealment
(selection bias)

Unclear risk

Not disclosed

Blinding of participants and
personnel (performance bias)

Unclear risk

Authors report that healthcare clinicians were not aware of the ongoing study

Blinding of outcome
assessment (detection bias)

Low risk

The assessed outcomes were binary in nature and could not be influenced by the outcome
assessor

Incomplete outcome data
(attrition bias)

Low risk

Authors report all data were analyzed

Selective reporting (reporting
bias)

Low risk

Other bias

High risk

Study design
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Cronin et al., 2012
Methods
Participants

Interventions
Outcomes
Notes

Randomized, open-label, non-inferiority trial
Setting: Tertiary urban pediatric ED in Dublin, Ireland, July 2011 to June 2012
Randomized into Study: 245 enrollments involving 226 patients. (19 patients were reenrolled but were
within inclusion criteria)
• Treatment group n=123
• Control group n=122
Completed Study:
• Treatment group n=120
• Control group n=115
Age: 2-16 years
Gender:
• Treatment group: 61.8% male
• Control group: 74.6% male
Inclusion Criteria:
• History of asthma
• Presenting with asthma exacerbation
Exclusion Criteria:
• Critical or life-threatening asthma
• Known TB exposure
• Active varicella or herpes simplex infection
• Documented concurrent RSV infection
• Fever > 39.5 degrees C
• Use of oral corticosteroids in the previous four weeks
• concurrent stridor
• Galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption
• Significant co-morbid dx: lung, cardiac, immune, liver, endocrine, neurologic or psychiatric
Power Analysis: Sample size of 232 subjects (105 in each group with an estimated 10% loss to follow-up)
required to reject the null hypothesis
Treatment Group: Oral dexamethasone (single dose of 0.3 mg/kg, maximum dose 12mg)
Control Group: Oral prednisolone (1mg/kg for 3 days, maximum dose 40mg per day)
1. Day 4 Asthma score (PRAM)
2. Hospital Admission
•

Patients who vomited dose of either steroid within 30 minutes of administration received a second
dose. If patient vomited second dose within 30 minutes of administration, no further dosages were
administered but remained in study to perform an intention-to-treat analysis
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•
•

Included in study were those patients who were hospitalized
Authors identify that including patients after hospital admission may be a confounding factor as
treatment may differ from home treatment

Risk of bias table
Scholars'
judgment

Support for judgment

Random sequence generation
(selection bias)

Low risk

Numeric codes generated in random permuted blocks of 12 subjects. The recruiting clinician
took the next available numbered envelope from the pre-randomized pack of study
envelopes contained in a locked storage cupboard in the ED

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Bias

Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)
Selective reporting (reporting
bias)

Unclear risk
Low risk
Unclear risk

•
•

Central allocation by pharmacy
Sequentially numbered, opaque sealed envelopes

Since treatment group received 1 dose of medication and control group received doses over
subsequent 2 days, it was impossible to blind participants
Outcome measures were assessed by physician blinded to treatment allocation
Seven percent of the patient population dropped from the study; however, even with study
dropouts both groups had greater than the needed sample size of 105 participants
Intention-to-treat analysis was performed

Davis, Burke, Hogan, & Smith, 2012
Methods
Participants

Retrospective Cohort Study
Participants: Children between the ages of 2 and 18 years who presented to the ED with an acute asthma
exacerbation and received oral prednisone or dexamethasone in the ED between 1 January 2007 and 31
December 2007
Setting: Connecticut Children's Medical Center in Farmington, CT, USA.
Completed Study: 882
• Treatment group, Corticosteroid <60 min group: n=477, 54%
• Control group, Corticosteroid >60 min group: n=405, 46%
Gender:
• Treatment group: 62.9% male
• Control group: 61% male
Age, years (CI)
• Treatment group: 6.7 (6.3-7.1)
• Control group: 6.7 (6.3-7.1)
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Inclusion Criteria:
• Children between the ages of 2 and 18 years who presented to the ED with an acute asthma
exacerbation and received oral prednisone or dexamethasone
Exclusion Criteria:
• Children who did not receive oral corticosteroids in the ED
• Had significant medical co-morbidities. Co-morbidities include cystic fibrosis, congenital heart
disease, and bronchopulmonary dysplasia
• Were already on corticosteroids prior to arriving in the ED
• Children who received any corticosteroids other than oral route
• Children who vomited and subsequently received a second dose intravenously or intramuscularly
• Children who returned to the CCMC ED with an asthma exacerbation within 7 days, data from
subsequent visit was not included
Power Analysis: Not specified by the authors
Interventions

Outcomes

Patients treated according to an Asthma Treatment Algorithm based on severity of exacerbation (Mild,
Moderate, and Severe)
Mild: Treat with beta-agonists (MDI treatment) and consider prednisone or equivalent (2 mg/kg - max 60
mg)
Moderate: Treat with both beta-agonist (short treatment with ipratropium then long treatment) and
prednisone/prednisolone (2 mg/kg - max 60mg) or Dexamethasone (1 mg/kg - max 12-16 mg)
Severe: Treat with both beta-agonist (Short treatment with Ipratropium then long treatment) and
prednisone/prednisolone (2 mg/kg - max 60mg) or dexamethasone (1 mg/kg - max 12-16 mg) and
consider ancillary medications
• MDI treatments (with spacer)
o Weight (Dose) Notes
▪ < 10 Kg: 4 puffs Use facemask or mouthpiece
▪ > 10 Kg: 8 puffs Use mouthpiece
• Short Albuterol Treatments
o Weight; Medication, Dosing albuterol (mg), ipratropium (500 μg/vial)
▪ < 10 Kg, albuterol 2.5 mg, ipratropium 1 vial
▪ > 10 Kg, albuterol 5 mg, ipratropium 1 vial
• Long Albuterol Treatments
o Weight, Albuterol (mg), Total Volume (with NS)
▪ < 10 Kg, albuterol 10 mg, 8 mL
▪ > 10 Kg, albuterol 20 mg, 8 mL
Primary Outcome - Length of Stay:
• Corticosteroid <60 min group: 157 minutes
• Corticosteroid >60 min group: 182 minutes
Secondary Outcome - Dose of Steroids:
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Prednisone/prednisolone 2mg/kg with a maximum of 60 mg.
Dexamethasone 1 mg/kg with a maximum of 12-16mg.
MDI treatments (with spacer)
Weight (Dose) Notes
< 10 Kg 4 puffs Use facemask or mouthpiece
> 10 Kg 8 puffs Use mouthpiece
Short albuterol Treatments
Weight albuterol (mg) ipratropium (500 μg)
< 10 Kg 2.5 1 vial
> 10 Kg 5 1 vial
Long albuterol Treatments
Weight albuterol (mg) Total Volume (with NS)
< 10 Kg 10 8 mL
> 10 Kg 20 8 mL
Results

Length of Stay:
•
Primary
o Corticosteroid <60 min group: 157 minutes
o Corticosteroid >60 min group: 182 minutes
•
Secondary:
•
We compared children treated with dexamethasone (n = 101) to those treated with
prednisolone (n = 781) with the primary outcome- LOS (Figure 3). There was a 19-minute
decrease in mean LOS for children who received dexamethasone compared with prednisolone
(95% CI: 4–35), p = 0.016. If dexamethasone was administered within the first 60 minutes of
triage, the mean LOS decreased by 34 minutes (95% CI: 7–60), p = 0.013
•

The impact of albuterol timing on LOS was also evaluated. Subjects who did not receive any
albuterol were excluded from the analysis. All subjects who received a corticosteroid (either
dexamethasone or prednisolone), within and after 60 minutes, were subdivided by the timing of
the first albuterol treatment, either within or after 60 minutes from triage. Within the group of
children who received corticosteroids within 60 minutes, we found no significant difference in
LOS when albuterol was administered within 60 minutes or after 60 minutes (p = 0.66)

Keskin et al., 2016
Methods
Participants

Cohort Study
Participants: Children between the ages of 6-18 with history of asthma presenting with an asthma
exacerbation
Setting: Gaziantep University, Turkey. Pediatric Allergy and Asthma Unit, January 2009-April 2010
Number Complete: N = 94
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Percent of Male Subjects: 66% (62/94)
Group 1: Nebulized fluticasone propionate (FP) (n=59)
Group 2: Oral prednisone (P) (n=35)
Inclusion criteria:
1) Child between ages of 6-18
2) Asthma exacerbation defined as increased symptoms of cough, wheezing, shortness of breath or
chest tightness and albuterol use.
3) Moderate or severe asthma score (Qureshi F scale, published by NIH, interrater reliability is good)
Exclusion criteria:
1) Fever
2) Fine rales with auscultation
3) Asthma score < 8
4) Use of systemic corticosteroid within 3 weeks prior to study
5) Those receiving inhaled corticosteroid at dose of >/= to 1000 mcg/day of budesonide or equivalent
6) Signs of systemic disease other than asthma
7) History of intubation for asthma exacerbation
Interventions

Outcomes

Results

All children received two nebulized albuterol (dosed at 0.15 mg/kg) treatments 20 minutes apart. After the
first hour of treatment, albuterol was given hourly until a decision was made to admit or discharge the
patient
Asthma scores were assessed before any treatment was started, including administration of a steroid, and
then hourly during the first four hours of treatment prior to administration of nebulized albuterol
Group 1: 4000 mcg of nebulized fluticasone propionate (FP)
Group 2: 1mg/kg dose of oral prednisone (P)
After discharge:
Group 1 (FP): treated with inhaled FP at a dose of 1000 mcg/daily with a pressurized meter dose inhaler
and spacer
Group 2 (P): treated with oral prednisone 1mg/kg per day for 6 days
Primary outcome: Changes in exhaled breath condensate (EBC) Ctys-LTs and 8-isoprostane levels after
four hours of single high-dose FP or oral prednisone.
Secondary outcome: Asthma Scores four hours after treatment

•

Changes in exhaled breath condensate Ctys-LTs and 8-isoprostane levels after four hours of single
high-dose FP or oral prednisone. No significant changes found.
• Asthma Scores four hours after treatment
o Fluticasone propionate group showed improvement of asthma score from 9 (8,10) to 6
(5,7), p < 0.0001.
o Oral prednisone group showed improvement of asthma score from 10 (9,10) to 6 (5,8), p <
0.0001.
*Here at CMH, dose oral prednisone at 2mg/kg for initial single dose and for a 4 (more) day burst after an
asthma exacerbation.”
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Krebs, Flood, Peter, & Gerard, 2013
Methods
Participants

Interventions

Retrospective Chart review examining 2 periods
Setting: ED of a 190-bed, not-for-profit, urban, tertiary care pediatric hospital, with an annual ED census of
47,000 visits, USA
Participants: Chart review examined 2 periods, March 1 to May 31, 2008 (pre-protocol implementation)
and March 1 to May 31, 2009 (post-protocol implementation). During these periods, all patients younger
than 21 years treated in the ED with a primary diagnosis of asthma were subject to chart review
Number Complete: 766 patients (393 pre-protocol and 373 post-protocol patients)
Gender, Males:
• Pre-protocol: 230
• Post-protocol: 242
Age, Mean years (SD):
• Pre-protocol: 8.1 (4.6)
• Post-protocol: 7.6 (4.7)
Inclusion Criteria: Disposition diagnoses of, or containing, the following terms were used to identify
patients:
• asthma, acute asthma, status asthmaticus, cough-variant asthma, and reactive obstructive airway
disease
Exclusion Criteria:
• Younger than 2 years
• First reported episode of wheezing
• Comorbid conditions including unrepaired congenital heart disease, sickle cell disease, cystic fibrosis,
pneumonia, and patients who did not receive albuterol during the ED visit
Pre-Protocol Implementation:
• No formalized scoring system used to assess asthma severity
• Continuous nebulized albuterol (CNA) versus intermittent nebulized albuterol (INA) dosing,
ipratropium administration, and steroid administration were determined on an individual basis by
treating physician
Post-Protocol Implementation:
• Asthma severity determined using a modified Wood and Downes clinical asthma score (CAS)
o CAS <3 receive INA delivered over 15min (2.5mg for pts <20kg, 5mg for pts >20kg)
o CAS >3 receive CNA with ipratropium delivered over 1 hour (10mg albuterol per 250mcg
ipratropium for pts <20kg, 20mg albuterol/500mcg ipratropium for patients >20kg) and
2mg/kg of oral or IV steroid (maximum dose 60mg).
o CAS determined by triage nurse and appropriate treatment pathway initiated
o Placed on continuous pulse oximetry
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o

Outcomes
Results

Based repeated CAS, patients continue to receive albuterol treatments as per the protocol
until a disposition is determined, either home or admission (CAS of 3 or greater are required
to receive 3 full hours of CNA before admission level is determined)

Adverse Events, ED length of stay (LOS), return visits to ED within 7 days

•
•
•

No significant adverse drug effects, including tachyarrhythmia and symptomatic hypokalemia, were
identified during the 2 study periods
ED LOS, mean (SD), min:
o Pre-protocol 187.2 (105.5)
o Post-protocol 217.8 (115.6) P=<0.01
Return visit to our ED w/in 7 days:
o Pre-protocol 12 (3.1)
o Post-protocol 6 (1.6) P=0.19

Wyatt, Borland, Doyle, & Geelhoed, 2015
Methods
Participants

Interventions

Randomized, single-blind, controlled equivalence trial
Setting: Princess Margaret Hospital for Children in Australia; June 2007 to January 2011
Randomized into study: n = 416
• Group 1: salbutamol (SABA) + prednisolone + ipratropium: n = 209
• Group 2: salbutamol + prednisolone; n = 207
Received allocated intervention: n = 410
• Group 1: n = 205, (174 analyzed)
• Group 2: n = 205 (173 analyzed)
Gender, males (%):
• Group 1: n = 105 (60.3%)
• Group 2: n = 110 (63.6%)
Age, years (median):
• Group 1 = 4.3
• Group 2 = 4.1
Inclusion Criteria: Age 2-15 years, acute wheezing illness of moderate severity (according to National
Asthma Council Australia), previous history of asthma or first presentation
Exclusion Criteria: Oxygen saturations less than 90%, cyanosis, inability to speak secondary to
breathlessness, silent chest or abnormal conscious state, chronic respiratory illness, received ipratropium in
the preceding 6 hours
Power: 173 subjects per arm are needed to show 15% difference with 80% power
Group 1:
• Salbutamol 100 mcg/puff x 3 doses (6 puffs per dose for 2-5 years; 12 puffs for 6-12)
• Oral prednisolone 1 mg/kg x 1 dose

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO

67

Question 4 – Optimal Dose Glucocorticosteroids
• Ipratropium 21 mcg/puff x 3 doses (4 puffs per dose for 2-5 years; 8 puffs for 6-12)
Group 2:
• Salbutamol 100 mcg/puff x 3 doses (6 puffs per dose for 2-5 years; 12 puffs for 6-12)
• Oral prednisolone 1 mg/kg x 1 dose
Outcomes

Notes

Primary Outcome:
• Hospital admission rates
Secondary Outcomes:
• Admission to emergency observational unit vs. inpatient ward
• Adverse events

•
•
•

•
•
•
•

Authors stated this was an intent-to-treat trial but only analyzed subjects who received allocated
intervention, met inclusion criteria, and were not missing any data. Therefore it is a per-protocol
analysis
Not all subjects received prednisolone due to a change in prescribing guidelines during the trial;
94.8% in group 1 and 91.9% in group 2 received steroids
Primary outcome measure included both emergency observation unit ( >4hr emergency care) AND
inpatient admissions; other hospitals may not have considered emergency observational unit as
"admissions" since they were not technically inpatient
o criteria for inpatient admission included oxygen requirement or unable to be discharged
from emergency observational unit within 24 hours
No criteria for admission was specified
Primary investigator was out of the country for 18 months during trial
Admission rate was considerably higher than expected (or predicted) for both groups (actual 67.1%
vs. pre-trial prediction of 40-44%)
Subjects with "language difficulties" were not approached for enrollment

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence generation
(selection bias)

Low risk

Randomized using blocked computerized random number generation

Allocation concealment
(selection bias)

Low risk

Treatment assignments concealed in opaque envelopes

Blinding of participants and
personnel (performance bias)

Low risk

Placebo option was not available so only physicians were blinded to treatment; blind was
likely adequate to maintain provider neutrality

Blinding of outcome
assessment (detection bias)

Low risk

No blinding of outcome assessment but outcome measurement (admission rates) unlikely to
be affected by blinding
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Incomplete outcome data
(attrition bias)

High risk

Authors stated they used intent-to-treat but actually analyzed per-protocol. Only 83% of
subjects randomized to the either the intervention or control arm were included in the
analysis.

Selective reporting (reporting
bias)

Unclear risk

Pre-specified outcomes were reported as expected but definition of admission seems
inappropriate; would have liked to have seen statistical analysis of emergency observational
unit vs. inpatient ward admissions

Other bias

Unclear risk

Not sure how much bias the notes above introduce, but there are a number of concerns

Zemek et al., 2012
Methods
Participants

Time-Series Controlled Trial (Before and After Initiation of a Medical Directive Permitting Triage Nurse
Initiation of Oral Steroids)
Setting: The ED in Children's Hospital of Eastern Ontario, Canada- a tertiary hospital
Before / After Participant Groups:
• Group 1: After Intervention: Nurse-initiated intervention phase, n = 308
• Group 2: Before intervention: Physician-initiated intervention phase, n = 336
Completed Study:
• Group 1: Nurse-initiated phase n = 308
• Group 2: Physician-initiated phase n = 336
Male gender, n (%) :
• Group 1: Nurse-Initiated phase males n = 199 (64.6)
• Group 2: Physician-initiated phase males n = 225 (67.0)
Mean age, years (SD):
• Group 1: Nurse-Initiated phase: 5.9 (3.8)
• Group 2: Physician-initiated phase: 6.3 (3.6)
Inclusion Criteria:
• Aged 2 to 17 years
• History of asthma defined by physician diagnosis or third or greater episode of wheezing responsive
to ß2 agonists
• Moderate to severe acute asthma exacerbation Pediatric Respiratory Assessment Measure (PRAM)
score > 4
Exclusion Criteria:
Children with the following:
• PRAM score < 4
• Chronic lung disease (e.g., bronchopulmonary dysplasia, cystic fibrosis);
• Chronic cardiac, metabolic, neuromuscular disorders;
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•

Those who had undergone tracheostomies or in whom treatment with steroids or inhaled ß 2 agonists
were contraindicated (e.g., patients on beta-blockers or those with known hypersensitivity to
salbutamol, ipratropium bromide, or dexamethasone, or a history of adrenal suppression);
• Those who had exposure to varicella in the preceding 3 weeks, in the absence of immunization;
• Those who required immediate life-sparing resuscitation;
• And those who had received treatment with oral steroids in the previous 14 days.
Power Analysis: Sample size calculated 242 patients per group
Interventions

Outcomes

Results

Group 1: Physician initiated phase (4 months immediately before introducing triage nurse initiated
corticosteroids)
• Children with moderate exacerbations (PRAM score of 4–7) received 3 salbutamol treatments by
metered-dose inhaler during the first hour and continued hourly treatment as needed.
• Children with severe exacerbations (PRAM score > 8) received 3 salbutamol plus ipratropium
bromide nebulizations for the first hour and continued hourly salbutamol treatment as needed.
Physicians were encouraged to prescribe oral corticosteroids for patients with moderate and severe
exacerbations.
Group 2: Triage initiated phase 4 months subsequent to the introduction of triage nurse initiated
corticosteroid
• PRAM score of 1–3: Patient will be managed per the initial bronchodilator medical directive only (the
authors did not describe this directive)
• PRAM score of 4–11: Patient will be managed per the initial bronchodilator medical directive (see
first point under Group 2 below) and receive 1 dose of oral dexamethasone (0.3 mg/kg per dose,
with maximum dose of 12 mg). The dose of dexamethasone will be given immediately after the first
bronchodilator treatment and before the second dose of the initial 3 back-to-back bronchodilator
treatments. (Specifically, the patient will receive the first inhaled treatment, then oral
dexamethasone, then the second inhaled treatment, and then the third inhaled treatment.)
• PRAM score of 12: Notify physician immediately.
Primary outcome(s):
• Time to clinical improvement (Time spent in the ED between arrival and a persistent reduction of the
PRAM score by greater than or equal to 3 points over 2 assessments).
Secondary outcome(s)
• Total time in the ED, admission rate, time to mild status (defined as PRAM score persistently less
than or equal to 3, indicative of overall improvement in discharged patients), and ED return visits
for asthma over 7 subsequent days.
Potential confounders:
• Previous hospitalizations, age, concurrent viral illness, such as upper respiratory tract infection,
tobacco smoke exposure, and degree of severity at presentation.

•

Children in the triage nurse–initiated phase improved significantly earlier compared with those in the
physician initiated phase, with a median difference of 24 minutes between phases (95% CI: 1–50
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minutes; 158 minutes [interquartile range: 139–177] vs 182 minutes [interquartile range: 168–
202]; P = .04
• Forty-one patients were admitted before PRAM score improvement of greater than or equal to 3, so
they were censored in the analysis (median time to censoring was 536 minutes in physician-initiated
vs 593 minutes in nurse-initiated phase).
• The physician-initiated phase had a higher proportion with preceding upper respiratory tract
infections.
• Significant efficiency gains were associated with the nurse-initiated phase:
o Hospital admission was significantly less likely,
o Children received steroids faster,
o Children improved to mild status faster,
o Children had an earlier time to discharge
• This strategy could optimize the function of multidisciplinary teams and have a significant impact on
the burden of asthma in Emergency Departments.
Description of procedure: (includes dosing)
a. Identify patients in the ED with breathing difficulties and a history of asthma, as per the asthma
critical pathway inclusion/exclusion criteria
b. Complete a respiratory assessment by using PRAM and baseline vital signs, and document on the
asthma critical pathway and/or triage document
c. Weigh the patient and document on the asthma critical pathway and/or triage document
d. Determine the treatment regimen based on the patient’s PRAM
e. PRAM score of 1–3: Patient will be managed per the initial bronchodilator medical directive only.
f. PRAM score of 4–11: Patient will be managed per the initial bronchodilator medical directive and
receive 1 dose of oral dexamethasone (0.3 mg/kg per dose, with maximum dose of 12 mg). The
dose of dexamethasone will be given immediately after the first bronchodilator treatment and before
the second dose of the initial 3 back-to-back bronchodilator treatments. (Specifically, the patient will
receive the first inhaled treatment, then oral dexamethasone, then the second inhaled treatment,
and then the third inhaled treatment.)
PRAM score of 12: Notify physician immediately
e. Any questions regarding the appropriateness or dosage of dexamethasone should be discussed
with the physician before administration.
f. If at any time the patient no longer responds appropriately to treatment or deteriorates,
immediately notify the physician
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Specific Care Question
Is oral dexamethasone more efficacious than prednisone/prednisolone for a pediatric asthma exacerbation?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. Children with an asthma exacerbation present to the ED/Urgent Care Center (UCC) with wheezing, tightness in their
chest and difficulty breathing. Glucocorticosteroids (CS) are a first line medication used to reduce inflammation and reduce the
symptoms of asthma. However, CS can have side effects, and reducing the side effects of treatment is an important goal. There are
three types of oral CS used: (a) dexamethasone, (b) prednisone (tablet) or (c) prednisolone (syrup). The medications are similar in
how well and how quickly they decrease asthma symptoms (Bravo-Soto, Harismendy, Rojas, Silva, & von Borries, 2017; Rowe,
Edmonds, Spooner, Diner, & Camargo, 2004).
Dexamethasone is a long acting steroid medication that is five times stronger than prednisone/prednisolone and has a longer half-life
(Hendeles, 2003). Prednisone and/or prednisolone have been the preferred medications to treat acute asthma because it is believed
there are fewer side effects, such as hyperactivity, nausea, and reduced growth. The heterogeneity in doses of both forms of CS is
great in the included studies, see Table 2). A smaller, less frequent dose of dexamethasone may increase the ability of the child to
take the medication. See Table 4 for a comparison of dexamethasone, hydrocortisone, and prednisone/prednisolone for (a) antiinflammatory potency, (b) salt retention, (c) suppression of the hypothalamic pituitary adrenal (HPA) axis, and (d.) biological half-life
(Cutrera et al., 2017). With dexamethasone there is longer adenocorticotropic hormone (ACTH) suppression with longer biological
half-life (Cutrera et al., 2017).
Study characteristics. The search for suitable studies was completed on April 6, 2018 and April 7, 2018. Irene Walsh, MD, Amanda
Nedved, MD, and Jeff Michael, DO reviewed the 31 titles and abstracts found in the search and identified six articles believed to
address the question. After an in-depth review three articles (Bravo-Soto et al., 2017, Paniagua et al., 2017, and Aljebab, Alanazi,
Choonara, and Conroy, 2018) are added to the previous Children’s Mercy Hospital Critically Appraised Topic, Dexamethasone versus.
Prednisone/olone, (2016). Bravo-Soto et al. (2017) is a systematic review that is included as a source for studies. It includes ten
studies, seven of which were in the previous CMH CAT, and three that were not. Of the three new studies, two were excluded
(Scarfone et., 1995; Mathew, 2015) (see Studies Excluded) and one is included (Kravitz, Dominici, Ufberg, Fisher, & Giraldo, 2011).
Paniagua et al. (2017) and Aljebab, Alanazi, Choonara, & Conroy (2018) are new RCTs, the former evaluated efficacy and the latter
evaluated palatability.
Key results CSs have similar efficacy, and short-term adverse events outcomes are not found in otherwise healthy children
(Fernandes et al., 2014). Long term adverse events (such as hypertension, adrenal suppression) outcomes are poorly studied. The
decision to select one or another for treatment may be based on compliance to treatment and adverse events including (a) vomiting
in the ED, (b) vomiting at home, and (c) adrenal suppression in children with frequent asthma exacerbations. No studies were
identified that evaluated these as primary outcomes.
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Summary by Outcome
Admission at initial presentation. Three studies (n = 1007) are included for this outcome (Altamimi et al., 2006; Cronin et al.,
2015; Qureshi, Zaritsky, & Poirier, 2001). The evidence is graded as very low based on (a) serious risk of bias as only one study
clearly stated randomization procedures, (b) serious inconsistency among the studies as the doses of the medications and the number
of days the medication was administered varied, and (c) serious imprecision of the results as (i.) there are low number of admissions
in the included studies, and (ii.) the confidence interval for the main effect crosses the line of no effect, OR = 1.33, 95% CI [0.90,
1.99] (see Figure 3).
Pulmonary score. Two studies (n = 345) are included for this outcome (Altamimi et al., 2006; Cronin et al., 2015). The evidence is
graded as very low based on (a) serious risk of bias as only one study clearly stated randomization procedures, (b) serious
inconsistency as two pulmonary scores were used, one study used the valid PRAM score, while the other used a modification of the
PSAS score. Furthermore, one study measured the score at discharge, while the other measured the score at Day 4 past the index
visit. The modification of the PSAS score was not tested for validity or reliability. The Mean Difference = -0.00, 95% CI [-.29, .29]
(see Figure 4).
Length of stay in the ED. Two studies (n = 667) are included for this outcome (Altamimi et al., 2006; Paniagua et al., 2017). The
evidence is graded as low based on (a) inconsistency as the doses of the medications and the number of days the medication was
administered varied, and (b) imprecision the difference in LOS as only 14 minutes shorter in the dexamethasone group compared to
the prednisone/prednisolone group. Mean difference = -.24, 95% CI [-.97, .48] (see Figure 5).
Peak expiratory flow rate (PEFR) at discharge. One study (n = 14) is included for this outcome (Altamimi et al., 2006). The
evidence is graded as very low due to imprecision, the difference in PEFR was 34 meters/min higher in the group treated with
dexamethasone compared to those treated with prednisone Mean difference = 34, 95% CI [54, 122] (see Figure 6).
Relapse. Six studies (n = 1734) are included for this outcome (Altamimi et al., 2006; Cronin et al., 2015; Gordon, Tompkins, &
Dayan, 2007; Greenberg, Kerby, & Roosevelt, 2008; Klig, Hodge, & Rutherford, 1997; Kravitz, Dominici, Ufberg, Fisher, & Giraldo,
2011). The evidence is graded as low based on (a) serious risk of bias as only two of the four studies described randomization clearly,
and (b) imprecision as only one study performed intention to treat analysis and the odds ratio crosses the line of no effect, OR = 0.75,
95% CI [0.49, 1.16] (see Figure 7).
Vomiting. Five studies (n = 1558) are included for this outcome (Altamimi et al., 2006; Cronin et al., 2015; Greenberg et al., 2008;
Paniagua et al., 2017; Qureshi et al., 2001). The evidence is graded as very low based on (a) serious risk of bias as randomization did
not occur in two of the five studies, (b) The studies compared different doses and different dosing schedules. The different dosing
schedules (dexamethasone once a day for two days, and prednisone/prednisolone twice a day for 5 days) allowed two opportunities to
vomit in the dexamethasone group per treatment course, while the prednisone/prednisolone group had up to 10 opportunities to
vomit per treatment course, and (c) serious imprecision, as vomiting was not the primary outcome in any of the studies. The studies
were not powered to find differences in vomiting (see Figure 8).
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Palatability. One study (n = 255) is included for this outcome (Aljebab, Alanazi, Choonara, & Conroy, 2018). Subjects 2- 18 years of
age with asthma or croup were included. All the croup patients received oral dexamethasone. Three different formulations of CS were
evaluated: (a) prednisolone base tablet, (b) prednisolone sodium phosphate (soluble tablet or syrup), (c) dexamethasone (elixir or
solution). All were disliked on the first day of treatment. Prednisolone base tablets had the lowest palatability scores, where 100%
disliked the taste, whereas 89% of the prednisolone sodium phosphate group, and 76% of the dexamethasone group disliked the
taste. However, all prednisolone palatability scores significantly improved with subsequent dosing. Subjects treated with
dexamethasone were more likely to have abdominal pain, while those treated with prednisolone were more likely to have nausea and
vomiting. This is an observational study.
Search Strategy and Results (see PRISMA diagram)
(“Asthma/drug therapy”[Mesh] OR "status asthmaticus") AND ((("Steroids"[Mesh] OR corticosteroids[tw] OR "Glucocorticoids"[Mesh]
OR "Glucocorticoids"[Pharmacological Action] OR "Dexamethasone 21-phosphate"[Supplementary Concept] OR Dexamethasone[tw]
OR "Adrenal Cortex Hormones" [Pharmacological Action]) AND ("Administration, Oral"[Mesh] OR "Administration, Intravenous"[Mesh]
OR "Injections"[Mesh])) OR Prednisone[tw] OR Prednisolone[tw] OR Methylprednisolone[tw]) AND ("2016/06/01"[PDAT] :
"2018/12/31"[PDAT]) AND English[lang] AND (child OR children OR childhood OR pediatr* OR paediatr*) 33 articles returned
Studies Included in this Review (in Alphabetical Order)
Aljebab et al. (2018)
Altamimi et al. (2006)
Bravo-Soto et al. (2017)
Cronin et al. (2015)
Gordon, Tompkins, & Dayan (2007)
Greenberg, Kerby, & Roosevelt (2008)
Gries, Moffitt, Pulos, & Carter (2000)
Klig, Hodge, & Rutherford (1997)
Kravitz, Dominici, Ufberg, Fisher, & Giraldo (2011)
Paniagua et al. (2017)
Qureshi, Zaritsky, & Poirier (2001)
Studies Not Included in this Review with Exclusion Rationale (in Alphabetical Order)
Authors (YYYY)
Reason for exclusion
Castro-Rodriguez, Rodrigo, & RodriguezDoes not answer the question; does not include dexamethasone
Martinez, (2015)
Mathew (2015
Not an RCT
Scarfone et al. (1995)
Nebulized dexamethasone
Taylor, Li, Almossawi, Dulfeker, & Jones,
Does not answer the question; does not include dexamethasone
(2016)
Method Used for Appraisal and Synthesis
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the XXX included
studies. GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
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aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version
5.1.0 ed.): The Cohcrane Collaboration, 2011.

Librarian responsible for the literature search
Keri Swaggart, MLIS, AHIP
EBP Scholar’s responsible for analyzing the literature
Erin Lindhorst, MS, RD, LD
Helen Murphy, BHS RRT AE-C
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
Nancy H. Allen, MS, MLS, RD, LD
Acronyms Used in this Document
Acronym
ED
CPG
ACTH
CS
CDSR
CMH CAT
HPA
IQR
LOS
OR
PRAM
PSAS
RCT
RSV

Explanation
Emergency Department
Clinical Practice Guideline
Adrenocorticotropic hormone
Corticosteroids
Cochrane Database Systematic Reviews
Children’s Mercy Hospital Critically Appraised Topic
Hypothalamic pituitary adrenal
Interquartile range
Length of stay
Odds ratio
Pediatric Respiratory Assessment Measure
Patient Self-Assessment Score
Randomized controlled trial
Respiratory syncytial virus

Date Developed/Updated August 23 2018
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Prednisone/Prednisolone

Records identified through
Database searching
(n = 33)

Additional records identified
through other sources
(n = 10)
Included in 2016 CAT and BravoSoto et al. (2017) SR/MA

Eligibility

Screening

Records after duplicates removed
(n = 43)

Records screened
(n = 43)

Records excluded
(n = 29)

Full-text articles assessed
for eligibility
(n = 14)

Full-text articles excluded,
with reasons
(n =4)

Included

Studies included in
qualitative synthesis
(systematic review)
(n = 10)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Figure 2. Risk of Bias Summary
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Table 1
Summary of Findings Table

Oral Dexamethasone Compared to Oral Prednisone/Prednisolone for Asthma
Exacerbation in the ED/UCC
Certainty assessment
№ of
particip
ant
(studies
)
Followup

Risk
Inconsis Indirec
of bias tency
t-ness

Summary of findings

Imprecisi
on

Publi
catio
n
bias

Overall
certain
ty of
eviden
ce

Study event rates (%)

Relati
ve
effect
(95%
CI)

Anticipated absolute
effects

With
Prednisone/
olone

With
Dexametha
sone

Risk with
Prednisone/
olone

Risk
difference
with
Dexametha
sone

none

⨁◯◯◯
VERY
LOW

48/499
(9.6%)

63/508
(12.4%)

OR
1.33
(0.90
to
1.99)

96 per 1,000

28 more
per 1,000
(9 fewer to
79 more)

none

⨁◯◯◯
VERY
LOW

169

176

-

MD 0
(0.29 lower
to 0.29
higher)

none

⨁⨁◯◯
LOW

330

337

-

MD 0.24
lower
(0.97 lower
to 0.48
higher)

Admission at initial presentation
1007
(3 RCTs)

serious

serious

b

a

not
serious

serious

c

Pulmonary score at discharge
345
(2 RCTs)

serious
a

very
serious

d

not
serious

not
serious

not
serious

serious

Length of stay in ED
667
(2 RCTs)

not
serious

serious

e

f

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO

78

Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Relapse
1734
(6 RCTs)

serious
g

not
serious

h

not
serious

serious

not
serious

very
serious

i

none

⨁⨁◯◯
LOW

53/886
(6.0%)

38/848
(4.5%)

OR
0.75
(0.49
to
1.16)

60 per 1,000

14 fewer
per 1,000
(30 fewer to
9 more)

none

⨁◯◯◯
VERY
LOW

46/766
(6.0%)

17/792
(2.1%)

OR
0.34
(0.19
to
0.59)

60 per 1,000

39 fewer
per 1,000
(48 fewer to
24 fewer)

Vomiting
1558
(5 RCTs)

serious
j

serious

k

l

CI: Confidence interval; OR: Odds ratio; MD: Mean difference
Explanations
a. Only one study clearly state randomization and allocation procedures.
b. There are only three studies, and two compare one dose of DEX to five days of PRED, while the other compares two doses of DEX vs five
days of PRED. Doses differed.
c. Low number of subjects, and low number of events decreases the precision of the findings.
d. Different 'Pulmonary Scores' were used. Cronin (2015) used the valid PRAM score and Altamimi (2006) used a modified PSAS score that
was adapted, but no evidence of psychometrics to test validity or reliability was found.
e. Only two studies for this outcome, one used one dose of DEX, the other two doses and both compared to 5 days of PRED
f. Overall in the two studies, the length of stay in the IM DEX group was 14 minutes shorter.
g. Two studies reported randomization clearly, the other four did not. Only one study performed intention to treat analysis
h. Two studies compared one dose DEX to five days of PRED, while four studies compared two days of DEX vs five days of PRED. Also
definitions of relapse varied among the studies.
i. There are low number of relapses in the included studies
j. Randomization did not occur in two of the five included studies, and only one of the included studies clearly used intention to treat analysis.
k. The studies compared different doses and different dosing schedules. The different dosing schedules allowed 2 opportunities to vomit in the
DEX group, while the PRED group had up to 10 opportunities to vomit.
l. Vomiting was not the primary outcome variable in any of the studies. Many studies excluded subjects who vomited in the ED. Studies were
not powered to find differences in vomiting.
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Table 2
Summary of Findings Table

Intramuscular Dexamethasone Compared to Oral Prednisone/Prednisolone Asthma
Exacerbation in the ED/UCC
Certainty assessment
№ of
particip
ants
(studies
)
Followup

Risk
of
bias

Inconsiste
ncy

Summary of findings

Indirect
ness

Impreci
sion

Public
ation
bias

Overal
Study event rates (%)
Relati
Anticipated absolute
l
ve
effects
certai
effect
With PO
With IM
Risk
nty of
(95% Risk with PO
prednisone/ difference
eviden prednisone/ dexametha
CI)
olone
sone
olone
with IM
ce
dexametha
sone

not
serious

very
serious

none

⨁◯◯◯ 11/94
(11.7%)
VERY
LOW

10/92
(10.9%)

not
serious

very
serious

none

⨁◯◯◯ 6/95 (6.3%)
VERY
LOW

0/91 (0.0%) OR
0.07
(0.00
to
1.35)

Relapse
186
(2 RCTs)

serio serious
us a

b

serio serious
us a

b

c,d

OR
0.94
(0.38
to
2.30)

117 per 1,000 6 fewer
per 1,000
(69 fewer to
117 more)

Vomiting
186
(2 RCTs)

c,d

63 per 1,000

58 fewer
per 1,000
(63 fewer to
20 more)

CI: Confidence interval; OR: Odds ratio
Explanations
a. The Gordon 2007, which provides ~95% of the weight of the MA was not blinded, nor did they include subjects who were admitted to the
hospital in the analysis. Approximately 20% of the subjects were admitted to the hospital, and it appears balanced across the two groups.
b. The doses of IM dexamethasone varied from .3 mg/kg to .6 mg/kg. For the prednisone group only the maximum varied it was 50 mg in
one study and 100 mg in the other.
c. Relapse was the primary outcome for Klig 1997, but not for Gordon 2007. Gordon provides ~95% of the weight for the meta-analysis.
d. There are very low number of events, either Relapse or Vomiting.
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Characteristics of Studies
Aljebab 2017
Methods

Participants

Cohort study
Participants: Children suffering from asthma or croup, prescribed oral prednisolone or dexamethasone and
able to understand the study's palatability scale and communicate their response were approached for the
study. Children in the study either had asthma or croup.
Setting: Emergency room of two pediatric EDs
• Gurayat General Hospital in Saudi Arabia
• Derbyshire Children's Hospital in the UK
Number enrolled:
Total N = 255
• Saudi Arabia: n = 122
o Group 1: Prednisolone base tablet, n = 52
o Group 2: Prednisolone sodium phosphate syrup, n = 37
o Group 3: Dexamethasone elixir, n = 33
• United Kingdom, n = 133
o Group 1: Prednisolone base tablet, n = 38
o Group 2: Prednisolone sodium phosphate soluble tablet, n = 42
o Dexamethasone sodium phosphate solution, n = 53
Age, years (Median, [IQR]):
• Saudi Arabia
o Group 1: Prednisolone base tablet, 4.5, [3,6]
o Group 2: Prednisolone sodium phosphate syrup, 4, [3-5]
o Group 3: Dexamethasone elixir, 3.5, [3, 4.75]
• United Kingdom
o Group 1: Prednisolone base tablet, 5, [3.38, 7.5]
o Group 2: Prednisolone sodium phosphate soluble tablet, 4, [3,7]
o Group 3: Dexamethasone sodium phosphate solution, 3, [2.5,5]
Inclusion criteria:
• Children with asthma or croup
• Less than or equal to 12 years of age in Saudi Arabia
• Children ages 2-18 years in the UK
Exclusion criteria:
• Patients >18 years of age
Covariates identified:
• Gender
• Weight (kg)
• Dose (mg/kg/day)
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Interventions

Outcomes

Notes

•
•

Dose duration (day)
Received oral steroids before (Y/N)

•

Saudi Arabia
o Group 1:
o Group 2:
o Group 3:
United Kingdom
o Group 1:
o Group 2:
o Group 3:

•

Prednisolone base tablet, 2 mg/kg/d times 3 days
Prednisolone sodium phosphate syrup, 2 mg/kg/d times 3 days
Dexamethasone elixir, 0.3 mg/kg/d times 1 day, 3.5 years
Prednisolone base tablet, 1.2 mg/kg/d times 3 days
Prednisolone sodium phosphate soluble tablet, 1.1 mg/kg/d times 3 days
Dexamethasone sodium phosphate solution, 0.2 mg/kg/d times 1 day

Primary outcome:
Palatability: 5-point facial Hedonic Scale (1= dislike very much, 2= dislike a little, 3= not sure, 4= like a little,
5= like very much) to assess palatability. If the patient was too young to select a face on the Hedonic Scale,
parents were asked to interpret their child's perception of the taste. No mention of reliability or validity of the
scoring tool.
Secondary analysis: Tolerability, as reported by patients or parents 30 to 60 minutes after medication was
given. For younger children who could not self-report, parents were asked if there was a change in their child's
state which could be an indicator of nausea. Specifically, parents were asked about dizziness, lethargy, or being
cold and clammy.
Both the primary and secondary outcomes were evaluated after each dose. The first dose in the ED,
subsequent doses were evaluated by telephone call, or data was recorded on a form and mailed into the
center.
Results:
• In both countries, dexamethasone had the highest palatability scores, while prednisolone base tablets
had the lowest.
• Although prednisolone base tablets received the lowest palatability scores, the palatability score
improved for all formulations with each subsequent daily dose.
• Children in Saudi Arabia experienced more nausea and vomiting with prednisolone base tablets vs.
sodium phosphate syrup. All subjects who received dexamethasone in this group were steroid naïve.
• Children in the UK experienced vomiting more frequently with prednisolone base than sodium
phosphate soluble tablets.
• In both countries, dexamethasone was associated with less side effects.
• Vomiting, nausea, and abdominal pain occurred more with dexamethasone sodium phosphate solution
than dexamethasone elixir.
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Altamimi 2006
Methods

Participants

RCT
Setting: An urban ED in British Columbia, Canada
Randomized into study: N = 134
• Group 1: Dexamethasone n = 67
• Group 2: Prednisone n = 67
Completed Study: N= 110
• Group 1: Dexamethasone n = 56
• Group 2: Prednisone n = 54
Gender, males:
• Group 1: Dexamethasone n = 43 (64%)
• Group 2: Prednisone n = 43 (64%)
Age, years (mean) (SD):
• Group 1: Dexamethasone n =
• Group 2: Prednisone n =
Inclusion Criteria:
• Age 2-6 years with mild to moderate asthma
• At least one episode of "asthma like" symptoms
• Mild to moderate asthma defined as Pulmonary Index Score (PIS) less than 9 and PEFR of 60% or more
of predicted value for height
Exclusion Criteria:
• Severe asthma defined as PIS >10,
• Use of oral steroids in the past 2 weeks
• Complete recovery after first salbutamol treatment
Power Analysis:
Non-inferiority was accepted if single does oral Dexamethasone was no worse than one extra day in producing a
PSAS score to return to baseline or PEFR to return to 80% predicted value for height. Sample size of 134
subjects, with 67 in each group was required to detect and alpha of 0.1 with 95% confidence.

•
Interventions

•

Group 1: Dexamethasone 0.6 mg/kg to a maximum of 18 mg, oral solution in the ED and placebo X 4
days at home
Group 2: Prednisone (1 mg/kg to a maximum of 30 mg), oral solution in the ED and (1 mg/kg to a
maximum of 30 mg) X 4 days at home

Primary outcome(s): PSAS score to return to baseline or PEFR to return to 80% predicted value for height.
Outcomes
Secondary outcome(s): Time to ED discharge, initial admission rate, return to ED with worsening symptoms.
Notes

This article is included for the outcome vomiting; however, two subjects were excluded due to vomiting. It is
not clear which group to which they were assigned.
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Risk of bias table
Bias

Scholar’s
judgment

Random sequence
generation (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of outcome
assessment (detection
bias)

Unclear risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting
(reporting bias)

Low risk

Other bias

High risk

Support for judgment

Not reported if personnel making the follow-up calls were blinded
They powered the study for 67 enrolled in each group but had inherent drop out points. Did not
meet power at time of analysis and analysis was by per protocol

Competing nurse projects implemented at the same time as the study started, patients were
quickly treated with beta agonists and oral steroids prior to study enrollment
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Bravo-Soto 2017
Methods

Quantitative Synthesis (meta-analysis) -Systemic corticosteroids, typically oral prednisone, constitute the
cornerstone in the treatment of asthmatic exacerbation in children. However, there is concern about their
adverse effects in both the short- and long-term. Dexamethasone allows administration for a shorter period of
time, which would reduce adverse effects and costs. It is not clear, however, whether its efficacy is similar.

Participants

Protocol and registration Not given
Study Selection
Ten primary studies were included.
Eligibility Criteria
•
Included studies were reported upon in six previously published systematic reviews.
•
All were randomized control trials in pediatric subjects.
•
The age range of participants in the included studies 0.5 - 18 years of age. Subjects had a history of a
clinical episode of wheezing (three studies), or a history of two or more episodes of wheezing (two
studies), or history of previous asthma (three studies).
•
Asthma exacerbations could be mild or moderate acute exacerbations (four studies), or moderate
exacerbation only (one study).
•
Three studies excluded life-threatening exacerbation, need of intubation, or previous history of severe
acute asthma exacerbation or need of intubation.
•
Other exclusion criteria a) if subjects received CS within the last two weeks, b) presence of chronic
comorbidity, and c) exposure to tuberculosis, chicken pox, and RSV infection.
Information sources
Epistemonikos Database
Search
Epistemonikos database, which is maintained by screening multiple information sources, to identify systematic
reviews and their included primary studies.
Data collection process
Not given.
Risk of Bias across studies

Interventions

Intervention group
•
All trials used Dexamethasone
•
It was administered orally in 4 trials, intermuscular in 3 and nebulized in 1
•
In five trials the treatment lasted one day
•
In two trials it lasted two days
•
Not able to get information in one trial
Control Group
•
Three trials compared prednisolone
•
Five trials compared against prednisolone
•
The comparison was oral in all trials
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•
•
•
•

Outcomes

Notes

The dose was from 1-2 mg/kg/day
The duration of treatment was 3-5 days for 6 trials
Two days for one trial
Unable to obtain information from 1 trial

Summary measures reported as risk ratios, NOT odds ratios
• Hospitalization at first consultation.
• Relapse, defined as revisit to doctor or emergency service
• Admission during relapse
• Asthma symptoms measured on PIS scale (Pulmonary InDEX Score), PSAS (Patient Self-Assessment
Score) or PRAM (Pediatric Respiratory Assessment Measure)
• Adverse effect: vomiting
• Severe adverse effects
• Time to complete recovery
For the
•
•
•

outcome:
Hospitalization at first consultation -three trials, 1007 subjects
Relapse - eight trials - 1,280 subjects
Vomiting - five trials - 1,112 subjects
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Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Cronin 2015
Methods

Participants

Randomized controlled trial
Setting: Emergency department of Our Lady's Children's Hospital, Crumlin in Dublin, Ireland
Randomized into study: N = 250
• Group 1: Dexamethasone n = unknown
• Group 2: Prednisone n = unknown
Completed Study N = 245
• Group 1: Dexamethasone n = 123
• Group 2: Prednisone n = 122
Gender, males:
• Group 1: Dexamethasone n = 76 (61.8%)
• Group 2: Prednisone = 91 (74.6%)
Age, years (mean)
• Group 1: Dexamethasone 5.65
• Group 2: Prednisone 5.76
Inclusion criteria:
• Aged 2-16 years
• History of asthma
o At least 1 previous episode of beta-agonist-responsive wheeze or a previous diagnosis of
asthma made by a pediatrician or clinician of comparable experience
• Present to ED with acute asthma exacerbation
o Includes all the following clinical features:
▪ Dyspnea
▪ Wheeze
▪ Acute cough
▪ Increased work of breathing
▪ Increased requirement of beta-agonist from baseline
▪ SaO2 less than 95%
Exclusion Criteria:
• Children with critical or life-threatening asthma exacerbation
• Active varicella or herpes complex infection
• Documented concurrent infection with RSV
• Temperature above 39.5 degrees
• Use of systemic corticosteroids in the previous 4 weeks
• Concurrent stridor
• Galactose malabsorption
• History of TB exposure
• Significant comorbid disease
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Power analysis:
The sample size calculation comparing DEX and PRED at day 4 assumed that DEX is non-inferior to PRED if the
mean PRAM score at day 4 for the DEX group was not more than 1 point higher than for the PRED group.
Assuming a similar effectiveness for DEX and PRED a sample size of 210 (105 subjects per group) would be
enough to conclude non-inferiority with a probability (power) of 90%.

Interventions

Outcomes

Notes

Group 1: single dose of oral DEX 0.3mg/kg (max dose 12 mg)
Group 2: 3-day course of once-daily PRED 1mg/kg per day (max dose of 40mg) given in tablet form
swallowed whole or dissolved in water
• Received first dose in the ED (day 1 enrollment)
• Those who vomited medication in ED within 30 minutes were given a second dose
• study packs given with instructions for giving remaining PRED at home
• instructions for beta-agonist use given
• asthma diary given
• Day 4 of enrollment participants were evaluated in ED with scripted questionnaire
o PRAM score
• Telephone call on day 14 to assess secondary outcomes with scripted questionnaire
Primary Outcome:
• Mean PRAM score at day 4.
o day 3 or 5 if they could not make day 4
Secondary Outcomes:
• Change in PRAM score from:
o ED arrival to follow-up
o ED discharge to hospital admit on day 1
• Length of stay in ED
• Unscheduled visits to healthcare provider for asthma
• Respiratory symptoms within 14 days of study enrolment
• Re-admission to hospital after ED discharge and within 14 days of study enrollment
• Administration of further systemic steroids with 14 days
• Number of salbutamol therapies administered after enrollment
• Incidence of vomiting within 30 minutes compared between 2 groups
• School and parental work days missed
• Days of restricted activity
There is a discrepancy between those who were randomized and those who completed the study.
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Risk of bias table
Bias
Random sequence
generation (selection bias)

Scholar’s
judgment
High risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of outcome
assessment (detection bias)

Unclear risk

Incomplete outcome data
(attrition bias)

Unclear risk

Selective reporting
(reporting bias)

Unclear risk

Other bias

Unclear risk

Support for judgment
Unclear as to who was randomized into each group and completed study
Not given in study
Open label study
250 subjects enrolled, 235 completed the study
Not all had primary outcome measured on day 4
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Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Gordon 2007
Methods

Participants

RCT
Setting: urban tertiary care center
Randomized: N = 181
Group 1: IM Dexamethasone group n = 88
Group 2: Oral prednisolone n= 93
Completed:
Group 1: IM Dexamethasone group n = 62 completed to 96-120-hour assessment
Group 2: Oral prednisolone n= 64 completed to the 96-120-hour assessment
Gender: (% male)
Group 1: 54% Dexamethasone group and
Group 2: 67% the prednisolone group
Inclusion:
•
Age: > 18 months and <7 years of age
•
Asthma score of 3 to 7 (range of possible scores 0 to 9), indicating moderate asthma exacerbations
Exclusion:
•
Used of systemic steroids within the last month
•
Allergy to any steroid medication
•
Known TB or varicella exposure,
•
Previous enrollment in the study
•
Co-existing conditions like heart disease, cystic fibrosis etc. SpO2< 88%, pectus excavatum
•
Need for an IV
•
Inability to return for follow up
Power analysis: Not reported
•

Interventions

Outcomes

Group 1: IM Dexamethasone Dose: 0.6 mg/kg/ to a maximum of 15 mg while in the ED. No other
corticosteroids were administered.
•
Group 2: oral prednisolone 2 mg/kg/ to a maximum of 50 mg while in the ED. They were prescribed
four additional daily doses of the same amount at discharge. If subjects vomited within 30 minutes
received a second oral dose. If subjects vomited again, they received 1 dose of IV methylprednisolone.
A study endpoint was admission to the hospital from the initial ED visit. Admission was defined as > 6 hours
stay in the ED after randomization.
Subjects returned between 96 to 120 hours after enrollment. If the subject was unable to attend, a structured
interview was done by telephone.
Primary outcome: change in Asthma Score from the initial score (ED presentation. Admission was defined if
the subject had not been discharged from the ED by 6 hours after study enrollment) to the score assigned 96
to 120 hours later.
Secondary outcomes: hospital admission on day of enrollment, hospitalization by 120 hours, and
hospitalization by 2 weeks (ascertained by phone interview)
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Risk of bias table
Bias

Scholar’s
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Randomized into the two groups in blocks of 6, 8, or 10

Allocation concealment
(selection bias)

Low risk

Used opaque study packets that were only opened after assignment

Blinding of outcome
assessment (detection bias)

High risk

Did not blind treating physicians, nor patients. There is no mention if personnel who made
follow-up phone calls were blinded

Incomplete outcome data
(attrition bias)

High risk

Per-protocol analysis- excluded patients who were admitted

Selective reporting
(reporting bias)

Low risk

Other bias

Low risk
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Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Greenberg 2008
Methods

Participants

Interventions
Outcomes
Notes

RCT
Setting: Children 2-18 years of age with a history of asthma (2 or more episodes of wheezing treated with
Beta agonists. Urban tertiary ED
Inclusion Criteria: none stated
Exclusion Criteria:
•
Use of oral steroids in the past month
•
History of intubation for a previous asthma exacerbation
•
Varicella exposure in the past 3 weeks
•
Possible foreign body aspiration
•
Any chronic lung disease (e.g., cystic fibrosis) that would affect the patient’s management
•
Chronic heart, liver, or kidney disease
•
Significant respiratory distress necessitating airway intervention (e.g., intubation)
•
Previous enrollment in this study
•
No telephone for follow-up
•
≥2 episodes of emesis after steroid administration in the ED.
Experimental: 2 doses of oral Dexamethasone 0.6 mg/kg, maximum dose 16 mg- rounded to nearest 2 mg.
Control: 5-day course of oral prednisone 2 mg/kg, maximum dose 80 mg. rounded to the nearest 5 mg.
Primary outcome: Relapse in 10 days
Secondary outcome: Vomiting in the ED
There were more Caucasians in the dexamethasone group and more "others" in the prednisone group

Risk of bias table
Bias

Scholars'
judgment

Random sequence
generation (selection bias)

Low risk

Allocation Concealment
(selection bias)

Low risk

Blinding of outcome
assessment (detection
bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Support for judgment
Block randomization < 7 years and > 7 years

Pharmacy prepared drugs to look identical as a white powder capsule.
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Selective reporting
(reporting bias)

Unclear risk

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO

93

Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Gries 2000
Methods

Participants

RCT
Setting: Pediatric Clinic in the US
Randomized into study: N = 33
• Group 1: IM Dexamethasone n = 16
• Group 2: PO Prednisone n = 17
Completed study:
• Group 1: IM Dexamethasone n = 15
• Group 2: PO Prednisone n = 17
Gender, males:
• Group 1: IM Dexamethasone n = 10, (63%)
• Group 2: PO Prednisone n = 7, (76%)
Age, months (mean) (SD):
• Group 1: IM Dexamethasone - 38 (18)
• Group 2: PO Prednisone - 36 (22)
Inclusion Criteria:
• Children with mild to moderate asthma (definition - recurrent coughing, wheezing, or shortness of
breath responsive to CS or SABA
• Asthma exacerbation defined as increased asthma signs, unresponsive to usual medications, and
requiring extra SABA therapy
• Six months to 7 years of age
• Were prescribed a short course of CS by the attending physician
Exclusion Criteria:
• Severe exacerbation requiring hospitalizations, without varicella exposure
• History of CS admin within 2 weeks of in DEX visit
• Fever > 101 degrees Fahrenheit
• RSV
Power Analysis: Performed. 16 subjects were required per group to detect a 2 point difference in the clinical
score at day 5. 80% power and .05 significance level.

•

Interventions

•

Group 1: IM Dexamethasone
o 6 - 12 months- 16 mg IM DEX (1 cc)
o 13-35 months - 24 mg IM DEX (1.5 cc)
o > 36 months - 36 mg IM DEX (2 cc)
Group 2: PO Prednisone - approximately 2 mg/kg/d for 5 days (suspension - 3mg/mL or tablet,
subject's choice)
o 6 - 12 months -10 mg PO PRED twice daily
o 13-35 months - 15 mg PO PRED twice daily for 5 days
o > 36 months - 20 mg PO PRED twice daily for 5 days
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Outcomes

Primary outcome(s):
• Change in clinical asthma score from days 1 through 5
• Clinical status returned to baseline
• Albuterol use
• Tolerance of CS medication - (no mention of vomiting)
Secondary outcome(s):
• Relapse - treatment with CS within 2 weeks of index visit
Safety outcome(s): Adrenal function - urine for urinary cortisol:creatinine ratio

Risk of bias table
Bias

Scholar’s
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Just state they randomized, no method given

Allocation concealment
(selection bias)

Unclear risk

Not reported

Unclear risk

Study personnel were blinded, parents and subjects were not blinded. Nurses who administered
the IM injection did not discuss with investigators. Investigator blinding was successful in all
but four subjects

Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)

High risk

Selective reporting
(reporting bias)

Unclear risk

Other bias

Unclear risk

Per protocol analysis
Primary outcome only reported as a graph, no numerical data available
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Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Klig 1997
Methods

Participants

Pilot study
Setting: Pediatric ED, Oakland CA
Randomized into study: N = 44
• Group 1: IM Dexamethasone n = 23
• Group 2: Oral Prednisone n = 21
Completed Study: N=
• Group 1: IM Dexamethasone n = 21
• Group 2: Oral Prednisone n = 21
Gender, males:
• Group 1: IM Dexamethasone n = 13 (52%)
• Group 2: Oral Prednisone n = 11 (52 %)
Age, years (mean) (SD):
• Group 1: IM Dexamethasone - 82 months (46)
• Group 2: Oral Prednisone - 63 months (36)
Inclusion Criteria:
• 3-16 years old
• More than 2 previous episodes of wheezing treated with SABAs
• All subjects were treated with nebulized albuterol (5 mg/ml solution) 0.5 cc in 2 cc or normal saline
administered by oxygen face mask set at 6L flow. Thirty minutes after SABA treatment, PI score and
pulse oximetry were obtained. Subjects with PI between 2 and 7 and a pulse oximetry saturation >
95% were enrolled.
Exclusion Criteria:
•
Chronic disease (congenital heart disease, liver disease, bronchopulmonary dysplasia, immune
disorders, endocrine disease, liver disease)
•
Recent significant wheezing exacerbation, (either hospitalization for asthma within last two months, or
outpatient treatment with corticosteroids in the previous month)
•
History of severe exacerbation that required corticosteroid therapy for greater than seven days
•
Admission to an intensive care unit for asthma in the past year
Power Analysis: Not reported

•
•

Interventions

Outcomes

Group 1: IM Dexamethasone 0.3 mg/kg (15 mg maximum)
Group 2: Oral prednisone tablets 2 mg/kg (100 mg maximum), If the subject could not swallow pills,
medication was crushed and mixed with applesauce. If oral prednisone was regurgitated within 30
minutes, it was re administered. Further, they were discharged with a 2-day supply of prednisone to
administer twice a day, at a dose of 1 mg/kg/dose.
Patients who had poor response to treatment or had evidence of hypoxia (oxygen saturation < 95%) were
removed from the study and admitted to the hospital.
Primary outcome(s): Relapse
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Secondary outcome(s): PI score at discharge
Safety outcome(s): Further CS use after ED discharge
Risk of bias table
Bias

Scholar’s
judgment

Support for judgment

Random sequence
generation (selection bias)

High risk

Consecutive enrollment

Allocation concealment
(selection bias)

Low risk

Used sealed packets, could not blind medication administration

Blinding of outcome
assessment (detection bias)

Low risk

Those who called the families were blinded to group

Incomplete outcome data
(attrition bias)

High risk

Two patients whose condition deteriorated in the ED were removed from the study.

Selective reporting
(reporting bias)
Other bias

Unclear risk
High risk

They misuse the term intention to treat. In the IM DEX group, they use the number of
completers, not the number randomized.
It is a pilot study

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO

97

Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Kravitz 2011
Methods

Participants

RCT
Setting: Albert Einstein Medical Center and Temple University, Philadelphia PA, 2004-2007. The study was
done in adults aged 18-45 years old.
Randomized into study: N = 257
• Group 1: Dexamethasone n = 129
• Group 2: Prednisone n = 128
Completed Study: N= 200
• Group 1: Dexamethasone n = 104
• Group 2: Prednisone n = 96
Gender, males:
• Group 1: Dexamethasone n = 40 (42%)
• Group 2: Prednisone n = 42 (40%)
Age, years (median) (IQR):
• Group 1: Dexamethasone 28 (22 - 27)
• Group 2: Prednisone 30 (23 - 38)
Inclusion Criteria:
• Age 18-45 years
• Peak expiratory flow rate (PEFR) < 80% predicted
Exclusion Criteria:
• Received oral CS within the past four weeks
• Chronic conditions -- chronic obstructive pulmonary disease, congestive heart failure, pneumonia,
sarcoidosis, pregnant or breastfeeding
• A history of CS allergy, tuberculosis, systemic fungal disease, gastritis, diabetes, unable to consent, or
unable to be available for follow-up
• Patients admitted to the hospital for their asthma exacerbation
Power Analysis: calculations showed with 80% power and alpha = .05, and a 2-tailed test, assuming 80% of
subjects would return to work in < three days, 88 subjects would be needed in each group to determine a
minimum improvement of 15% in the Dexamethasone group.

•

Interventions

All subjects were treated with 5 mg of nebulized albuterol and 2.5 mg of nebulized ipratropium
bromide. All medications were packaged in a similar manner. There were five packets for each group.
The first dose of either regimen below was taken in the ED, and packets were numbered 1-5, subjects
were to take them in order.
o Group 1: Dexamethasone group -- received 5 medication packets. The first two contained 16
mg of oral Dexamethasone, and the remaining three contained placebo
o Group 2: Prednisolone group -- received 5 medication packets. Each contained 60 mg of
prednisone
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Outcomes

Primary outcome(s): Return to normal activity (days), determined by phone interview two weeks post ED
visit
Secondary outcome(s): Relapse - return to ED or primary care provider or admission to the hospital for
worsening of asthma exacerbation within 2-week follow up period

Risk of bias table
Bias
Random sequence
generation (selection bias)
Allocation concealment
(selection bias)
Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)

Scholar’s
judgment
Unclear risk
Low risk

Support for judgment
They randomized 285, but 28 were excluded after randomization because they were admitted.
It is not clear to which group these excluded subjects were randomized
The pharmacy kept to codes

Unclear risk

Unclear risk

Selective reporting
(reporting bias)

Low risk

Other bias

Low risk

19% of the Dexamethasone group and 25% of the prednisone group were lost to follow-up.
They perform per protocol analysis. There was also missing data for the primary outcome (days
to return to normal) for nine subjects, six from the prednisone group and 3 from the
Dexamethasone group.
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Paniagua 2017

Methods

Participants

RCT -- non-inferiority study
Definition of asthma
• Previous diagnosis of asthma OR
• At least 2 previous episodes of B2 agonist- responsive wheeze OR
• First episode of wheezing in children > 2 years old with a history of atopy
Definition of exacerbation
• Acute asthma that prompts an ED assessment
• Symptoms include:
o Dyspnea
o Wheeze
o Acute cough
o Increased work of breathing AND/OR
o increase use of short acting bronchodilators over usual use
Setting: acute care teaching tertiary hospital, Spain (Basque Country), Sept 2014-October 2015
Randomized into study: N =
• Group 1: Dexamethasone, n = 294
• Group 2: Prednisone/olone, n = 29
Completed Study: N=
• Group 1: Dexamethasone, n = 281
• Group 2: Prednisone/olone, n = 276
Gender, males:
• Group 1: n = 169, (60.1%)
• Group 2: n = 166 (60.1%)
Age, years (mean) (SD):
• Group 1: 4.7 (3.4)
• Group 2: 4.5 (3.4)
Inclusion Criteria:
• Aged 1-14 years
• Respiratory symptomso Cough, shortness of breath, tachypnea attributed to bronchospasm (wheezing, prolong
expiration)
o History of previous episodes
Exclusion Criteria:
• Other airway pathology
• Other diseases that require hospitalization for safety
• Need for stabilization of the airway
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Power Analysis: Sample size calculation based on a PACT score at day seven was not more than 6% of the
score of the prednisone/prednisolone group a sample size of 556 subjects.

•

Interventions

Outcomes

Both groups treated with salbutamol (one dose) and did not respond, indicating the need for CS.
Ipratropium administered per attending provider. If either treatment was vomited within 30 minutes,
the dose was re-administered.
o Group 1: Dexamethasone, oral, (1 mg/ml), 0.6 mg/kg, maximum 12 mg, one dose in the ED,
one the following 24 hours
o Group 2: Prednisone/prednisolone, oral, 1.5 mg/kg, maximum 60 mg, one dose in the ED,
followed by 1 mg/kg/d, maximum 60 mg twice daily on days 2 - 5 post index visit. Choice of
liquid or tablet formulate was based on the subjects age.
Subjects were contacted by phone and the pediatric asthma control (PACT) questionnaire and the asthma
related quality of life ARQoL instrument was completed. Both tools are validated.
Trial registered - clinicaltrialsregister.eu: 2013-003145-42, the registry states it is ongoing July 2 2018
Primary outcome(s):
• Percent subjects with symptoms at 7 days [PACT score] and their quality of life score [ARQoL score].
Secondary outcome(s):
• Admission rate
• Unscheduled returns to ED
• Hospital re-admissions
• Visits to Primary Care Provider
• School and work absenteeism

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Statisticians performed the randomization

Allocation concealment
(selection bias)

Low risk

Randomization schedule was kept with the statisticians, and treatment group allocation was
kept in opaque envelopes, they were opened sequentially after enrollment

Blinding of outcome
assessment (detection bias)

Unclear risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

Low risk

Unclear if study personnel who made the follow up phone calls knew to which group the
subjects had been allocated
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Other bias

Low risk
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Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Qureshi 2001
Methods

Participants

PRCT used PEFR% to classify asthma severity or an "asthma score"
Setting: Urban pediatric hospital USA
Randomized: N= 618
Group 1: Dexamethasone group: n = 309
Group 2: Prednisone group: n = 309
Completed:
Group 1: Dexamethasone group: n = 272 (88%)
Group 2: Prednisone group: n = 261 (82%
Gender:
Group 1: Dexamethasone group: 65% male
Group 2: Prednisone: group: 66% male
Age: mean
Both groups: 6.5 years
Inclusion criteria:
•
Known history of asthma (2 or more episodes of wheezing treated with beta agonists)
•
Greater than 2 years of age
Exclusion criteria:
•
Reported use of any oral corticosteroid four weeks prior to the visit
•
History of intubation
•
Varicella exposure in the previous 3 weeks
•
Concurrent stridor
•
Possible presence of an intra-thoracic body
•
Chronic respiratory disease (cystic fibrosis)
•
Heart disease
Power analysis: a sample size of 250 per group was needed to detect an absolute difference in relapse rate of
5% between groups. Power was met.
•

Interventions

Outcomes

•

Group 1: Dexamethasone group: PO, even days- 0.6 mg/kg/ maximum of 16 mg of dexamethasone
rounded to nearest 2 mg
Group 2: Prednisone group: (Prelone) odd days- 2 mg/kg with a maximum of 60 mg/d (liquid or
tablet) rounded to nearest 5 mg

Primary outcome:
•
Rate of relapse within 10 days of enrollment in the study.
Secondary Outcomes:
•
Rate of hospitalization from the initial visit and within 10 days
•
Frequency of vomiting
•
Medication compliance
•
Persistence of symptoms a
•
School and or work days missed.

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO

103

Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone
Risk of bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence
generation (selection bias)

High risk

Odd even day assignment to treatment

Allocation concealment
(selection bias)

High risk

Odd even day assignment

Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)

Unclear risk
High risk

Selective reporting
(reporting bias)

Unclear risk

Other bias

Unclear risk

Only those discharged from the ED were included in the analysis, those subjects admitted to
the hospital were not
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Table 4

Comparison of glucocorticosteroids
Glucocorticosteroid
Hydrocortisone
(Ref.)
Prednisone/olone
Dexamethasone

Equivalent dose
(mg)

Antiinflammatory
potency

Salt retention

Suppressive HPA
potency

Biological halflife (hours)

Activity

20

1

1

1

8-12

Short

5
0.75

4
25

0.8
0

1
50

12-36
36-72

Intermediate
Long
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Figure 3. Comparison: Oral Dexamethasone versus Oral Prednisone/olone, Outcome: Admission at Initial Presentation
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Figure 4. Comparison: Oral Dexamethasone versus Oral Prednisone/olone, Outcome: Pulmonary Score at Discharge
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Figure 5 Comparison: Oral Dexamethasone versus Oral Prednisone/olone, Outcome: Length of Stay in the ED

Figure 6 Comparison: Oral Dexamethasone versus Oral Prednisone/olone, Outcome: PEFR at Discharge
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Figure 7. Comparison: Oral Dexamethasone versus Oral Prednisone/olone, Outcome: Relapse

If you have questions regarding this Specific Care Question – please contact Amanda Nedved MD, Erin Scott, DO, or Jeff Michael, DO

109

Question 6 – Specific Care Question: Dexamethasone versus Prednisone/Prednisolone

Figure 8. Comparison: Oral Dexamethasone versus Oral Prednisone/olone, Outcome: Vomiting
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Figure 9. Comparison: IM Dexamethasone versus Oral Prednisone/olone, Outcome: Relapse

Figure 10. Comparison: IM Dexamethasone versus Oral Prednisone/olone, Outcome: Vomiting
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Specific Care Question
For the patient who presents to the Emergency Department/Urgent Care Clinic (ED/UCC) with an asthma exacerbation, is treatment
with inhaled glucocorticosteroids (ICS) as efficacious as treatment with oral glucocorticosteroids (CS)?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. Standard treatment for asthma exacerbations is to treat with short-acting beta2-agonists and oral systemic CS
(DynaMed Plus, 2017). ICS are the most potent and consistently effective long-term control medication for asthma (National Asthma
Education and Prevention Program-Expert Panel Report-3 [NAEP-EPR-3], 2007). Neither the governing guideline (Global Initiative for
Asthma [GINA], 2016) nor the U.S. Expert Panel Report (NAEP-EPR-3, 2007) recommend doubling the dose of ICS in children > 5
years with an asthma exacerbation, and the use of ICS in patients < 5 years of age is not well studied. Both guidelines state the
evidence for treating an exacerbation with ICS alone is insufficient (GINA, 2016; NAEP-EPR-3, 2007).
The administration of ICS reduces hospitalization in patients not receiving any steroid, but when ICS are given in addition to
systemic steroids the evidence is conflicting (GINA, 2016). When considering treatment options for ED/UCC discharge, the GINA
guideline suggests via a consensus statement that ICS may be prescribed for a few weeks or months, but the potential side effects
of ICS should be considered (GINA, 2016, p. 117). For patients already on ICS as a controller medication, this medication should be
continued (GINA, 2016).
Since the governing guideline is based on low quality evidence, the purpose of this update is to include research published since the
search performed for the governing guideline which was performed in 2016, no specific date is provided.
Study characteristics. The search for suitable studies was completed on October 16, 2017. Drs. Scott and Walsh reviewed the 68
titles and abstracts found in the search and identified 13 articles believed to answer the question. After an in-depth review one single
study (Alangari et al., 2014) and one Cochrane Data Base Systematic review (CDSR) (Edmonds, Milan, Camargo, Pollack, & Rowe,
2012), were identified to answer the question. The systematic review (SR) included 32 studies with 14 of the studies based on
pediatric populations. Overall, the risk of bias across studies is high.
Key results. Based on very low-quality evidence a recommendation cannot be made supporting the use of ICS for the treatment of
an acute asthma exacerbation in the ED or UCC. Sixty-nine percent of the studies did not either perform or report randomization and
allocation concealment clearly, and only 12% performed or reported including all subjects randomized in analyses, see Figure 1.
Meta-analysis for the outcome Hospital Admission, which was identified by the Asthma ED CPG Update Team is included in the
synopsis. Although the findings show that Hospital Admission is lower in the groups treated with ICS, the biases identified in the
studies can either underestimate or overestimate the estimate of the effect (see Figure 1). Also, for the two comparisons, (a) ICS
versus systemic corticosteroid, and (b) ICS plus systemic corticosteroid versus systemic corticosteroid alone, the sum of Hospital
Admission from both treatment groups were low, 8, 68, and 203, respectively. When there are low numbers of outcome events,
differences in frequencies may have easily occurred by chance, and may be mistakenly attributed to differences between treatments
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(Higgins & Green, 2011). Other outcomes identified as critical by the Asthma ED CPG Update Team, such as measures of pulmonary
function, length of stay in the ED, readmission within 72 hours, and adverse events, were not consistently reported upon. Therefore,
Edmonds, Milan, Camargo, et al. (2012) is the most recent synthesis for this group of outcomes.
Summary by Outcome
Hospital Admission. For mild to moderate asthma exacerbation two comparisons (ICS vs. Systemic CS and ICS plus Systemic CS
vs. Systemic CS) were made for the outcome Hospital Admission.
ICS vs. Systemic CS. Five Randomized Control Trials (RCTs) included in this comparison were from the CDSR by Edmonds,
Milan, Camargo et al. (2012). The studies were Ancheta et al., (2008); Devidayal et al., (1999); Macias, Felner & Gan, 2003;
Scarfone et al., (1995), and Volovitz et al., (1998). The studies included 389 subjects. Subjects treated with ICS vs. CS were
less likely to be admitted to the hospital, OR = .39, 95% CI [.21, .71]. If treated with CS, 229 subjects per 1,000 would be
admitted. The anticipated absolute effects if treated with ICS are 125 fewer per 1,000 admitted versus when treated with
systemic CS with a range of 171 to 55 fewer hospital admissions.
The studies were graded down for selection bias (randomization procedures were not clear), attrition bias (procedures for
handling data from subjects who did not complete the study were not clear) and imprecision (the number of hospitalizations was
low). Further research, if performed is likely to have an important influence on our confidence in the estimate of effect and
change the estimate (see Table 1 and Figure 3).
ICS plus Systemic CS vs. Systemic CS. A total of three studies are included for this comparison. Two RCTs were from the
CDSR by Edmonds, Milan, Camargo, et al. (2012). The studies were Razi, Turktas, & Bakirtas (2008) and Sung, Osmond, &
Klassen (1998). A more recent study, Alangari et al., (2014) is added to the comparison for this outcome. The studies included
1050 subjects. Subjects treated with ICS plus CS vs. CS alone were less likely to be admitted to the hospital OR = 0.71, 95% CI
[.52, .97]. If treated with CS alone 220 subjects per 1,000 would be admitted. The anticipated absolute effects if treated with
ICS plus CS are 53 fewer patients per 1,000 admitted versus when treated with systemic CS with a range of 92 fewer to 5 fewer
hospital admissions.
The studies were graded down for selection bias (randomization procedures not clearly described) attrition bias (unclear how
subjects that were randomized but did not complete the study were handled). They were further graded down for inconsistency
as the I2 statistic, an indicator of heterogeneity among the studies, was 73%. A desired I2 statistic is < 50% (Higgins & Green,
2011). Finally, the studies were graded down for imprecision as the number of hospitalizations were low. Further research, if
performed is likely to have an important influence on our confidence in the estimate of effect and change the estimate (see Table
2 and Figure 4).
Clinical Score. For mild to moderate asthma exacerbation, two comparisons (ICS vs. Systemic CS and ICS plus Systemic CS
were made for the outcome Clinical Score. Each paper used a different clinical score. All scores were based on checklists that
gave different points for respiratory rate, wheezing, retractions, dyspnea, and oxygen saturation. Nuhoglu, Yasar Kilic, and Ceran
(2006) and Tsai et al. (2001) used variations of the Pulmonary Index Score (PIS), while (Alangari, et al. (2014) and Milani,
Rosario Filho, Riedi, & Figueiredo (2004) used scores from other sources. Due to the variation in scores used, the outcome was
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named Clinical Score, and standardized mean difference was used for analysis (Higgins & Green, 2011). For mild to moderate
asthma exacerbation two comparisons (ICS plus Systemic CS vs. Systemic CS) were made for the outcome Clinical Score
ICS plus Systemic CS vs. Systemic CS. One randomized control trial that included 26 subjects reported upon this comparison
and outcome. The change in Clinical Score was not different in subjects treated with ICS plus systemic CS vs. those treated with
CS alone, in the included study (Nuhoglu, Yasar Kilic, & Ceran, 2006). Mean Difference = -0.46, 95% CI [-1.33, .41].
The risk of bias is high in the included study because randomization was based on the last digit of a social security number. The
evidence was also downgraded for imprecision, as only 26 total subjects were enrolled in the study (see Table 2 and Figure 5).
Search Strategy and Results (see PRISMA diagram, p. 139)
PubMed
Search: ((("Asthma" OR asthma[tw]) AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR
"Emergency Medical Services"[Mesh] OR "Emergency Medicine"[Mesh] OR "emergency department"[tw])) AND
(("Glucocorticoids"[Mesh] OR "corticosteroids"[tw] OR budesonide[tw] OR "Budesonide, Formoterol Fumarate Drug
Combination"[Mesh] OR "Budesonide"[Mesh] OR "Fluticasone"[Mesh] OR fluticason[tw] OR "Fluticasone Propionate, Salmeterol
Xinafoate Drug Combination"[Mesh]) AND ("Nebulizers and Vaporizers"[Mesh] OR "Administration, Inhalation"[Mesh] OR
"Aerosols"[Mesh] OR "Respiratory Therapy"[Mesh] OR "Inhalation Spacers"[Mesh] OR "Metered Dose Inhalers"[Mesh] OR
inhale*[tw] OR inhalation[tw] OR nebulize*[tw]))) AND (Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized
Controlled Trial[ptyp] OR Guideline[ptyp] OR Comparative Study[ptyp] OR "Cohort Studies"[Mesh] OR systematic[sb]) AND
(infant OR child OR paediatr* OR pediatr* OR adolescent OR adolescence OR children) AND ("2010/01/01"[PDAT] :
"2017/12/31"[PDAT]) Search performed on Oct. 16 2017. (68 results.)
Studies Included in this Review
Alangari et al. (2014)
Edmonds, Milan, Camargo, et al. (2012)
Studies Not Included in this Review with Exclusion Rationale
Authors
Reason for exclusion
Andrews, Wong, Heine, & Scott Russell
Does not answer the question. It is a cost comparison study of oral
(2012)
steroids.
Arulparithi et al. (2015)
Does not include desired outcomes.
Chen et al. (2013)
Data provide in graphic, not data table form.
Chong, Haran, Chauhan, & Asher (2015)
Does not answer the question. It is an outpatient study.
Edmonds, Milan, Brenner, et al. (2012)
Does not answer the question. Addresses ICS after ED discharge
Hagiwara, Delea, & Stanford (2014)
Does not answer the question. It is an outpatient study.
Keskin et al. (2016)
Does not include desired outcomes. It measures a compound in breath.
Kew, Quinn, Quon, & Ducharme (2016)
Studies outcomes related to ICS dose increases.
Martinez et al. (2011)
Does not answer the question. It is an outpatient study.
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Miller, Breslin, Pineda, & Fox (2015)
Papi et al. (2013)
Sills, Ginde, Clark, & Camargo (2012)
van Aalderen et al. (2015)
Yousef, Hossain, Mannan, Skorpinski, &
McGeady (2012)

Does not answer the question. It is a time to treatment in the ED QI
report.
Does not answer the question. It is an outpatient study.
Quality study to see if there is an association of quality outcome
measures used by ED and the ability to predict successful ED discharge.
Does not answer the question. It is an outpatient study.
Does not answer the question. It is an outpatient study.

Method Used for Appraisal and Synthesis
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011)a was used to synthesize the XXX included
studies. GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version
5.1.0 ed.): The Cohcrane Collaboration, 2011.

Medical Librarian Responsible for the Search Strategy
Keri Swaggart, MLIS, AHIP
EBP Scholar’s Responsible for Analyzing the Literature
Jennifer Foley, RT(R)(N), CNMT
Helen Murphy, BHS RRT AE-C
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
Nancy H Allen, MS, MLS, RD, LD
Acronyms Used in this Document
Acronym
RCTs
SR
CDSR
GINA
NAEP-EPR-3
CPG
ED/UCC
ICS
CS
PIS

Explanation
Randomized Control Trials
Systematic Review
Cochrane Data Base Systematic Review
Global Initiative for Asthma
National Asthma Education and Prevention Program-Expert Panel
Report-3
Clinical Practice Guideline
Emergency Department/Urgent Care Clinic
Inhaled Glucocorticosteroid
Oral Glucocorticosteroid
Pulmonary Index Score

Date Developed/Updated
March, 2018
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Records identified through
Database searching
(n = 68)

Additional records identified
through other sources
(n = 32)
Studies from Edmonds, Milan,
Camargo, et al. (2012)

Included

Eligibility

Screening

Records after duplicates removed
(n = 100)

Records screened
(n = 100)

Records excluded
(n = 69)

Full-text articles assessed
for eligibility
(n =31)
17 new studies and 14
from Edmonds, Milan,

Full-text articles excluded,
with reasons
(n =16)

Camargo, et al. (2012)

Studies included in
qualitative synthesis
(systematic review)
(n =15)

Studies included in
quantitative synthesis
(meta-analysis)
(n =15)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Figure 2. Risk of Bias Summary
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Table 1
Summary of Findings Table ICS Compared to Systemic Steroid for Asthma Exacerbation

ICS compared to Systemic Steroid for asthma exacerbation
Certainty assessment
№ of
participants
(studies)
Follow-up

Risk
of
bias

Summary of findings

Inconsistency Indirectness Imprecision Publication Overall
bias
certainty
of
evidence

Study event rates
(%)
With
Systemic
Steroid

With
ICS

Relative
effect
(95% CI)

Anticipated absolute
effects
Risk
with
Systemic
Steroid

Risk
difference
with ICS

229 per
1,000

125 fewer
per 1,000
(171 fewer
to 55
fewer)

Hospital admission
389
(5 RCTs)

serious not serious
a

not serious

very serious
b

none

⨁◯◯◯
VERY
LOW

50/218
(22.9%)

18/171
OR 0.39
(10.5%) (0.21 to
0.71)

CI: Confidence interval; OR: Odds ratio

Explanations

a. Attrition bias is strong across the included studies. Attrition bias refers to differences in how withdrawal from studies are handled. Attrition can be due to (a)
some subject’s data are omitted from analysis, or (b) or outcome data for all randomized subjects are not available.
c. Only one of the five studies reports a significant decrease in hospital admissions. There are a small number of events (hospitalizations) recorded. Overall 68
events are included, precision is enhanced when number of events are near 3000.
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Table 2
Summary of Findings Table ICS plus Systemic Steroids Compared to Systemic Steroids for Asthma Exacerbation

ICS plus Systemic Steroids Compared to Systemic Steroids for Asthma Exacerbation
Certainty assessment
№ of
participants
(studies)
Follow-up

Risk of
bias

Summary of findings

Inconsistency Indirectness Imprecision Publication Overall
bias
certainty
of
evidence

Study event rates
(%)
With
With ICS
Systemic
plus
Steroids Systemic
Steroids

Relative
effect
(95%
CI)

Anticipated absolute
effects
Risk
Risk
with
difference
Systemic with ICS
Steroids
plus
Systemic
Steroids

Hospital Admission
1050
(3 RCTs)

serious serious

b

not serious

serious

not serious

Very
serious

c

none

⨁◯◯◯
VERY
LOW

114/518
(22.0%)

89/532
(16.7%)

OR
0.71
(0.52 to
0.97)

220 per
1,000

53 fewer
per
1,000
(92 fewer
to 5
fewer)

none

⨁◯◯◯
VERY
LOW

14

12

-

-

MD 0.46
lower
(1.33
lower to
0.41
higher)

a

Clinical Score
26
(1 RCT)

serious not serious
d

e

Notes. a. Only one of the three studies is assessed as having low risk of bias. In the other two studies randomization and allocation concealment are not well

described, therefore confidence in methods to perform these functions is low. Finally, in the same two studies, it is not clear how subject attrition was handled.
b. The I2 statistic, which quantifies the proportion of the variation in point estimates due to among-study differences, is large. The range for the I2 is 0-100%.
Heterogeneity as measured by I2 for this set of studies is 73%. This is an indicator of substantial heterogeneity among the included studies.
c. There are low number of studies, and low number of events (hospitalizations) reported. Precision increases as number of events increases. There are 203
events in the included studies, it is desired to have near 3000 events for strong precision.
d. The last digit of patients’ social security number was used for randomization; allocation concealment is not reported.
e. 26 subjects had a PIS (Clinical Score) assessment.
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Characteristics of Studies
Alangari 2014
Methods
Participants

Double blind RCT
Setting: November 2010-March 2012, Emergency Department, Saudi Arabia
Randomized into study: N = 945
• Standard treatment plus budesonide: n = 474
• Standard treatment plus placebo: n = 471
Completed Study: N = 906
• Standard treatment plus budesonide: n = 458
• Standard treatment plus placebo: n = 448
Gender, males:
• Standard treatment plus budesonide: n = 305 (67%)
• Standard treatment plus placebo: n = 287 (64%)
Age in years (%):
• Standard treatment plus budesonide:
o 2-6 years: 305 (67%)
o 7-12 years: 153 (33%)
• Standard treatment plus placebo:
o 2-6 years: 310 (69%)
o 7-12 years: 138 (31%)
Inclusion Criteria:
Moderate or severe acute asthma using clinical score developed by Qureshi et al, (Qureshi, Pestian, Davis, &
Zaritsky, 1998)

•
•
•

2-12 years of age
Previous episode of shortness of breath that responded to Beta2 agonist
Subjects could be enrolled more than once

Exclusion Criteria:
• Heart disease, chronic lung disease other than asthma
• Received systematic steroids within the past 7 days
Power Analysis: Power analysis sufficient to detect at least a 12% difference between treatment groups in
admission rate with a minimum of 90% statistical power with a two-side 5% significance level.
Interventions

•
•

Group 1: Standard treatment plus nebulized budesonide 1500 micrograms, 500 micrograms/dose
times three doses
Group 2: Standard treatment plus placebo
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Standard treatment: Beta-agonist (2.5 milligrams salbutamol for weight < 20 kgs or 5 milligrams if weight
was > 20 kg). Prednisolone 2 milligrams/kg with a maximum dose of 60 milligrams at the beginning of the
study.
Outcomes

Notes

Primary outcome(s):
• Hospital admission evaluated four hours after administration of treatment
Secondary outcome(s)
• Change in asthma score
• Total length of stay
It is not clear if the asthma score used is a validated tool. They report internal inter-rater reliability. The intraclass R2 = .85, 95% CI, [.76, .94], which indicates strong inter-rater reliability.

Risk of bias table
Bias

Scholar’s
Judgment

Random sequence
generation (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance
bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting
(reporting bias)

Support for Judgment

Same volume of medications in opaque syringes

39 subjects withdrew after randomization. 14 (36%) due to protocol violation and 25 (64%)
due to subject withdrawal

Unclear risk
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Figure 3. Comparison: ICS versus Systemic Steroid, Outcome: Hospital admission
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Figure 4. Comparison: ICS plus systemic CS versus Systemic CS, Outcome: Hospital admission
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Figure 5. Comparison: ICS plus systemic CS versus Systemic CS, Outcome: Clinical Score
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Specific Care Question
In the patient greater than 2 years old and less than 5 years old who presents to the ED/UCC with an asthma exacerbation, should
ipratropium bromide (IB) be considered as an adjunct to standard treatment with albuterol for severe asthma at presentation, or
asthma that does not respond to initial treatment to reduce hospital admissions and adverse effects and improve tests of pulmonary
function?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. Standard treatment for acute asthma exacerbations includes albuterol and corticosteroids (GINA, 2018, p 74). For
exacerbations that are moderate to severe at initial presentation or do not respond to initial treatment, anticholinergic agents such as
IB are recommended (GINA, 2018, p. 119;Griffiths & Ducharme, 2013)
Study characteristics. The search for suitable studies was completed on February 21, 2018. One Cochrane Database Systematic
Review (Griffiths & Ducharme, 2013) that included 20 relevant studies and two RCTs published since the CDSR are included (see
Figure 1). The included studies were randomized trials that compared treatment with anticholinergics (IB) with short-term betaagonists (SABA) to treatment with SABA alone. Subjects were between the age of 18 months and 18 years. Overall, there was low risk
of bias across the included studies (see Figure 2). Subjects were being treated for an acute asthma exacerbation.
Key results. We concur with the (GINA, 2018) guideline and recommend IB be used in conjunction with albuterol and corticosteroids
in patients with severe asthma exacerbations, or exacerbations that do not respond to initial therapy. This recommendation is based
on high quality evidence that the addition of IB decreases hospital admissions in the population (OR = 0.6, 95% CI [0.45, 0.60]), and
moderate quality evidence that the change from baseline forced expiratory volume in 1 second, percent predicted (FEV1, %
predicted) at 60 minutes past the IB treatment is greater (Mean difference = 10.08, 95% CI [6.25, 13.92].
Summary by Outcome
Hospital Admission. Sixteen trials (2842 subjects) were included for this outcome. The trials were placed in the following sub-groups
a) severe, b) moderate-severe, c) moderate, d) mild-moderate, and e) mild. Subjects in the moderate, mild-moderate and mild subgroups did not have decrease in hospital admission. Importantly, for subjects in the severe and moderate-severe sub-groups those
that were treated with IB with SABA had significantly less hospital admissions than those treated with SABA alone (OR = 0.6, 95% CI
[0.45, 0.60]. See Table 1 and Figure 3.
Change from baseline FEV1, % predicted at 60 minutes. Five trials (402 subjects) were included for this outcome. Subjects
treated with IB plus SABA had greater increase in % predicted FEV1 at 60 minutes past last treatment than did subjects treated with
SABA alone Mean difference = 10.08, 95% CI [4.11, 14.89]. (See Table 2 and Figure 4)
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Change in clinical score at 120 minutes (+ 30 minutes). Four trials (1134 subjects) were included for this outcome. Various
scoring tools were used in each trial. Subjects treated with IB plus SABA had greater reduction in the clinical score than subjects
treated with SABA alone Mean difference = 0.39, 95% CI [-0.66, 0.11] (see Table 2 and Figure 5).
Relapse. Nine trials (1389 subjects) were included for this outcome. Relapse was defined as less than 72 hours in five trials, within 48
hours in one trial, and no definition was given in three trials. Relapse rate was not different between the group treated with IB plus
SABA and the group treated with SABA alone OR = 1.08, 95% CI, [0.66, 1.77] (See Table 2 and Figure 6).
Adverse Events. Three adverse events (AE) were reported upon. For the outcome Tremor seven trial were included (542 subjects).
Subjects in the IB plus SABA group had significantly less tremor than those in the SABA alone group OR = 0.53, 95% CI, [.31, .90].
For the outcome Nausea, seven trials (757 subjects) were included. Subjects in the IB plus SABA group had significantly less nausea
than those in the SABA alone group OR = 0.54, 95% CI [.31, .93]. Finally, for the outcome Vomiting, eight trials (1230 subjects) were
included. There was no difference in the occurrence of vomiting when groups treated with IB plus SABA and groups treated with SABA
alone OR = 0.87, 95% CI [0.47, 1.61].
Search Strategy and Results (see PRISMA diagram, page 56)
PubMed - (asthma OR wheez* OR respiratory sounds) AND (random* OR trial* OR placebo* OR comparative study OR controlled
study OR double blind OR single-blind) AND (child OR children OR infan* OR adolescen* OR pediatr* OR paediatr*) AND (emergenc*
OR acute*) AND (ipratropium* OR anticholinerg* OR atropin*) Filters: From 2012/01/01 to 2018/12/31
Thirty-five articles were identified in the PubMed search. Amanda Nedved, MD, Erin Scott, DO and Irene Walsh MD reviewed the 35
titles and abstracts found in the search and identified 14 articles believed to answer the question. After an in-depth review 3 articles
answered the question. One of the three was the CDSR by (Griffiths & Ducharme, 2013)), which included 20 trials. Therefore, the total
number of trials is 22 trials (Griffiths (2013), the 20 trials analyzed by (Griffiths & Ducharme, 2013) and two new trials (Memon,
Parkash, Ahmed Khan, Gowa, & Bai, 2016; Wyatt, Borland, Doyle, & Geelhoed, 2015).
Studies Included in this Review (in Alphabetical Order)
Studies with * are from in Griffiths & Ducharme, 2013
*Beck, Robertson, Galdes-Sebaldt, & Levison (1985)
*Benito Fernandez, Mintegui Raso, Sanchez Echaniz, Vazquez Ronco, & Pijoan Zubizarreta (2000)
*BI (2009)
*Calvo, Calvo, Marin, & Moya (1998)
*Chakraborti, Lodha, Pandey, & Kabra ( 2006)
*Cook, Fergusson, & Dawson (1985)
*Ducharme & Davis (1998)
*Guill, Maloney, & DuRant (1987)
*Iramain et al. (2011)
Memon, Parkash, Ahmed Khan, Gowa & Bai (2016)
*Peterson et al. (1996)
*Phanichyakam, Kraisarin, & Sasisakulporn (1990)
*Qureshi, Zaritsky, & Lakkis 1997)
*Qureshi, Pestian, Davis, & Zaritsky (1998)
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*Reisman, Galdes-Sebalt, Kazim, Canny, & Levison (1988)
*Schuh, Johnson, Callahan, Canny, & Levison (1995)
*Sharma & Madaan (2004)
*Sienra Monge, Bermijo Guevara, del Rio Navarro, Rosas Vargas, & Rayes Ruiz (2000)
*Watanasomsiri & Phipatanakul (2006)
*Watson, Becker, & Simons (1988)
Wyatt, Borland, Doyle & Geelhoed (2015)
*Zorc, Pusic, Ogborn, Lebet, & Duggan (1999)
Studies Not Included in this Review with Exclusion Rationale (in Alphabetical Order)
Authors
Reason for exclusion
(Castro-Rodriguez, G, & C, 2015)
Overview of reviews
(Everard et al., 2005)
Includes patients < 2 years of age
(Nomura et al., 2017)
Article in Japanese
(Hon & Leung, 2017)
Narrative review
(Lebedenko & Semernik, 2015)
Article in Russian
(Pardue Jones, Fleming, Otillio, Asokan, & Arnold,
Narrative review
2016)
(Rodrigo & Neffen, 2017)
Medication is a controller medication, not for an exacerbation
(Salo et al., 2006)
Included adults only
(Teoh et al., 2012)
The pre-Griffiths CDSR
(Vezina, Chauhan, & Ducharme, 2014)
Hospitalized patients
Method Used for Appraisal and Synthesis
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the 2 included studies.
GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version
5.1.0 ed.): The Cohcrane Collaboration, 2011.

EBP Scholar’s responsible for analyzing the literature
Jennifer Foley, RT(R)(N), CNMT
Becky Frederick, PharmD
EBP team member responsible for reviewing, synthesizing, and developing this document
Nancy H Allen, MS, MLS, RD, LD
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Acronyms used in this document:
Acronym
CDSR
FEV1
IB
SABA

Explanation
Cochrane Database of Systematic Reviews
Forced expiratory volume in one second
Ipratropium bromide
Short acting beta-agonist

Date Developed/Updated May 2018
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Records identified through
Database searching
(n = 35)

Additional records identified
through other sources
(n = 20)
(Griffiths et al. 2016)

Screening

Records after duplicates removed
(n = 55)

Records screened
(n = 55)

Included

Eligibility

Full-text articles assessed
for eligibility
(n = 35)

Records excluded
(n = 20)

Full-text articles excluded,
with reasons
(n = 11)

Studies included in
qualitative synthesis
(systematic review)
(n = 24)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 24)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Figure 2. Risk of Bias Summary
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Table 1
Summary of Findings Table

Anticholinergic (IB) and SABA Compared to SABA Alone for Asthma Exacerbation in the ED or UCC:
Hospital Admission
Certainty assessment
№ of
participants
(studies)
Follow-up

Risk
of
bias

Inconsisten
cy

Indirectnes
s

Summary of findings

Imprecisio
n

Publicatio
n bias

Overall
certainty
of
evidence

Study event rates (%)
With
SABA
Alone

With
Anticholinergi
c (IB) and
SABA

Relativ
e effect
(95%
CI)

Anticipated absolute
effects
Risk
with
SAB
A
Alon
e

Risk
difference
with
Anticholinergi
c (IB) and
SABA

Hospital Admission
2842
(19 RCTs)

not
not serious
serious

not serious

not serious

none

⨁⨁⨁⨁
HIGH

395/139
7
(28.3%)

346/1445
(23.9%)

OR
0.73
(0.60 to
0.88)

283
per
1,000

59 fewer
per 1,000
(91 fewer to
25 fewer)

⨁⨁⨁◯

173/580
(29.8%)

139/608
(22.9%)

OR
0.60
(0.45 to
0.80)

298
per
1,000

95 fewer
per 1,000
(138 fewer to
45 fewer)

49/182
(26.9%)

30/189
(15.9%)

OR
0.51
(0.30 to
0.86)

269
per
1,000

111 fewer
per 1,000
(170 fewer to
29 fewer)

Hospital Admission - Severe
1188
(8 RCTs)

not
not serious
serious

not serious

serious

a

none

MODERAT
E

Hospital Admission - Moderate-severe
371
(4 RCTs)

not
not serious
serious

not serious

serious

a,b

none

⨁⨁⨁◯
MODERAT
E

Hospital Admission - Moderate
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Anticholinergic (IB) and SABA Compared to SABA Alone for Asthma Exacerbation in the ED or UCC:
Hospital Admission
Certainty assessment
808
(4 RCTs)

not
not serious
serious

not serious

serious

Summary of findings
b,c

none

⨁⨁⨁◯
MODERAT
E

145/406
(35.7%)

148/402
(36.8%)

OR
1.04
(0.73 to
1.48)

357
per
1,000

9 more per
1,000
(69 fewer to
94 more)

Hospital Admission - Mild-moderate
358
(2 RCTs)

not
not serious
serious

not serious

very
serious

a

none

⨁⨁◯◯
LOW

24/172
23/186
(14.0%) (12.4%)

OR 0.85
(0.46 to
1.59)

140 per
1,000

18 fewer
per 1,000
(70 fewer to
65 more)

4/57
(7.0%)

OR 1.47
(0.39 to
5.51)

70 per
1,000

30 more
per 1,000
(42 fewer to
224 more)

Hospital Admission - Mild
117
(1 RCT)

not
not serious
serious

not serious

very
serious

d

-

6/60 (10.0%)

CI: Confidence interval; OR: Odds ratio; MD: Mean difference

Explanations

a. Low number of subjects categorized as severe asthma exacerbation.
b. One study reported no hospitalizations in either group,
c. Low number of subjects categorized as moderate asthma exacerbation.
d. Only one trial is included for this sub-group n = 117
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Table 2
Summary of Findings Table

Anticholinergic (IB) and SABA compared to SABA Alone for health problem or population Asthma
Exacerbation in the ED or UCC: Change in baseline FEV1, Change in clinical score, and Relapse
Certainty assessment
№ of
Risk
participants of
(studies)
bias
Follow-up

Inconsisten
cy

Indirectne
ss

Summary of findings

Imprecisio
n

Publicatio
n bias

Overall
certainty
of
evidence

Study event rates
(%)
With
SABA
Alone

With
Anticholinerg
ic (IB) and
SABA

Relativ Anticipated absolute
e effect effects
(95%
Risk with Risk
CI)
SABA
difference
Alone
with
Anticholinergi
c (IB) and
SABA

Change from baseline in % predicted FEV1, 60 minutes post last ipratropium
402
(5 RCTs)

not
not serious
serious

not serious

serious

a

none

⨁⨁⨁◯

180

222

-

The mean
change
from
baseline in
%
predicted
FEV1, 60
minutes
post last
ipratropiu
m was 0

MD 10.08
higher
(6.24 higher to
13.92 higher)

573

561

-

The mean
change in
clinical
score at
120
minutes
(+/- 30
minutes)
was 0

MD 0.39
lower
(0.66 lower to
0.11 lower)

MODERAT
E

Change in clinical score at 120 minutes (+/- 30 minutes)
1134
(4 RCTs)

serious not serious
b

not serious

serious

c

none

⨁⨁◯◯
LOW

Relapse
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Anticholinergic (IB) and SABA compared to SABA Alone for health problem or population Asthma
Exacerbation in the ED or UCC: Change in baseline FEV1, Change in clinical score, and Relapse
Certainty assessment
1389
(10 RCTs)

not
not serious
serious

not serious

serious

Summary of findings
d

-

30/666
(4.5%)

37/723
(5.1%)

OR 1.08
(0.66 to
1.77)

45 per
1,000

3 more per
1,000
(15 fewer to
32 more)

CI: Confidence interval; OR: Odds ratio; MD: Mean difference

Explanations
a. Low number of subjects in the included trials (N = 402, IB +SABA group n = 222; IB alone group n = 180)
b. One of the four studies did not conceal allocation nor blind subjects, personnel, nor outcome assessors.
c. Low number of subjects in the included trials (N = 561, IB +SABA group n = 573; IB alone group n = 180)
d. Wide confidence intervals across all studies

Characteristics of Studies
(Characteristics of Studies tables, and Risk of bias tables from the CDSR can be found in (Griffiths & Ducharme, 2013).
Memon 2016
Methods

Participants

RCT
Setting: Emergency department, Pakistan from October 1, 2009, to March 31, 2010,
Randomized into study: N = 200
• Group 1 (salbutamol): n = 100
• Group 2 (salbutamol plus ipratropium bromide): n = 100
Completed Study: N = 177
• Group 1 (salbutamol): n = 84
• Group 2 (salbutamol plus ipratropium bromide): n = 93
Gender, males:
• Group 1(salbutamol): n = 58 (58%)
• Group 2 (salbutamol plus ipratropium bromide): n = 54 (54%)
Age, years:
• Group 1 (salbutamol): 9.1+3
o 2-6 years: n = 18
o 7-11 years: n = 57
o >11 years: n = 25
• Group 2 (salbutamol plus ipratropium bromide): 9.3+2.8
o 2-6 years: n = 15
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7-11 years: n = 63
>11 years: n = 22
Inclusion Criteria:
• Ages 2-14 years
• Visiting emergency department for acute severe asthma
o For asthma evaluation, clinical score by Bentur Modification (BM) 5-10 (moderate) and >10
(serve exacerbation) was used. Bentur Modification is based on 4 parameters: heart rate (HR),
respiratory rate (RR), wheezing, accessory muscle usage. Each parameter has minimum 0 and
maximum 3 score.
Exclusion Criteria:
• None disclosed
·Power Analysis: "The sample size was calculated on the basis of frequency of asthma disease being 8.5%. It
was calculated at 95% confidence interval (CI) with 4% precision, using EPI software 6."

o
o

Interventions

Outcomes
Notes

•
•

Group 1 (salbutamol): received 3 doses of salbutamol (0.03 ml/kg/dose) only 15 minutes apart
Group 2 (salbutamol plus ipratropium bromide): received 3 doses of ipratropium (250
microgram/dose) in combination with salbutamol (0.03 ml/kg/dose) with same time interval
Response to treatment was assessed after 15 minutes of the last dose and a change in severity category
(improvement) from baseline to lower category was taken as improvement.
Primary outcome(s):
· Clinical score, specifically Bentur Modification score
They only report the clinical score of those subjects whose score after treatment was less than 10.

Risk of bias table
Bias
Random sequence
generation (selection bias)

Scholars'
judgment
Unclear risk

Support for judgment
The authors did not describe the method of randomization. "The patients were randomly
allocated to two equal groups."

Allocation concealment
(selection bias)

High risk

Not described

Blinding of participants and
personnel (performance
bias)

High risk

Not described

Incomplete outcome data
(attrition bias)
Selective reporting
(reporting bias)

Unclear risk
Low risk

No missing outcome data
All outcomes reported
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Other bias

Unclear risk

Wyatt 2015
Methods

Randomized, single-blinded controlled trial
Setting: Princess Margaret Hospital for Children (PMH) Emergency Department, Australia
Randomized into study: N = 416
• Group 1: n = 209
• Group 2: n = 207
Completed Study: N= 410
• Group 1: n = 205
•
Group 2: n = 205
Gender, males
• Group 1: n = 105 (60%, reported from per protocol 174)
• Group 2: n = 110 (64%, reported from per protocol 173)

Participants

Age, years median (IQR)
• Group 1: 4.3 (2.8, 6.4)
• Group 2: 4.1 (3.0, 6.3)
Inclusion Criteria
• Age 2 to 15 years old
• Presenting with acute wheezing illness of moderate severity based on criteria suggested by the National
Asthma Council Australia. Includes one or more of the following; oxygen saturations of 90-94%,
speaking in phrases, and moderate to loud wheeze.
Exclusion Criteria
•
Age less than 2 years to avoid overlap with bronchiolitis
•
Adolescents 16 and older due to upper age limit of institution’s ED acceptance
•
Severe asthma defined with oxygen saturations less than 90%, cyanosis, inability to speak secondary
to breathlessness, silent chest or abnormal conscious state
•
Current chronic respiratory illness
•
Had received Ipratropium Bromide in the preceding 6 hours
Power Analysis
• The study is an equivalence trial with a 15% margin of equivalence, using the outcome: Hospital
admission.
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•

With a sample size of 173 subjects per group, there would be 80% power to detect a significant
difference (p < 0.05).

•

Group 1: Salbutamol + Prednisolone + Ipratropium
o Salbutamol, Metered Dose Inhaler (MDI) (100 mcg/actuation) with spacer 3 times at 20-minute
intervals (age 2 to 5 years 6 actuations per dose, age 6 to 15 years 12 actuations per dose)
o PLUS Oral Prednisolone 1 mg/kg to maximum 50 mg dose.
o PLUS Ipratropium Bromide MDI (21 mcg/actuation) with spacer 3 times at 20 minute intervals
(age 2 to 5 years 4 actuations per dose, age 6-15 years 8 actuations per dose)
Group 2: Salbutamol + Prednisolone
o Salbutamol MDI 100 mcg/actuation with spacer 3 times at 20-minute intervals (age 2 to 5
years 6 actuations per dose, age 6 to 15 years 12 actuations per dose)
PLUS Oral Prednisolone 1 mg/kg to maximum 50mg dose.

Interventions

•

•
Outcomes
Notes

•
•

Primary outcome(s)
o Rate of hospital admission
Secondary outcome(s)
Safety outcomes

Unable to double blind this intervention. However, the treating providers were blinded to the intervention.

Risk of bias table
Bias

Scholar’s
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Blocked computerized random number generation

Allocation concealment
(selection bias)

Low risk

Concealed in opaque envelopes

Blinding of participants and
personnel (performance
bias)

Low risk

Doctor managing patient was not present during administration by nursing staff and exact
treatment was not documented in patient record

Incomplete outcome data
(attrition bias)
Selective reporting
(reporting bias)
Other bias

Unclear risk

17% of the group randomized to receive ipratropium and 16% of the group who did not receive
ipratropium were not included in the analysis. The reason of excluding appears to be balanced
between among the same reasons between groups.

Unclear risk
Low risk
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Figure 3. Comparison Anticholinergic + SABA vs. SABA, Outcome: Hospital Admission (Lower is better)
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Figure 4. Comparison Anticholinergic + SABA vs. SABA, Outcome: Change from baseline in % predicted FEV 1 (Higher is better)

Figure 5. Comparison Anticholinergic + SABA vs. SABA, Outcome: Change in clinical score at 120 minutes (Lower is better)
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Figure 6. Comparison Anticholinergic + SABA vs. SABA, Outcome: Relapse (within 72 hours, Lower is better)
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Specific Care Question:
For the child who presents to the Emergency Department (ED) / Urgent Care Clinics (UCC) with an asthma exacerbation, should the
child be treated with intravenous (IV) magnesium sulfate versus not treated, as measured by the outcomes of (a) admission to the
hospital, (b) length of stay (LOS) in the ED/UCC, (c) a measure of pulmonary function (PEF (L/min)), (d) Readmission to the ED/UCC,
(e) score on a validated symptom score, or (f) adverse events.
Question Originator:
Asthma in the ED CPG Team
Literature Summary
Background. Children with an asthma exacerbation present to the ED/UCC with wheezing, tightness in their chest and difficulty
breathing. Intravenous magnesium sulfate is recommended for instances of acute asthma that do not respond to standard treatment with
albuterol and corticosteroids (GINA, 2018; NAEP - EPR – 3, 2007). Intravenous magnesium has been shown to be an efficacious
treatment in adults, in pediatrics the determination is difficult to make the limited number of RCTs and small sample size of completed
research.
Study characteristics. The search for suitable studies that were published since the prior Asthma CPG Guideline (2012) was completed
on July 13, 2017. Drs. Walsh and Michael reviewed the 46 titles and abstracts found in the search. Twenty-three studies were identified
that addressed the question. After an in-depth review two articles Griffiths and Kew (2016), and Kritchuk, & Mitchell (2014), two
systematic reviews, meta-analyses are included as evidence for this question. However, none of the authors measured the effect the
asthma exacerbation severity or other interventions prescribed in the ED had on hospitalizations. The included pediatric studies had
small sample sizes therefore benefits to this intervention will be clearer with additional studies in the pediatric population. The review
supports the use of magnesium sulfate based on low quality evidence.
Key Results. Based on low certainty in the evidence, the GINA (2018) guideline recommends the use of magnesium sulfate (50 mg/kg
to a maximum of 2 grams) as a single infusion over 20 minutes. Magnesium IV should be used in patients who do not respond to initial
treatment or those who present with severe exacerbations (GINA, 2018, p. 85 The certainty in evidence is low because there are three
studies with less than 100 subjects total in pediatrics, that suggest improvement in pulmonary function. The CM Asthma in the ED CPG
team concurs with the GINA (2018) recommendation.
Summary by Outcome
Admission to the Hospital. Three pediatric studies (N = 115) were included in Griffiths and Kew (2016) SR with a low quality of
evidence (due to different dosages of magnesium sulfate being used in all three studies and an overall small sample size) resulted in an
OR = 0.32, 95% CI [0.14, 0.74]. The magnitude of effect of magnesium sulfate in the adult population (N = 1769) reported by Kew,
Kirtchuk, and Michell (2014) was OR = 0.75, 95% CI [0.60, 0.92], see Figure 1.
Length of Stay in the ED / UCC. Based on one study (N = 27) there was no clear benefit for magnesium sulfate based on the mean
difference of the intervention group staying 5 minutes longer than the placebo group 95% CI [-24.40, 34.40] (Griffiths & Kew, 2016).
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Kew, Kirtchuk, and Michell (2014) did not find benefit in the adult population with the intervention group staying 4 minutes longer then
the placebo group 95% CI [-37.02, 29.02].
Length of Stay in the Hospital. Based on one study (N = 47) magnesium sulfate provided a possible benefit in decreasing, Mean
Difference = -5.30, 95% CI [-9.46, -1.14] the pediatric patients mean length of stay, in hours (Griffiths & Kew, 2016). In the adult
population (N = 949), Kew, Kirtchuk, and Michell (2014) reported no clear benefit with the use of magnesium sulfate in the patient’s
hospital length of stay, Mean difference = -0.03, 95% CI [-0.33, 0.27].
Pulmonary Function. Griffiths and Kew (2016) found no studies that reported pulmonary function results in the pediatric population.
Kew, Kirtchuk, and Michell (2014) identified eight studies (N = 1460) that measured the PEF mean difference in the magnesium sulfate
group to be 17.40 L/min, 95% CI [8.64, 26.17] higher than the placebo group.
Readmission to the ED / UCC Within 48 Hours. Based on two pediatric studies (N = 85) there was no clear benefit for magnesium
sulfate OR = 0.40, 95% CI [0.02, 10.30] and the readmission to the ED/UCC within 48 hours. Also, Kew, Kirtchuk, and Michell (2014)
reported no clear benefit for readmission to the ED/UCC when magnesium sulfate was used in the adult population OR = 2.30, 95% CI
[0.66, 7.99].
Validated Symptom Score. Validated symptom scoring was used in four adult studies; however, individual measures were not
available, and therefore an analysis was not undertaken (Kew, Kirtchuk, & Michell, 2014).
EBP Scholar’s responsible for analyzing the literature:
David Keeler, RN, BSN, CPN
Robert Rhodes, MHA, RRT-NPS
Kim Robertson, MBA, MT-BC
Audrey Snell, MS, RD, CSP, LD
Rhonda Sullivan, MS, RD, LD
EBP team member responsible for reviewing, synthesizing, and developing this document:
Jacqueline Bartlett, PhD, RN
Search Strategy and Results:
Search: (("status asthmaticus") OR (("Asthma"[Mesh] OR asthma[tw]) AND ("accident and emergency" OR "A and E" OR "Emergency
Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical Services"[Mesh] OR "Emergency Medicine"[Mesh] OR
"emergency department"[tw]))) AND (magnesium[tw] OR "Magnesium"[Mesh] OR "Magnesium Sulfate"[Mesh]) AND (infant OR child OR
paediatr* OR pediatr* OR adolescence OR children OR childhood) AND ("2010/01/01"[PDAT] : "2017/12/31"[PDAT]) 46 results, of which 37
included IV Magnesium for treatment of asthma and 4 articles mentioned both IV and INH magnesium.
The Team Leaders selected 23 of the articles for IV Magnesium Sulfate for the treatment of asthma exacerbation, two studies answered the
question (Griffiths & Kew, 2016; Kew et al., 2014) see Figure 2, page 73.
Studies included in this review:
Griffiths 2016
Kew 2014
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Studies not included in this review with exclusion rationale:
First Author
Year
Rehder
2017
Bidwell
2017
Hon
2017
Liu
2016
Griffiths
2016
Pardue Jones
2016
Vaiyani
2016
Izarzuzta
2016
Castro Rodriquez
2015
Wong
2014
Goodacre
2014
Shedd
2014
Koninckx
2013
Jones
2013
Nievas
2013
Shan
2013
Egelund
2013
Izarzuzta
2012
Bittar
2012
Pollart
2011

Reason for exclusion
Narrative review
Review of Griffiths 2016
Narrative review
Systematic review
Exclude
Griffiths' Cochrane republished in a different journal
Systematic review
Does not include identified outcomes
Does not include identified outcomes
Does not include identified outcomes
Griffiths is more recent SR/MA
Narrative review
Narrative review
Case study
Narrative review
Systematic review, all studies included in Griffiths 2016
Narrative review
Narrative review
Does not include identified outcomes
Does not include identified outcomes

Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the two systematic
reviews included in this analysis. GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this
analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0
ed.): The Cohcrane Collaboration, 2011.

Date Developed/Updated: November 2017
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Figure 1. Magnesium sulfate versus Placebo; Outcome: Hospital Admission
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)
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Specific Care Question:
In the child who presents to the ED/UCC with an asthma exacerbation should non-invasive ventilation be used to reduce (1) admission
to the hospital, (2) ED length of stay, or (3) improve pulmonary function?
Question Originator:
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. In an asthma attack, the airways, or the small tubes in the lungs, grow narrow and swell making it difficult to move air
through the lungs, or breathe. Chest tightness, coughing, and wheezing are usually present as well making the patient feel “short of
breath”. Continuous positive airway pressure (non-invasive CPAP) or non-invasive spontaneous/timed positive airway pressure are two
forms of non-invasive ventilation (NIV). Both treatments provide a small amount of air pressure to keep airways open. Since during an
asthma attack the airways are swollen it is thought that NIV works by forcing air into the lungs. By forcing air into the lungs, two
important things occur: (1) the patient will not feel so short of breath, and (2) using NIV may help deliver medications that are given by
breathing them, such as albuterol.
Study Characteristics. Since the publication of GINA (2016) our parent guideline, four papers are identified for this question. Basnet
et al. (2012) is an RCT, Mayordomo-Colunga et al. (2011) is a cohort study, and Abramo et al. (2017) and Williams et al. (2011) are
quality improvement projects. Only Williams et al. (2011) was completed in the Emergency Department. The other three papers
occurred within the PICU. The outcomes of hospital admission and length of stay in the emergency department and urgent care were
not reported in the identified studies.
Key Results. We found that not enough research has been done to either recommend or not recommend this treatment. Only one pilot
study was found that asked the question if adding non-invasive spontaneous/timed airway pressure to standard treatment, would make
the patient feel better. The research team found that symptoms resolved more quickly when medications are delivered using noninvasive spontaneous/timed airway pressure, but only 20 patients were studied. As studies become available that test this therapy in a
larger number of patients in the ED, our confidence in using this therapy may change. Currently, there is not enough evidence to
support a recommendation either for against this treatment.
Literature Summary:
Pulmonary Function
An RCT by Basnet et al. (2012) reported the use of a Clinical Asthma Score (CAS) which included the measure of patient’s pulmonary
function in its rubric. The study is a prospective, not blinded, pilot study that enrolled 20 subjects (10 in each group) in the PICU. They
found a more rapid improvement in the Clinical Asthma Score (CAS), a non-validated asthma score. The only statistical data reported
was a p value of p < .01. The CAS includes the assessment of respiratory rate, use of accessory muscles to breathe, air exchange,
wheeze, and inhalation: exhalation ratio.
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Adverse Events –
Adverse events are not clearly reported; however, ondansetron and ketamine were added in one report (Abramo et al., 2017) to assist
with the risk of vomiting, aspiration and non-invasive spontaneous timed airway pressure failure. Basnet and colleagues (2012)
reported one subject withdrew due to coughing and excessive secretions. In a 4.5-year prospective observational study (MayordomaColunga et al., 2011), one case of massive subcutaneous emphysema was reported while no other serious adverse events occurred in
the 122 subjects treated with NIV in the PICU. Williams et al. (2011) reports no adverse events (such as death, pneumothoraces, or
aspirations) occurred while subjects were on NIV.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, BSN, MSNed, CPEN
Helen Murphy, BHS RRT AE-C
Jennifer Foley, RT(R)(N), CNMT
EBP team member responsible for reviewing, synthesizing, and developing this document:
Nancy H. Allen, MS, MLS, RD, LD
Search Strategy and Results:
Search: (("status asthmaticus") OR (("Asthma"[Mesh] OR asthma[tw]) AND ("accident and emergency" OR "A and E" OR "Emergency
Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical Services"[Mesh] OR "Emergency Medicine"[Mesh] OR
"emergency department"[tw]))) AND ("Positive-Pressure Respiration"[Mesh] OR "bi-level positive airway pressure" OR "bilevel positive
airway pressure" OR BiPap[tw] OR CPAP[tw] OR "continuous positive airway pressure" OR NHF[tw] OR "Nasal high flow" OR "High-flow
nasal cannula" OR HFNC[tw] OR "High Flow Nasal Cannula" OR "high flow oxygen" OR "nasal cannula") AND (infant OR child OR paediatr*
OR pediatr* OR adolescence OR children OR childhood) AND ("2010/01/01"[PDAT] : "2017/12/31"[PDAT]).
Studies Included in this Review:
Abramo et al. (2017)
Basnet et al. (2012)
Silva Pde & Barreto (2015)
Mayordomo-Colunga et al. (2011)
Williams et al. (2011)
Studies not included in this review with exclusion rationale:
First Author
Reason for exclusion
Baudin et al. (2017)
Retrospective study
Coletti (2017)
Does not answer the question- PICU patients
Pardue Jones (2016)
Narrative review
Schibler (2016)
Narrative review
Golden (2015)
Narrative review
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Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the four included studies.
GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0
ed.): The Cohcrane Collaboration, 2011.

Date Developed/Updated: November 2017
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Records identified through
database searching
(n = 24)

Additional records identified
through other sources
(n = 0)

Included

Eligibility

Screening

Records after duplicates removed
(n = 24)

Records screened
(n = 24)

Records excluded
(n = 14)

Full-text articles assessed
for eligibility
(n = 10)

Full-text articles excluded,
with reasons
(n = 6)

Studies included in
qualitative synthesis
(n = 0)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 4)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Characteristics of Studies
Abramo 2017
Methods
Participants

Interventions

Cohort Study - Continuous Quality Improvement Program (CQIP)
Participants: Pediatric Emergency Department (PED) patients presenting with moderate or severe asthma.
Over eight years, 2005-2013.
Setting: Academic Pediatric ED, Vanderbilt Children's Hospital, Tennessee USA
Number with moderate/severe asthma: N = 21,798
Number enrolled: n = 1157 (5.3%)
Number complete: n = 1157
Gender, males: n = 692 (59.8%)
Age, years (median): 4 years, 95% CI [2.3, 6.5]; range [9 months - 18.25 years]
Inclusion criteria: Pediatric patients presenting to ED with moderate to severe asthma
Exclusion Criteria: Emesis within the first 30 minutes of non-invasive spontaneous timed
pressure placement and therapy (13 patients- 1%)
A PED non-invasive spontaneous timedpressure CQIP from 2005 to 2013 for the usage, safety, non-invasive
spontaneous timed pressure settings, therapeutic response parameters and patient disposition was
evaluated using descriptive analytics.
• From 2005 to 2009 used the Pediatric Asthma Severity (PAS) score, a validated screening tool.
• From 2009 to 2013, an individualized component input-derived pediatric asthma severity (PAS). The
score is derived from respiratory rate, oxygen saturation, auscultation, retractions, and dyspnea.
PAS score: mild=PAS score 0–7, moderate=PAS score 8–11, severe=PAS score 12–15.

Outcomes

Primary outcome: Safety
Secondary outcomes: usage, compliance, therapeutic response parameters, non-invasive spontaneous
timed pressure settings and patient disposition.

Notes

Results:
• 1157 patients had compliance without complications.
•
Only 6 (0.5%) non-invasive spontaneous timed pressure patients were intubated.
• Non-invasive spontaneous timed pressure -median settings:
o IPAP 18 (16, 20) cm H2O range 12–28
o EPAP 8 cmH2O (8,8) range 6–10
• Inspiratory-to-expiratory time (I:E) ratio 1.75 (1.5, 1.75).
• Pediatric Asthma Severity score and RR decreased (p<.001) while tidal volume increased (p<.001).
• Patient disposition:
• 325 pediatric intensive care units (PICU)
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•

•

•

•

•

832 wards, with 52 of these PED ward patients were discharged home with only 2 hours of
PED non-invasive spontaneous timed pressure with
• No returning to the PED within 72 hours.
A review of Vanderbilt Children’s PED and PICU intubation for the 21,789 PED asthma encounters
(2005–2013) showed a 4.8% intubation rate. Of these 4.8% PED intubated patients with asthma, only
6 (0.027%) patients had non-invasive spontaneous timed airway pressure before intubation. Of the
4.7% PED intubated asthmatics none had documented non-invasive spontaneous timed airway
pressure attempts or non-invasive spontaneous timed airway pressure charges as noted in their PED
EMR.
PICU length of stay, median total hours (95% CI):
• PED non-invasive spontaneous timed airway pressure patients admitted to PICU (n = 325):
23.7 hours (20.7 to 30.4)
• PED non- non-invasive spontaneous timed airway pressure patients admitted to PICU (n =
1105): 50.4 hours (48.6 to 57.6)
Median PAS scores for all PED non-invasive spontaneous timed airway pressure patients (95% CI):
• Just before start of non-invasive spontaneous timed airway pressure PAS: 12 (11 - 14)
• Initial PAS: 13 (12 -14)
• Final PAS off non-invasive spontaneous timed airway pressure: 4 (4 - 6)
Note: This was a quality improvement study. The investigators changed their evaluations and
processes during the process. The usage of non-invasive spontaneous timed airway pressure
increased in the ED as physicians and staff became more comfortable with its use. Ondansetron and
ketamine were added to the process to assist with risk of vomiting, aspiration, and non-invasive
spontaneous timed airway pressure failure.
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Basnet 2012
Methods

Participants

Interventions

Prospective Randomized Control trial
Setting:
• Children 1-18 admitted to PICU for asthma at St. John's Children's Hospital, Springfield, IL, Jan 2009 January 2010.
Randomized into study: N = 20
• Noninvasive positive pressure (NPPV) & standard care: n = 10
• Standard care: n = 10
Completed Study: N = 19
• NPPV & standard care: n = 9
• Standard care: n = 10
Gender, males:
• NPPV & standard care: n = 4
• Standard care: n = 7
Age, years (range):
• NPPV & standard care: n = 6 (5-11)
• Standard care: n = 3 (3-11)
Inclusion Criteria:
• Known history of asthma with status asthmaticus
• Clinical asthma score (CAS) between 3 and 8 after receiving one dose of methylprednisolone, 1 hour of
continuous albuterol and 3 doses of ipratropium bromide
Exclusion Criteria:
• No previous history of asthma
• Absence of airway protective reflexes
• Absence of respiratory drive
• Need for emergent intubation
• Facial or airway anomaly
• Injury precluding the use of a tight-fitting mask
Power Analysis:
None given
Both Groups received Standard Care:
• Medications
o Continuous albuterol at 0.5 mg/kg, max of 15 mg/kg
o IV methylprednisone 2 mg/kg/day max of 80 mg/day
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•

o Oxygen to keep saturations >92%
Adjunct therapy with magnesium sulfate and/or heliox added at physician discretion at any point after 2
hours study initiation if CAS was greater than score at initiation

Experimental -NPPV & Standard care: fitted with masks with gel seal and placed on bi-level PPV machines
(Vision BiPAP)
• Inspiratory positive pressure was gradually increased to 8cmH2O to achieve tidal volume of 6-9 ml/kg and
end-expiratory positive pressure to 5 cm H2O
• Nasal masks used unless pressures of 8/5 could not be maintained
• Settings remained unchanged throughout 24-hour study period, interrupted only for feeding
• Humidification, albuterol and oxygen administered through the circuit
Control: Standard Care only

Outcomes

Primary:
• CAS score the higher the score the more severe the exacerbation
o Improvement in CAS at 2, 4-8, 12-16 and 24 hours
Secondary:
• Respiratory rate
• Oxygen requirement
• Adjunct therapy
• Side effects of NPPV
Per Protocol - CAS median (interquartile range)

Notes

NPPV & Standard care

Standard care

Significance

0-2 hours

3 (3-5)

6.5 (5-7.3)

p< .01

4-8 hours

3 (3-5)

5.5 (4-7)

p< .01

12-16 hours

2 (2-3)

4 (3.8-6.3)

p< .01

2 (2-2.8)

3.5 (3-5.5)

p< .01

24 hours

Difference in mean CAS (at all assessment periods)
Per protocol - Difference in mean Respiratory Rate at 24 hours (p< .01)
NPPV & Standard care: 26 breaths per minute, 95% CI, [20, 32]
Standard care: 30 breaths per minute, 95% CI [25, 36]
Risk of bias table

Bias

Scholars'
judgment

Support for judgment
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Random sequence generation
(selection bias)
Allocation concealment
(selection bias)

Low risk
Unclear risk

Stratified method of randomization based on 3 age groups
Information not given

Blinding of participants and
personnel (performance bias)

High risk

CAS performed by respiratory therapists not involved in study, but they were not blinded by
treatment.

Blinding of outcome
assessment (detection bias)

Unclear

No information given

Incomplete outcome data
(attrition bias)

High risk

Intent to treat and per protocol data given, but Intent to treat individual data not given on all
outcomes. Pilot study with small sample size.

High risk

They report the reduction in respiratory rate from baseline to 24 hours post therapy in both
groups, however the baseline respiratory rate was higher (not significantly) in the treatment
group. When the 24-hour assessment of both treatments are compared, the respiratory rate is not
significantly different.

Selective reporting (reporting
bias)
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Mayordomo-Colunga 2011
Methods

Participants

Cohort
Participants: Children with asthma in an 8 bed PICU from July 2004-December 2009
Setting: Hospital Universitario Central de Asturias, Austrias Spain
Number complete: N = 72
% male: 69.4%
Inclusion criteria:
• Previous diagnosis of asthma (2 previous visits at regular health provider and prescribed beta-agonist to
treat acute symptoms)
• Over 6 months of age
• Status asthmaticus unresponsive to initial treatment in the emergency department or inpatient floors
Exclusion Criteria:
• Cardiorespiratory arrest
• Hemodynamic instability despite fluids
• Absence of cough reflex
• Vocal cord palsy
• Progressive obtundation
• Inadequate management of secretions
• Undrained pneumothorax
• Upper GI bleeding
• Intubation
Power analysis: none noted
•

Interventions

•
•
Outcomes

Patient with status asthmaticus unresponsive to initial treatment
o Initial treatment
▪ 3 doses of salbutamol (0.03 mg/kg up to 5 mg)
▪ Ipratropium bromide (250 mcg in children <20 kg, and 500mcg >20 kg)
▪ IV methyl-prednisone (2 mg/kg) or hydrocortisone (4-8 mg/kg).
o Unresponsive
▪ Woods clinical asthma score (m-WCAS) remained > 4 with severe respiratory distress
signs (dyspnea, marked retractions)
▪ Assessment made in PICU right before initiation of non-invasive ventilation
Non-invasive ventilation given through pressure support ventilation with E-PAP set at 5 cm H2O and I-PAP
started at 6-8 cm H2O and increased per physician, as needed
Continuous nebulized salbutamol and ipratropium every 2 hours and decreased with patient improvement

Primary Outcome: Failed NIV and required intubation
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Secondary Outcomes:
• Asthma score (m-WCAS)
• Heart Rate, Respiratory Rate
• Fio2
• PCO2

Notes

Primary Outcome: n = 5
• One patient with Down syndrome and corrected atrial septal defect died due to arrhythmia after
intubation and inotropic support
Secondary Outcome:
• m-WCAS score
o After 1st hour m-WCAS fell 2.3 + - 1.5 points (p < 0.01)
o At 6 hours the decrease form baseline was 2.7 + - 1.3 points (p < 0.01)
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Williams 2011
Methods

Retrospective and prospective descriptive analysis
Study was a segment of a QI program for non-invasive spontaneous timed airway pressure use in pediatric ED
asthma patients

Participants

Setting: USA: Large, urban children's hospital pediatric emergency department
Number in study: n = 165 (prospective study n = 53, retrospective study n = 112)
Number in study who had a documented asthma score after 4 hours of non-invasive spontaneous
timed airway pressure: 109
Age: 0.6-8.27 years (average 3.7 years, SD 1.6 years)
Gender: 64% male
Inclusion Criteria:
Received non-invasive spontaneous timed airway pressure therapy while admitted to the PED
• Weight of 20 kg or less
• Diagnosis of status asthmaticus -or• Reactive airway disease -or• Acute bronchospasm
Exclusion Criteria:
• Non-invasive spontaneous timed airway pressure < 30 minutes
• Routine home non-invasive spontaneous timedl airway pressure
• Chronic lung dx
• Neuromuscular disorders
• Cardiovascular disorders
• Gestational age <28 weeks
• Pediatric Asthma Score (PAS) < 8
Power Analysis: Authors did not disclose
•
•

Interventions

All patients received inhaled beta-2 agonists and either oral/iv steroids prior to non-invasive spontaneous
timed airway pressure
Some patients also received other medications in addition to above PRIOR to non-invasive spontaneous
timed airway pressure:
1. IV magnesium sulfate (80%)
2. Epinephrine (aerosol or subcutaneous) (52%)
3. Terbutaline (46%)
• some patients also received other medications in addition to above DURING non-invasive
spontaneous timed airway pressure:
1. IV mag sulfate (18%)
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2. Epinephrine (aerosol or subcutaneous) (44%)
3. Terbutaline (24%)
• Non-invasive spontaneous timed airway pressure settings as directed by physicians, IPAP=820cm H2O, EPAP 4-10cm H2O for 30-270 minutes (mean 210 min, SD 158 min) while in the ED
Outcomes

Notes

Pediatric Asthma Score (PAS)
109 of subjects had documented PAS after 4 hours on non-invasive spontaneous timed airway pressure or upon
discontinuation of non-invasive spontaneous timed airway pressure
• Initial PAS upon initiation of non-invasive spontaneous timed airway pressure ranged from 8-15 (mean
12.1, SD 1.6)
• PAS upon non-invasive spontaneous timed airway pressure termination ranged from 0-15 (mean 6.3, SD
2.2)
• 86 (of the 109) had an improvement of >4 points on the PAS (score decreased)
• 2 (of the 109) had no change
• 1 (of the 109) had an increased score of 3 points
Study reports "no mortality, pneumothoraxes, aspirations, or morbidity" were demonstrated during the study.
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Figure 2. Comparison Non-invasive Ventilation vs. Standard Care, Outcome: Respiratory Rate at 24 hours
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Specific Care Question
For the child who presents to the Emergency Department or Urgent Care Center (ED/UCC) should epinephrine 1:1000 IM be considered in a severe
exacerbation with impending respiratory failure?
Question Originator
The Asthma in the Emergency Department/ Urgent Care Center Clinical Practice Guideline Team
Literature Summary
Background. Standard treatment for asthma exacerbations is short-acting beta2-agonists (SABA) and oral systemic corticosteroids (Plus, 2017,
December 11). The Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention (2018, p. 84) makes a strong
recommendation that epinephrine be used for confirmed food allergy, and is indicated in, along with standard therapy, for asthma exacerbation
associated with anaphylaxis and angioedema. GINA states epinephrine “is not a routinely indicated for other asthma exacerbations” (GINA, 2018, p.
84). Patients should be identified as high risk, and the education concerning the difference between anaphylaxis and asthma exacerbation should occur
regularly (GINA, 2018, p. 65). The Expert Panel Report-3, Guidelines for the Diagnosis and Management of Asthma (NAEP-EPR-3, 2007) recommends
against epinephrine as a quick-relief medication in children < 12 years of age (NAEP-EPR- 3. 2007, p. 317), youths > 12 years of age (NAEP-EPR-3
2007, p. 350), and during exacerbations (NAEP-EPR-3, 2007, p. 386). The primary reasons are there is no proven benefit over aerosol medication and
in high doses there is potential for excessive cardiac stimulation (NAEP-EPR-3, 2007, p. 317).
Study characteristics. The search for suitable studies was completed on April 24, 2018. Amanda Nedved, MD reviewed the 39 titles and abstracts
found in the search and identified no articles believed to address the question. On June 8, 2018, two additional searches, expanding the search date
back to 1980, were performed. The first search centered on studies with adults as subjects and yielded 67 studies. The second search filtered for
pediatrics studies only and yielded 18 studies. Duplicates were removed, and 92 articles addressed the question (39 from the original search plus 53
from the latter two searches. Amanda Nedved, MD and Irene Walsh, MD reviewed the additional 53 studies and selected 13 studies by reviewing title
and abstracts. Following an in-depth review evaluating intervention, comparison, and outcomes reported four studies were selected to provide evidence
for this question. Three RCTs compared epinephrine with SABA versus SABA alone for the outcome peak expiratory flow rate (PEFR) at 20 minutes
(Becker, Nelson, & Simons, 1983; Kornberg, Zuckerman, Welliver, Mezzadri, & Aquino, 1991; Sharma & Madan, 2001). Becker et al. (1983) provided
figures with no data; therefore, it could not be included in the meta-analysis. Becker et al. (1983) also reported on the outcome Adverse Events.
Schwartz, Lipton, Warburton, Johnson, and Twarog, (1980) compared epinephrine to terbutaline with an outcome of FEV1 (% predicted) at 20 minutes.
Key results. Our parent guideline (GINA, 2018, p. 84) recommends EPI IM in addition to conventional therapy for an asthma exacerbation associated
with anaphylaxis and angioedema. We make a conditional recommendation to consider epinephrine 1:1000, IM, 0.1 mg, (EPI IM) for the patient in the
ED with an asthma exacerbation that is not responding to conventional treatment. If the patient is not responding to conventional therapy, the use of
EPI IM likely outweighs any adverse side effects. EPI IM may decrease risk of intubation and mechanical intubation. When epinephrine, 0.1 mg
(1:1000) (IM), was added to treatment with SABA improvement in PEFR at 20 minutes after treatment was not significantly different from treatment
with SABA alone (Becker et al., 1983; Kornberg et al., 1991; Sharma & Madan, 2001), see Table 2 and Figure 3. When epinephrine was compared to
terbutaline, change in FEV1 (% predicted) was not different (Schwartz et al., 1980), see Figure 5.
Summary by Outcome
Pulmonary Function. Three studies (N = 121) compared epinephrine to SABA (Becker et al., 1983; Kornberg et al., 1991; Sharma & Madan, 2001)
and one study (N = 124) compared epinephrine to terbutaline (Schwartz et al., 1980). The evidence is graded as very low for both comparisons. Risk of
bias was very serious as subjects, study personnel, or outcomes assessors were not blinded, or it was not reported if they were blinded. Per protocol
analysis was performed, see Figure 2. Imprecision is very serious as there is a small number of studies, with a small number of subjects for both
comparisons. Sample size was not calculated in the studies, it is unknown if the sample was adequate to detect a difference in this outcome. For the
two studies comparing epinephrine to SABA, Kornberg et al. (1991) and Sharma and Madan, (2001), the change % predicted PERF from baseline was
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not statistically different when subjects were treated with epinephrine 0.1 mg (IM) versus those treated with SABA nebulized (NEB), MD = 0.02. 95%
CI [-0.29, 0.32]. Becker et al. (1983) reported there was not significant difference between groups treated with epinephrine 0.1 mg/kg, maximum 0.4
ml) versus those treated with SABA (INH) in FEV1 at 15 minutes post treatment. A summary statistic was not provided. Schwartz et al., (1980)
reported no difference in % predicted FEV1 when epinephrine was compared with terbutaline MD = 2.6, 95% CI [-10.34, 5.14], see Figure 5.
Adverse Events. One study (N = 40) reported on adverse events (Becker et al., 1983). The evidence is graded as low. Risk of bias is low in this study
(see Figure 2), however, imprecision is very serious. There were no adverse events (nausea, vomiting, tremor, headache, palpitations, excitement, and
pallor) in the SABA group, but 10 subjects in the epinephrine group reported at least one adverse event. Adverse events are not the primary outcome,
it is uncertain if there were enough subjects to detect a difference on this outcome. A summary statistic was not reported, see Figure 4.
Search Strategy and Results (see PRISMA diagram p. 167)
April 24, 2018 PubMed
Specific study types:
Search: ("Asthma"[tw] OR "status asthmaticus") AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical
Services"[Mesh] OR "Emergency Medicine"[tw] OR "emergency department"[tw] OR "accident and emergency"[tw] OR "Acute Disease"[Mesh] OR
exacerbation[All Fields] OR attack[All Fields]) AND "Epinephrine"[tw] AND ("humans"[MeSH Terms] AND (Meta-Analysis[ptyp] OR Practice
Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Guideline[ptyp] OR "Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR
systematic[sb]) AND English[lang] AND (child OR children OR childhood OR pediatr* OR paediatr*) AND ("2010"[PDAT] : "2018"[PDAT]) ) 15 results
All study types:
Search: ("Asthma"[tw] OR "status asthmaticus") AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical
Services"[Mesh] OR "Emergency Medicine"[tw] OR "emergency department"[tw] OR "accident and emergency"[tw] OR "Acute Disease"[Mesh] OR
exacerbation[All Fields] OR attack[All Fields]) AND "Epinephrine"[tw] AND ((child OR children OR childhood OR pediatr* OR paediatr*) AND
("2010"[PDAT] : "2018"[PDAT])) 33 results
June 8 2018 PubMed
Pediatrics only:
("Asthma"[tw] OR "status asthmaticus") AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency Medical
Services"[Mesh] OR "Emergency Medicine"[tw] OR "emergency department"[tw] OR "accident and emergency"[tw] OR "Acute Disease"[Mesh] OR
exacerbation[All Fields] OR attack[All Fields]) AND "Epinephrine"[tw] AND ("humans"[MeSH Terms] AND (Meta-Analysis[ptyp] OR Practice
Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Guideline[ptyp] OR "Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR
systematic[sb]) AND English[lang] AND (child OR children OR childhood OR pediatr* OR paediatr*) AND ("1960"[PDAT] : "2010"[PDAT]) ) 18 results
All ages:
("Asthma"[tw] OR "status asthmaticus"[All Fields]) AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR "Emergency
Medical Services"[Mesh] OR "Emergency Medicine"[tw] OR "emergency department"[tw] OR "accident and emergency"[tw] OR "Acute
Disease"[Mesh] OR exacerbation[All Fields] OR attack[All Fields]) AND "Epinephrine"[tw] AND ("humans"[MeSH Terms] AND (Meta-Analysis[ptyp]
OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Guideline[ptyp] OR "Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh]
OR systematic[sb]) AND English[lang] AND ("1960"[PDAT] : "2018"[PDAT])) 67 results
Studies Included in this Review (in Alphabetical Order)
Becker et al. (1983)
Kornberg et al. (1991)
Schwartz et al. (1980)
Sharma and Madan, (2001)
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Studies Not Included in this Review with Exclusion Rationale (in Alphabetical Order)
Author (YYYY)
Reason for exclusion
Biagini and Myers (2015)
Doesn’t answer the question
Brandstetter et al. (1980)
Doesn’t answer the question -- dose comparison study
Gotz et al. (1981)
Doesn’t answer the question -- dose comparison study
Hon and Leung, (2017)
Indinnimeo, Chiappini, Miraglia Del Giudice, & Italian
Panel for the Management of Acute Asthma Attack in
Children, (2018)
Karetzky (1980)
Mondal et al. (2014)
Schwartz et al. (1980)
Turnbull et al. (2010)
Wade and Chang, (2015)

Systematic review that references papers already excluded
Make a recommendation to not use epinephrine based on GINA (2015), EPR-3 (2007)
and British Thoracic Society, SIGN guideline (2016)
Doesn’t answer the question -- dose comparison study
Studied inhaled epinephrine
Doesn’t answer the question
Case report
IV epinephrine

Method Used for Appraisal and Synthesis
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the XXX included studies. GRADEpro GDT
(Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cohcrane Collaboration, 2011.

Librarian responsible for the literature search:
Keri Swaggart, MLIS, AHIP
EBP Scholar’s responsible for analyzing the literature

Kelly Huntington, RN, BSN, CPN
Kim Robertson, MBA, MT-BC
Hope Scott, RN CPEN
Rhonda Sullivan, MS, RD, LD
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
Nancy H. Allen, MS, MLS, RD, LD, CPHQ
Acronyms Used in this Document
Acronym
Explanation
ED
Emergency department
EPR-3
Expert Panel Report-3, Guidelines for the Diagnosis and Management of Asthma
FEV1
Forced expiratory volume in one second
GINA
Global Initiative for Asthma
IM
Intramuscular
INH
Inhaled
MD
Mean Difference
NEB
Nebulized
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PEFR
SABA
SIGN
UCC

Peak expiratory flow rate
Short acting beta2 agonist
Scottish Intercollegiate Guidelines Network
Urgent Care Center

Date Developed/Updated: October 2018
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Identification

Question 10 – Specific Care Question: Epinephrine (IM) for Severe Exacerbation

Records identified through
Database searching
(n = 133)

Additional records identified
through other sources
(n = 0)

Records screened
(n = 92)

Records excluded
(n = 79)

Full-text articles assessed
for eligibility
(n = 13)

Full-text articles excluded,
with reasons
(n = 9)

Included

Eligibility

Screening

Records after duplicates removed
(n = 92)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b
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Question 10 – Specific Care Question: Epinephrine (IM) for Severe Exacerbation

Figure 2 Risk of Bias Summary
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Subcutaneous Epinephrine Compared to Nebulized SABA for Asthma Exacerbation in the
ED/UCC
Certainty assessment
№ of
participants
(studies)
Follow-up

Risk
of
bias

Summary of findings

Inconsistency Indirectness Imprecision Publication Overall
bias
certainty
of
evidence

Study event
rates (%)
With
Neb
SABA

Relative
effect
(95% CI)

With
Sub q
Epi

Anticipated absolute
effects
Risk
with
Neb
SABA

Risk
difference
with Sub q
Epi

Percent predicted PEFR change from baseline
81
(2 RCTs)

very
not serious
serious

not serious

very serious
b

none

a

⨁◯◯
◯

39

42

-

The
mean
percent
predicted
PEFR
change
from
baseline
was 0

MD 0.02
higher
(0.29 lower
to 0.32
higher)

0/20
(0.0%)

10/20
(50.0%)

OR
41.00

0 per
1,000

0 fewer
per 1,000
(0 fewer to
0 fewer)

VERY
LOW

Adverse events
40
(1 RCT)

not
not serious
serious

not serious

very serious
c

none

⨁⨁◯◯
LOW

(2.18 to
770.08)

Explanations
a. Neither study blinded personnel, participants, or outcome assessors.
b. There is only two included studies, and a low number of subjects for this comparison N = 81.
c. There is only one study that reported this outcome, with a total of 40 subjects. There were zero adverse events in the SABA group.
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Epinephrine Compared to Terbutaline for Asthma Exacerbation in the ED/UCC
Certainty assessment
№ of
participant
s
(studies)
Follow-up

Risk
of
bias

Inconsistenc
y

Indirectnes
s

Summary of findings

Imprecisio
n

Publicatio
n bias

Overall
certaint
y of
evidenc
e

Study event rates (%)
With
Terbutalin
e

With
Epinephrin
e

64

60

Relativ
e effect
(95%
CI)

Anticipated absolute
effects
Risk with
Terbutalin
e

Risk
difference
with
Epinephrin
e

The mean
percent
predicted
FEV2 was 0

MD 2.6
lower
(10.34
lower to
5.14 higher)

Percent predicted FEV1
124
(1 RCT)

very
seriou
sa

not serious

not serious

serious

b

none

⨁◯◯
◯
VERY
LOW

-

CI: Confidence interval; MD: Mean difference

Explanations

a. Poorly reported study. Selection bias (randomization, and allocation concealment), performance (blinding of participants and personnel), and detection bias
(blinding of outcome assessment are not discussed, and per protocol analysis was performed.
b. Comparison includes one study with 124 subjects.
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Characteristics of Studies
Becker 1983
Methods

Participants

Interventions

Outcomes

Notes

Double blind randomized control trial
Setting: Children's Hospital at the University of Manitoba in Winnipeg Canada
Randomized into study: N = 40
• Group 1: Epinephrine subcutaneously n = 20
• Group 2: Inhaled salbutamol n = 20
Completed Study: N = 40
• Group 1: Epinephrine subcutaneously n = 20
• Group 2: Inhaled salbutamol n = 20
Gender, males:
• Group 1: Epinephrine subcutaneously n = (60%)
• Group 2: Inhaled salbutamol n = (65%)
Age, years (mean) (SE):
• Group 1: Epinephrine subcutaneously 10.4 + 0.7
• Group 2: Inhaled salbutamol 10.6 + 0.7
Inclusion Criteria:
• Children ages 6-17 years
• Came to the emergency room because of acute asthma during September and October 1981
• Previously documented reversible airway obstruction by pulmonary function testing
• Had not received treatment for the acute episode within 2 hours
Exclusion Criteria:
• No previously documented reversible airway obstruction by pulmonary function testing
• Received treatment for the acute episode within 2 hours
Power Analysis: Not reported

•
•

Group 1: Epinephrine subcutaneously (1:1000, 0.01 ml/kg, maximum 0.4 ml) + inhaled saline
Group 2: Inhaled salbutamol (0.5% solution, 0.02 ml/kg, maximum 0.4 ml) + injected saline

Primary outcome(s):
• Efficacy and safety of inhaled salbutamol and subcutaneous epinephrine
Safety outcome(s): adverse effects including nausea, vomiting, tremor, headache, palpitations, excitement
and pallor seen in 10 of 20 patients given epinephrine and no adverse effects were seen in the group
given salbutamol and other than sinus tachycardia no arrhythmias were noted

•

There was no significant difference between groups in improvement in percent FEV1/FVC 30 minutes
after therapy
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•
•

No significant difference between groups in pulmonary index, respiratory rate, heart rate, and diastolic
blood pressures 30 minutes after therapy
No significant difference between groups in the outcome of acute episode with regard to treatment,
admission at initial visit, return to emergency room, subsequent admission on return, or total number
of admissions within seven days

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Table of random numbers

Allocation concealment
(selection bias)

Low risk

Group assignment by a pharmacist who was not treating the patient

Blinding of participants and
personnel (performance
bias)

Low risk

Each participant received a placebo of saline injection or inhaler, a nurse covered the injection
site with gauze to prevent observation of presence or absence of skin blanching from injection

Blinding of outcome
assessment (detection bias)

Unclear risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

Low risk

Other bias

Low risk

Not stated
All completed the study
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Kornberg 1991
Methods

Prospective, randomized, controlled trial, ED

Participants

Setting: Children's Hospital of Buffalo pediatric emergency department between November 1987 and June
1988
Randomized into study: N = 43
• Group 1 (Sus-Phrine + albuterol): n = 20
• Group 2 (Albuterol alone): n = 23
Completed study: N = 43
• Group 1 (Sus-Phrine + albuterol): n = 20
• Group 2 (Albuterol alone): n = 23
Gender, males: N = 22
• Group 1 (Sus-Phrine + albuterol): n = 8
• Group 2 (Albuterol alone): n = 14
Age, years (mean): 8.9
• Group 1 (Sus-Phrine + albuterol): 9.6 +/- 3.5
• Group 2 (Albuterol alone): 8.2 +/- 3.8
Inclusion criteria:
• Diagnosis of asthma according to the criteria of the American Thoracic Society
• Acute asthma presentation
• > 6 years of age
Exclusion criteria:
• History of cardiac disease
• Chronic pulmonary disease aside from asthma
• Current use of SABA
Power analysis:
Power analysis PEFR and respiratory rate was conducted. Using an alpha = 0.05 (two-sided) and a beta 0.20
(one-sided), study sample size would detect an additional improvement in the predicted PEFR of 10% and a
decrease of 5 breaths per minute (with 80% assurance) for Group 1.

Interventions

Group 1 (Sus-Phrine + albuterol):
• Single subcutaneous injection of Sus-Phrine, 0.005 ml/kg, to a maximum dose of 0.15 ml at
enrollment
• Nebulized, non-pressurized albuterol 2.5 mg in 3 ml of normal saline within 5 minutes of enrollment
Group 2 (Albuterol alone):
• Nebulized, non-pressurized albuterol 2.5 mg in 3 ml of normal saline within 5 minutes of enrollment
Both groups received albuterol treatments every 20-30 minutes as clinically necessary after initial enrollment
therapy.
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Outcomes

Notes

Primary outcomes:
Recorded at pre-treatment, 20 minutes and 2 hours
• Clinical score
• PEFR - best of three readings were accepted.
• Respiratory rate
• Heart rate
Only patients who were six years and over were given PEFR testing resulting in the following:
• Group 1 (Sus-Phrine + albuterol): n= 17
• Group 2 (Albuterol alone): n= 14
Sus-Phrine contains 5 mg of epinephrine per 1 ml, compared to 1 mg per ml for standard epinephrine solution
for subcutaneous injection. Eighty percent of the available epinephrine in Sus-Phrine is in a suspension that is
absorbed over six to eight hours. The remaining 20% is available in the rapidly absorbing form.
Results: PEFR, % predicted (percentage of increase compared to pretreatment data) at 20 minutes
Sus-Phrine + albuterol, PEFR, % predicted: 13% +/- 2.2%
albuterol alone, PEFR, % predicted: 15% +/- 2.3%
The difference in PEFR % predicted was not statistically different, nor was clinical score, respiratory rate
decrease, or heart rate decrease at either 20 minutes or 2 hours after administration.

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Low risk

Coin toss was used to randomize participants in to group

Allocation concealment
(selection bias)

High risk

Study was not blinded

Blinding of participants and
personnel (performance
bias)

High risk

Study was not blinded

Blinding of outcome
assessment (detection bias)

High risk

Study was not blinded

Incomplete outcome data
(attrition bias)

Low risk

Reported an all stated outcomes

Selective reporting
(reporting bias)

Low risk

Reported on all participants
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Schwartz 1980
Methods

Participants

Randomized Controlled Trial
Setting: Four month study conducted in the Emergency Ward at the Children's Hospital Medical Center in
Boston, MA
Randomized into study: N = 280
• Group 1: Epinephrine, Did not report
• Group 2: Terbutaline sulfate, Did not report
• Group 3: Isoetharine hydrochloride, Did not report
Completed Study: N = 269
• Group 1: Epinephrine n = 66
• Group 2: Terbutaline sulfate n = 76
• Group 3: Isoetharine hydrochloride n = 127
Gender, males:
• Group 1: Epinephrine, Did not report
• Group 2: Terbutaline sulfate, Did not report
• Group 3: Isoetharine hydrochloride, Did not report
Age, years (mean):
• Group 1: Epinephrine, Did not report
• Group 2: Terbutaline sulfate, Did not report
• Group 3: Isoetharine hydrochloride, Did not report
Inclusion Criteria:
• Diagnosis of acute asthma
• Between the ages of 5 and 21 years
• Came to the Emergency ward
Exclusion Criteria:
• Received parenteral therapy for the present attack
• Were in "impending respiratory failure"
• Pregnant
• Experiencing their first attack of asthma
Power Analysis: Did not report

•
Interventions

Parenteral Treatment Protocol
o Group 1
▪ Epinephrine (1mg/mL concentration) was administered at 15-minute intervals to a
total of three doses (0.01 mg/kg, with a maximum dose of 0.4mL)
o Group 2
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Terbutaline sulfate (1mg/mL concentration) was administered at 15-minute intervals to
a total of three doses (0.01 mg/kg, with a maximum dose of 0.4mL)
o Both Group 1 and Group 2
▪ When required, further therapy was provided by inhaled isoetharine hydrochloride
(Bronkosol). After two doses of isoetharine, aminophylline was administered
intravenously (5 to 7 mg/kg during 20-minute period), if clinically indicated. Ten
minutes after completion of the aminophylline administration, a decision regarding
discharge or admission to hospital was made by the house officer and senior resident
in charge of the emergency ward
Inhalation
o Group 3
▪ Inhalation of 0.5 mL of isoetharine hydrochloride in 2 mL of saline solution delivered by
intermittent positive pressure breathing (IPPB) using a respirator powered with 40%
oxygen at a pressure of approximately 15 cm H2O.
▪ Repeated when necessary for a total of three treatments at 20-minute intervals.
▪ Further therapy included up to two doses of a subcutaneous adrenergic agent and, if
required, IV aminophyline
o At any stage, treatment was discontinued, and the patient was discharged from the emergency
ward when he/she was clinically judged to be free of asthma by resolution of respiratory
distress and improvement in auscultatory findings

▪

•

Outcomes

Primary Outcomes
• Compare the efficacy of subcutaneous epinephrine with terbutaline sulfate
• Compare routes of administration of adrenergic agents (subcutaneous vs inhaled)
o Frequency of adverse side effects
o Clinical outcomes (discharge disposition)
o Clinical scores and FEV

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Did not discuss

Allocation concealment
(selection bias)

Unclear risk

Did not discuss
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Blinding of participants and
personnel (performance
bias)

Unclear risk

Double-blind coded vials

Blinding of outcome
assessment (detection bias)

Unclear risk

Did not report

Incomplete outcome data
(attrition bias)

High risk

Used per protocol analysis

Selective reporting
(reporting bias)

Low risk

All outcomes are reported on

Other bias

Unclear risk

The study appears to be free of other sources of bias
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Sharma 2001
Methods

Participants

Interventions

Prospective RCT
Setting: Emergency Department, India, Pediatrics
Randomized into study: N = 50
• Group 1, Subcutaneous epinephrine: n = 25
• Group 2, Nebulized salbutamol: n = 25
Completed Study: N =
• Group 1, Subcutaneous epinephrine: n = 25
• Group 2, Nebulized salbutamol: n = 25
Gender, males: (%)
• Not reported
Age, years (mean) (SD):
• Group 1, Subcutaneous epinephrine: 11.08 (0.4)
• Group 2, Nebulized salbutamol: 10.3 (0.5)
Inclusion Criteria:
• 6-14 years of age
• acute exacerbation of asthma
o Increase coughing
o Inability to speak in a sentence
o Inability to take a drink
o Wheeze
o Chest recession
Exclusion Criteria:
• Severe exacerbation, life-threatening
o Cyanosis
o Silent chest
o Poor air entry
o Inability to speak 3-4 words
o PERF < 30%for height
• Bronchodilator within 6 hours of prior to presentation
• History of a prior intensive care unit admission for asthma
·
Power Analysis: Not reported
Both groups received oxygen, and kept a minimum of four hours under observation
• Group 1, Subcutaneous epinephrine: 0.01 ml/kg/dose of subcutaneous epinephrine 1:1000 (1
mg/ml), maximum 0.3 ml, to be repeated twice at 20 minute intervals
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•

Group 2: Nebulized salbutamol: 0.03 ml/kg. dose (150 microgram/kg/dose) of 0.5% respiratory
solution to a maximum of 1 ml (5 mg) per dose, repeated twice at 20 minute intervals

Primary outcome(s): % predicted PEFR
Outcomes

Secondary outcome(s): Improvement in respiratory rate, heart rate, dyspnea, use of accessory muscles,
auscultation, ability to drink and speak in a sentence

Notes
Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

State randomization, but do not describe method

Allocation concealment
(selection bias)

Unclear risk

Not described

Blinding of participants and
personnel (performance
bias)

High risk

Not stated, although it would have been easy to blind subjects and personnel

Blinding of outcome
assessment (detection bias)

High risk

Not stated, although it would have been easy to blind outcome assessors

Incomplete outcome data
(attrition bias)

Low risk

All completed the study

Selective reporting
(reporting bias)

Low risk

Other bias

Unclear risk
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Figure 3. Comparison: Epinephrine (IM) vs. SABA (NEB), Outcome: PEFR (% predicted) change from baseline
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Figure 4. Comparison Epinephrine (IM) vs. SABA (NEB), Outcome: Adverse Events
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Figure 5. Comparison: Epinephrine versus Terbutaline, Outcome: FEV1 % predicted at 20 minutes
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